## ঔষধ নিয়ন্ত্রণ কমিটির ১৬ এপ্রিল, ২০১৮ তারিখে অনুষ্ঠিত ২৪৯তম সভার কার্যবিবরণী

স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়ের স্বাস্থ্য সেবা বিভাগের সচিব জনাব মোঃ সিরাজুল হক খান এঁর সভাপতিত্বে ঔষধ নিয়ন্ত্রণ কমিটির ২৪৯৩ম সভা বিগত ১৬ এপ্রিল ২০১৮ তারিখ সকাল ১০:০০ ঘটিকায় মন্ত্রণালয়ের সভা কক্ষে অনুষ্ঠিত হয়।

## সভায় কমিটির নিমুবর্ণিত সদস্যগণ উপস্থিত ছিলেন (জ্যেষ্ঠতার ক্রমানুসারে নয়)ঃ

- ১. অধ্যাপক ডাঃ মোঃ ইসমাইল খান, উপাচার্য, চট্টগ্রাম মেডিকেল বিশ্ববিদ্যালয়, চট্টগ্রাম।
- ২. অধ্যাপক মীর মিজবাহ উদ্দিন, ফার্মাকোলজী বিভাগ, বঙ্গবন্ধু শেখ মুজিব মেডিক্যাল বিশ্ববিদ্যালয়, শাহবাগ, ঢাকা।
- ৩. অধ্যাপক ডাঃ নাসিমা সুলতানা, অতিরিক্ত মহাপরিচালক (প্রশাসন), স্বাস্থ্য অধিদপ্তর, মহাখালী, ঢাকা।
- ৪. তাঃ মোঃ রেজাউল ইসলাম, পরিচালক (গ,প্র,মূ), প্রাণি সম্পদ অধিদপ্তর, ঢাকা।
- ৫. জনাব আব্দুল ওহাব খান, উপসচিব (ঔষধ প্রশাসন), স্বাস্থ্য সেবা বিভাগ, স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়, বাংলাদেশ সচিবালয়, ঢাকা।
- ৬. ডাঃ কাজী আফজালুর রহমান, সহযোগী অধ্যাপক, চিকিৎসা অনুষদ, ঢাকা বিশ্ববিদ্যালয়, ঢাকা।
- ৭. অধ্যাপক ডাঃ জাকির হোসাইন গালিব, চর্ম ও যৌন রোগ বিশেষজ্ঞ, স্যার সলিমুল্লাহ্ মেডিকেল কলেজ, ঢাকা।
- ৮. ডাঃ ফাহমিদা হক, সহকারী অধ্যাপক, গাইনী এন্ড অবসটেট্রিক্স বিভাগ, স্যার সলিমুল্লাহ্ মেডিকেল কলেজ, ঢাকা।
- ৯. জনাব মোঃ আবদুর রাজ্জাক, ব্যবস্থাপনা পরিচালক, জেএমআই সিরিঞ্জেস এন্ড মেডিকেল ডিভাইসেস লিঃ, কুমিল্লা।
- ১০. জনাব রাব্বুর রেজা, বিশেষজ্ঞ প্রতিনিধি, বাংলাদেশ ঔষধ শিল্প সমিতি, ঢাকা।
- ১১. জনাব মোঃ শফিউজ্জামান, বিশেষজ্ঞ প্রতিনিধি, মহাসচিব, বাংলাদেশ ঔষধ শিল্প সমিতি, ঢাকা।
- ১২. অধ্যাপক ড. মোঃ আনোয়ারুল ইসলাম, বিশেষজ্ঞ প্রতিনিধি, বাংলাদেশ ফার্মাসিউটিক্যাল সোসাইটি, ঢাকা।
- ১৩. জনাব এম মোছাদ্দেক হোসেন, বিশেষজ্ঞ প্রতিনিধি, বাংলাদেশ ফার্মেসী কাউন্সিল, ঢাকা।
- ১৪. মেজর জেনারেল মোঃ মোম্ভাফিজুর রহমান, মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তর, ঢাকা।

## সভায় আলোচ্য বিষয় সমূহ নিমুরূপঃ

- ক) ঔষধ নিয়ন্ত্রণ কমিটির ২৪৮ তম সভার কার্যবিবরণী নিশ্চিতকরণ।
- খ) ঔষধ নিয়ন্ত্রণ কমিটির টেকনিক্যাল সাব কমিটির গত ০৪/০১/২০১৮ তারিখে অনুষ্ঠিত সভার সুপারিশসমূহঃ
  - ১) জাতীয় মাদকদ্রব্য নিয়ন্ত্রণ বোর্ডের চতুর্দশ সভার সিদ্ধান্ত মোতাবেক সিলডেনাফিল সাইট্রেট জাতীয় পদ উৎপাদন ও বাজারজাত না করার বিষয়ে আলোচনা ও সিদ্ধান্ত গ্রহণ।
  - ২) স্থানীয়ভাবে উৎপাদনের জন্য ১৬৪টি হিউম্যান ঔষধের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
  - ৩) আমদানীর জন্য ০১টি হিউম্যান ঔষধের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
  - 8) স্থানীয়ভাবে উৎপাদনের জন্য ০৪টি ভেটেরিনারী ঔষধের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
  - ৫) আমদানীর জন্য ১৩টি ভেটেরিনারী ঔষধের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
- গ) ঔষধ নিয়ন্ত্রণ কমিটির মেডিকেল ডিভাইসের টেকনিক্যাল সাব কমিটির গত ০৪/০১/২০১৮ তারিখে অনুষ্ঠিত সভার সুপারিশসমূহঃ
  - ১) স্থানীয়ভাবে উৎপাদনের জন্য ০২টি মেডিকেল ডিভাইসের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
  - ২) আমদানীর জন্য ০৮টি মেডিকেল ডিভাইসের রেজিস্ট্রেশনের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।
- ঘ) হার্বাল এডভাইজরী কমিটি (ঔষধ নিয়ন্ত্রণ কমিটির টেকনিক্যাল সাব কমিটি)-এর ২৯/০১/২০১৮ তারিখে অনুষ্ঠিত সভার সুপারিশসমূহঃ
  - ১) স্থানীয়ভাবে উৎপাদনের জন্য ৫৫টি হার্বাল মেডিসিনের রেজিস্ট্রেশনের বিষয়ে হার্বাল ঔষধ এডভাইজরী কমিটির সুপারিশের উপর আলোচনা ও সিদ্ধান্ত গ্রহণ।

## <u>সভার আলোচনা ও সিদ্ধান্তঃ</u>

সভাপতি উপস্থিত সকলকে স্বাগত জানিয়ে সভার কার্যক্রম শুরু করেন। অতঃপর তিনি সদস্য-সচিব মেজর জেনারেল মোঃ মোল্ডাফিজুর রহমান, মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তরকে আলোচ্য সূচী অনুযায়ী বিষয়সমূহ উপস্থাপন করার জন্য অনুরোধ করেন।

## ক) <u>ঔষধ নিয়ন্ত্রণ কমিটির ২৪৮তম সভার কার্যবিবরণী নিশ্চিতকরণ প্রসঙ্গে।</u>

বিগত আগষ্ট ১৬, ২০১৭ তারিখে অনুষ্ঠিত ঔষধ নিয়ন্ত্রণ কমিটির ২৪৮তম সভার কার্যবিবরণী সভায় উপস্থাপন করা হয়। সভায় উপস্থিত সদস্যগণ ২৪৮তম সভার কার্যবিবরণী সঠিকভাবে লিপিবদ্ধ হয়েছে বলে মত প্রকাশ করেন। সভায় সর্বসম্মতিক্রতে ২৪৮তম সভার কার্যবিবরণী নিশ্চিত করা হয়।

- খ) ঔষধ নিয়ন্ত্রণ কমিটির টেকনিক্যাল সাব কমিটির গত ০৪ জানুয়ারী, ২০১৮ তারিখে অনুষ্ঠিত সভার সুপারিশসমূহঃ
  - ১। জাতীয় মাদকদ্রব্য নিয়ন্ত্রণ বোর্ডের চতুর্দশ সভার সিদ্ধান্ত মোতাবেক সিলডেনাফিল সাইট্রেট জাতীয় পদ উৎপাদন ও বাজারজাত না করার বিষয়ে আলোচনা ও সিদ্ধান্ত গ্রহণ।

জাতীয় মাদকদ্রব্য নিয়ন্ত্রণ বোর্ডের চেয়ারম্যান মাননীয় স্বরাষ্ট্রমন্ত্রী জনাব আসাদুজ্জামান খাঁন এর সভাপতিত্বে বিগত ৮ অক্টোবর ২০১৫ তারিখে অনুষ্ঠিত চতুর্দশ সভায় বাংলাদেশের কোন কারখানায় ভায়াগ্রা বা অন্য কোন নামে সিলডেনাফিল সাইট্রেট উপাদান হিসেবে কোন যৌন উত্তেজক ট্যাবলেট, সিরাপ বা ইঞ্জেকশন যাতে উৎপাদন ও বিপণন হতে না পারে সে বিষয়ে স্বাস্থ্য মন্ত্রণালয় প্রয়োজনীয় ব্যবস্থা গ্রহণ করবে বিষয়ে পুনঃ সিদ্ধান্ত গৃহীত হয়।

শ্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয় কর্তৃক সিলডেনাফিল সাইট্রেট নামীয় পদ উৎপাদন ও বাজারজাত না করার বিষয়ে প্রয়োজনীয় ব্যবস্থা গ্রহণের জন্য ১১ ডিসেম্বর ২০১৭ তারিখে ঔষধ প্রশাসন অধিদপ্তরকে অবহিত করা হয়।

ঔষধ প্রশাসন অধিদপ্তর কর্তৃক বিভিন্ন বিশেষজ্ঞদের নিকট সিলডেনাফিল সাইট্রেট নামীয় পদটির ব্যবহারের উপযোগিতা সম্পর্কে সুচিন্তিত মতামত চাওয়া হয়।

উল্লিখিত বিষয়ে অধ্যাপক ড. সীতেশ চন্দ্র বাছার, চেয়ারম্যান, ফার্মেসী বিভাগ, ঢাকা বিশ্ববিদ্যালয় মতামত প্রদান করেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি Pulmonary Arterial Hypertension ও Erectile dysfunction চিকিৎসায় নির্দেশিত এবং Tertiary level Hospital গুলোতে নবজাতকদের চিকিৎসায় ব্যবহার করা হচ্ছে, যা অনেক নবজাতক শিশুদের জীবন রক্ষা করছে।

জনাব এম মোসান্দেক হোসেন, ভাইস প্রেসিডেন্ট, বাংলাদেশ ফার্মেসী কাউন্সিল মতামত প্রদান করেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি মাদক নয় এবং কোন ঔষধ মাদক হিসেবে বিবেচিত হতে হলে ইন্টারন্যাশনাল নারকোটিক কন্ট্রোল বোর্ড ও বিশ্ব স্বাস্থ্য সংস্থা কর্তৃক তালিকাভুক্ত হতে হয়। বিশেষজ্ঞগণ সিলডেনাফিল সাইট্রেট পদটির উৎপাদন ও বাজারজাতকরণ অব্যাহত রাখার বিষয়ে মতামত প্রদান করেন।

ঔষধ নিয়ন্ত্রণ কমিটির টেকনিক্যাল সাব-কমিটির সভায় সিলডেনাফিল সাইট্রেট পদটির উৎপাদন ও বাজারজাতকরণ বিষয়ে আলোচনাকালে সদস্যগণ ঔষধটি সম্পর্কে নিমুবর্ণিত বিষয়াদি উল্লেখ করেনঃ

ঔষধ নিয়ন্ত্রণ কমিটির বিগত ২০ মে, ২০১২ তারিখে অনুষ্ঠিত ২৪১তম সভায় সিলডেনাফিল সাইট্রেট নামীয় ঔষধটি Pulmonary Arterial Hypertension ও Erectile dysfunction চিকিৎসার জন্য কার্যকর ঔষধ হিসেবে অনুমোদিত হয়।

সিলডেনাফিল সাইট্রেট ঔষধটি USFDA কর্তৃক অনুমোদিত, যা Pfizer নামীয় প্রতিষ্ঠানের অনুকূলে ভায়াগ্রা নামে সর্বপ্রথম ১৯৯৮ সালে অনুমোদিত হয়। ঔষধটি যুক্তরাষ্ট্র, যুক্তরাজ্য, ইউরোপীয় ইউনিয়ন, কানাডা এবং ভারতসহ বিশ্বের বিভিন্ন দেশে নিবন্ধিত আছে।

সিলডেনাফিল সাইট্রেট ঔষধটি স্থানীয়ভাবে উৎপাদিত হয় বিধায় স্বল্প মূল্যে পাওয়া যায়। ঔষধটি স্থানীয়ভাবে উৎপাদনের পূর্বে স্মাগলিং হয়ে প্রচুর পরিমানে দেশে প্রবেশ করতো। ঔষধটির উৎপাদন বন্ধ করা হলে পার্শ্ববর্তী দেশ হতে স্মাগলিং হয়ে দেশে প্রবেশ করবে।

ঔষধটি Erectile dysfunction চিকিৎসায় এবং নবজাতক শিশুদের Pulmonary Arterial Hypertension চিকিৎসায় একটি জীবন রক্ষাকারী ঔষধ এবং এর কোন বিকল্প নেই বিধায় রেজিস্ট্রেশন বহাল রাখা জরুরী। ঔষধটির যৌক্তিক ব্যবহার নিশ্চিতকল্পে মোড়কে লাল কালিতে "প্রেসক্রিপশন ছাড়া ব্যবহার করা যাবে না" মর্মে উল্লেখ করতে হবে। থেরাপিউটিক প্রয়োজনীয়তা বিবেচনায় এটি বহাল রাখা যেতে পারে।

## টেকনিক্যাল সাব-কমিটির সুপারিশঃ

- ১) সিলডেনাফিল সাইট্রেট ঔষধটি Erectile dysfunction এবং নবজাতক শিশুদের Pulmonary Arterial Hypertension (PHN) চিকিৎসায় জীবনরক্ষাকারী ঔষধ বিধায় সভায় উপস্থিত সদস্যগণ কর্তৃক সর্বসম্মতিক্রমে সিলডেনাফিল সাইট্রেট ঔষধটির উৎপাদন ও বাজারজাতকরণ বহাল রাখার সুপারিশ করা হয়।
- ২) নবজাতক শিশুদের Pulmonary Arterial Hypertension (PHN)-ব্যবস্থাপনায় সিলডেনাফিল সাইট্রেট ঔষধটির উপযোগিতা সম্পর্কে পরিচালক, ঢাকা শিশু হাসপাতাল-এর মতামত গ্রহণ করার সিদ্ধান্ত গৃহীত হয়।
- ৩)সিলডেনাফিল সাইট্রেট ঔষধটির বিতরন নিয়ন্ত্রণ করার জন্য উৎপাদনকারী প্রতিষ্ঠানকে ঔষধটির মোড়কে লাল কালিতে **"প্রেসক্রিপশন** ছাড়া ব্যবহার করা যাবে না" উল্লেখ করতে হবে।

ঔষধ নিয়ন্ত্রণ কমিটির টেকনিক্যাল সাব-কমিটির সভার সিদ্ধান্ত মোতাবেক ঢাকা শিশু হাসপাতালের পরিচালক-এর নিকট সিলডেনাফিল সাইট্রেট ঔষধটির বিষয়ে মতামতের জন্য প্রেরণ করা হলে তিনি ঔষধটির রেজিস্ট্রেশন বহাল রাখার পক্ষে মত প্রদান করেন।

## ঔষধ নিয়ন্ত্রণ কমিটির সভার আলোচনাঃ

সভার সদস্য-সচিব মেজর জেনারেল মোঃ মোন্ডাফিজুর রহমান, মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তর বলেন যে, জাতীয় মাদকদ্রব্য নিয়ন্ত্রণ বোর্ডের চতুর্দশ সভার সিদ্ধান্ত মোতাবেক সিলডেনাফিল সাইট্রেট জাতীয় পদ উৎপাদন ও বাজারজাত না করার বিষয়ে টেকনিক্যাল সাব-কমিটির সভায় বিস্তারিত আলোচনা হয়। তিনি বলেন টেকনিক্যাল সাব-কমিটির সভায় উপস্থিত বিশেষজ্ঞ সদস্যগণ মত প্রকাশ করেছেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি Erectile dysfunction এবং নবজাতক শিশুদের Pulmonary Arterial Hypertension (PHN) চিকিৎসায় জীবন রক্ষাকারী ঔষধ। ঔষধটির রেজিস্ট্রেশন বহাল রেখে নিয়ন্ত্রিত ব্যবস্থায় উৎপাদন ও বাজারজাত করার সুপারিশ করেন। বিষয়টির উপর মতামত প্রদানের জন্য তিনি স্বাইকে অনুরোধ করেন।

বঙ্গবন্ধু শেখ মুজিব মেডিক্যাল বিশ্ববিদ্যালয়ের ফার্মাকোলজী বিভাগের অধ্যাপক মীর মিজবাহ উদ্দিন বলেন যে, বাংলাদেশে কতজন Pulmonary Arterial Hypertension (PHN) ও Erectile dysfunction এর রোগী আছে এবং সিলডেনাফিল সাইট্রেট ঔষধ উৎপাদনকারী প্রতিষ্ঠানগুলো কী পরিমান উৎপাদন ও বিক্রি করছে তার পরিসংখ্যান থাকা প্রয়োজন। তিনি ঔষধটির অপব্যবহার হচ্ছে বলে অভিমত ব্যক্ত করেন।

বাংলাদেশ ফার্মেসী কাউন্সিল-এর বিশেষজ্ঞ প্রতিনিধি জনাব এম মোছাদ্দেক হোসেন বলেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি নবজাতক শিশুদের জন্য একটি জীবনরক্ষাকারী ঔষধ। Erectile dysfunction এর চিকিৎসায় বিশেষজ্ঞ ইউরোলজিস্টগণ প্রেসক্রাইব করে থাকেন। ঔষধ নিয়ন্ত্রণ কমিটির ২৪১তম সভায় শুধুমাত্র চিকিৎসকদের প্রেসক্রিপশনে ঔষধটি ব্যবহার হবে মর্মে সিদ্ধান্ত ছিল। এটি পৃথিবীর প্রায় অধিকাংশ দেশে অনুমোদন রয়েছে।

স্যার সলিমুল্লাহ্ মেডিকেল কলেজের চর্ম ও যৌন রোগ বিশেষজ্ঞ অধ্যাপক ডাঃ জাকির হোসাইন গালিব বলেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি USFDA কর্তৃক অনুমোদিত। ঔষধটির আবিষ্কারক নোবেল পুরষ্কার পেয়েছেন, প্রথমে Pfizer কোম্পানী ঔষধটি বাজারজাত করে। বাংলাদেশের ৭% নবজাতক শিশু Pulmonary Arterial Hypertension (PHN) রোগে ভোগে এবং এদের চিকিৎসায় ঔষধটির বিকল্প নাই। শিশুদের চিকিৎসার জন্য স্বল্প মাত্রায়ও ঔষধটি উৎপাদন করার পক্ষে তিনি মত প্রকাশ করেন।

চউগ্রাম মেডিক্যাল বিশ্ববিদ্যালয়ের উপাচার্য অধ্যাপক ডাঃ মোঃ ইসমাইল খান বলেন যে, ঔষধটি বৈজ্ঞানিক বিবেচনায় এবং চিকিৎসার প্রয়োজনে অতীব প্রয়োজনীয় ঔষধ। ঔষধটি কোন Addiction সৃষ্টি করে না। যুক্তরাজ্যে এটি OTC (Over the Counter) ড্রাগ হিসেবে স্বীকৃত।

ঔষধ প্রশাসন অধিদপ্তরের মহাপরিচালক মেজর জেনারেল মোঃ মোন্তাফিজুর রহমান বলেন যে, সিলডেনাফিল সাইট্রেট ঔষধটি নিয়ন্ত্রণের জন্য নজরদারী বাড়ানো যেতে পারে। এক্ষেত্রে ঔষধ প্রশাসন অধিদপ্তরের সাথে মাদকদ্রব্য নিয়ন্ত্রণ অধিদপ্তর মনিটরিং করতে পারে।

সভাপতি মহোদয় বলেন যে, যেহেতু স্বরাস্ট্রমন্ত্রণালয় হতে সিলডেনাফিল সাইট্রেট ঔষধটির উৎপাদন ও বাজারজাত না করার ব্যবস্থা গ্রহণের জন্য অনুরোধ করা হয়েছে সেহেতু বিষয়টি অত্যন্ত গুরুত্ত্বের সাথে বিবেচনা করা আবশ্যক। তিনি আরও বলেন যে, চিকিৎসার স্বার্থে ঔষধটির প্রয়োজনীয়তা রয়েছে তবে এর অপব্যবহার রোধকল্পে কার্যকর ব্যবস্থা গ্রহণ করতে হবে। অপব্যবহার রোধে সংশ্লিষ্ট সবাইকে যৌথভাবে কাজ করতে হবে বলে তিনি মত প্রকাশ করেন।

#### সভার সিদ্ধান্তঃ

- ক) সিলডেনাফিল সাইট্রেট ঔষধটি Erectile dysfunction চিকিৎসায় এবং নবজাতক শিশুদের Pulmonary Arterial Hypertension (PHN) চিকিৎসায় অতীব প্রয়োজন বিধায় ঔষধটির রেজিস্ট্রেশন বহাল রাখার সিদ্ধান্ত গৃহীত হয়।
- খ) ঔষধটির উৎপাদন ও বাজারজাতকরণে মনিটরিং আরও জোরদার করতে হবে। সেক্ষেত্রে ঔষধ প্রশাসন অধিদপ্তরের সাথে মাদকদ্রব্য নিয়ন্ত্রণ অধিদপ্তর যৌথভাবে মনিটরিং করবে।
- গ) ঔষধটির মোড়কে লাল কালিতে "Prescription only medicine" এবং "প্রেসক্রিপশন ছাড়া ব্যবহার করা যাবে না" উল্লেখ করতে হবে।
- ২। স্থানীয়ভাবে উৎপাদনের জন্য আবেদিত ১৬৪টি হিউম্যান ঔষধের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

স্থানীয় উৎপাদনের জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ১৬৪টি নতুন ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিম্নবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

- ক) অনুমোদিত = ৬৮ টি;
- খ) নামঞ্জুরকৃত = ৯৬ টি; (Annex-A)
- ৩। আমদানীর জন্য আবেদিত ০১ (এক)টি হিউম্যান ঔষধের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

আমদানীর জন্য হিউম্যান ঔষধের রেজিস্ট্রেশনের নিমিত্তে আবেদিত নিম্নবর্ণিত ঔষধটি সভায় উপস্থাপন করা হয়। টেকনিক্যাল সাব কমিটি সভার সুপারিশ মোতাবেক Insulin Glargine 300U/3ml স্থানীয়ভাবে উৎপাদনের জন্য অনুমোদিত বিধায় 300U/ml (Annex-B) কেন প্রয়োজন সে বিষয়ে ব্যাখা প্রদানের জন্য মেসার্স সানোফি বাংলাদেশ লিঃ-কে বলা হয়। কিন্তু অদ্যাবধি কোন উত্তর পাওয়া যায়নি।

<u>সিদ্ধাঞ্জ</u> প্রতিষ্ঠানটির ব্যাখ্যা পাওয়া গেলে পরবর্তীতে টেকনিক্যাল সাব-কমিটির সভায় উপস্থাপন করার সিদ্ধান্ত গৃহীত হয়।

৪। স্থানীয়ভাবে উৎপাদনের জন্য আবেদিত ০৪টি ভেটেরিনারী ঔষধের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

স্থানীয় উৎপাদনের জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ০৪টি নতুন ভেটেরিনারি ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিম্নবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

- ক) অনুমোদিত = ০৪টি; (Annex-C)
- ৫। আমদানীর জন্য আবেদিত ১৪টি ভেটেরিনারী ঔষধের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

আমদানীর জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ১৪টি নতুন ভেটেরিনারি ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিমুবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

- ক) অনুমোদিত = ০৬ টি
- খ) স্থগিতকৃত= ০১টি, এবং
- গ) নামঞ্জুরকৃত = ০৬ টি; (Annex-D)
- গ) ঔষধ নিয়ন্ত্রণ কমিটির মেডিকেল ডিভাইসের টেকনিক্যাল সাব কমিটির গত ০৪ জানুয়ারী, ২০১৮ তারিখে অনুষ্ঠিত সভার সুপারিশসমূহঃ
- ১। স্থানীয়ভাবে উৎপাদনের জন্য আবেদিত ০২টি মেডিকেল ডিভাইসের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

স্থানীয় উৎপাদনের জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ০২টি নতুন মেডিক্যাল ডিভাইসের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিম্নবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

ক। অনুমোদিত = ০২ টি; (Annex-E)

## ২। আমদানীর জন্য আবেদিত ০৮টি মেডিকেল ডিভাইসের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

আমদানির জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ০৮টি নতুন মেডিক্যাল ডিভাইসের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিমুবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

- ক) অনুমোদিত = 08 টি, এবং
- খ) স্থগিতকৃত = ০৪টি, (Annex-F)
- ঘ) স্থানীয়ভাবে উৎপাদনের জন্য আবেদিত ৫৫টি হার্বাল ঔষধের রেজিস্ট্রেশন অনুমোদন বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের আলোকে সিদ্ধান্ত গ্রহণ প্রসঙ্গে।

স্থানীয় উৎপাদনের জন্য রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ৫৫টি নতুন হার্বাল ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের ভিত্তিতে নিমুবর্ণিত সিদ্ধান্ত গৃহীত হয়ঃ

- ক) অনুমোদিত = 88 টি;
- খ) নামজুরকৃত = ১১ টি; (Annex-G)।

## বিবিধ আলোচনাঃ

ঙ। স্থানীয়ভাবে মেডিকেল ডিভাইস উৎপাদনকারী প্রতিষ্ঠানকে সহযোগিতা ও উৎসাহ প্রদান প্রসঙ্গেঃ

#### সভার আলোচনাঃ

বঙ্গবন্ধু শেখ মুজিব মেডিক্যাল বিশ্ববিদ্যালয়ের ফার্মাকোলজী বিভাগের অধ্যাপক মীর মিজবাহ উদ্দিন বলেন যে, বাংলাদেশে স্থানীয়ভাবে উৎপাদনের জন্য মেডিকেল ডিভাইস শিল্পকে উৎসাহিত করা উচিত।

জেএমআই সিরিঞ্জেস এন্ড মেডিকেল ডিভাইসেস লিঃ-এর ব্যবস্থাপনা পরিচালক জনাব মোঃ আবদুর রাজ্জাক বলেন যে, বাংলাদেশে বর্তমানে প্রায় চিবিশ হাজার কোটি টাকার মেডিকেল ডিভাইসের মার্কেট রয়েছে যার মধ্যে মাত্র ৫% মেডিকেল ডিভাইস দেশে উৎপাদন করা হয়। স্থানীয়ভাবে মেডিকলে ডিভাইস উৎপাদন ও বাজারজাতকরণের ক্ষেত্রে বিভিন্ন প্রতিবন্ধকতার বিষয়ে উল্লেখ করে তিনি বলেন, কাঁচামাল ও মেশিনারী আমদানীর সময় উচ্চ শুল্ক প্রদান করতে হয়, রপ্তানীর ক্ষেত্রে কোন প্রণোদনা পাওয়া যায় না। মেডিকেল ডিভাইস রপ্তানির ক্ষেত্রে চীন সরকার ১৭% প্রণোদনা দিয়ে থাকে। ফলে চীনের তৈরি মেডিকেল ডিভাইসসমূহ স্বল্প মূল্যে আমদানি ও বিক্রয় করা যায়। বাংলাদেশে উৎপাদিত মেডিকেল ডিভাইস চীনের তৈরি মেডিকেল ডিভাইসসমূহের সাথে প্রতিযোগিতায় টিকে থাকা কঠিন। আর্থিকভাবে টিকে থাকতে না পারায় ইতোমধ্যে বাংলাদেশে বেশ কয়েকটি মেডিকেল ডিভাইস উৎপাদনকারী প্রতিষ্ঠান বন্ধ হয়ে গিয়েছে। মেডিকেল ডিভাইস রেজিস্ট্রেশন গাইডলাইন-২০১৫ স্বাস্থ্য মন্ত্রণালয় কর্তৃক অনুমোদিত হলেও অদ্যাবিধি তার গেজেট প্রকাশিত হয়নি। তিনি মেডিকেল ডিভাইস উৎপাদনকারী প্রতিষ্ঠানগুলোকে সহযোগিতা প্রদানের অনুরোধ করেন।

সভাপতি মহোদয় বলেন যে. প্রণীত গাইডলাইনটি গেজেট আকারে প্রকাশের নিমিত্তে ব্যবস্থা গ্রহণ করা হবে।

<u>সিদ্ধান্তঃ</u> ১। প্রণীত মেডিকেল ডিভাইস রেজিস্ট্রেশন গাইডলাইন-২০১৫টি গেজেট প্রকাশিত করার স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয় ব্যবস্থা গ্রহণ করবে।

২। মেডিকেল ডিভাইস উৎপাদনকারী প্রতিষ্ঠানসমূহকে প্রয়োজনীয় বিভিন্ন সহযোগিতা প্রদান এবং মেডিকেল ডিভাইস রপ্তানির ক্ষেত্রে প্রণোদনা প্রদানের পদক্ষেপ গ্রহণ করা হবে।

## চ। হার্বাল ঔষধ ও অত্যাবশ্যকীয় নিউট্রিশনাল সাপ্লিমেন্ট আমদানী প্রসঙ্গেঃ

## সভার আলোচনাঃ

বাংলাদেশ ফার্মাসিউটিক্যাল সোসাইটি-এর সহ সভাপতি অধ্যাপক ড. মোঃ আনোয়ারুল ইসলাম উল্লেখ করেন যে, হার্বাল ঔষধ ও অত্যাবশ্যকীয় নিউট্রাসিট্রিক্যাল আমদানির বিষয়ে তিনি সচিব, স্বাস্থ্য সোবা বিভাগ, স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয় বরাবর আবেদন করেছেন। তিনি আবেদনে উল্লেখ করেছেন যে, মন্ত্রণালয়ের স্মারক নং-স্বাপকম/স্বাঃসেঃবিঃ/ঔষধ প্রশাসন-১/নীতি-১/২০১৭(৮৬)১২; তারিখ: ১৪-০৬-২০১৭ মোতাবেক প্রস্তুতকৃত হার্বাল ঔষধ আমদানির উপর নিষেধাজ্ঞা আরোপ করা হয়েছে। এমতাবস্থায়, গুরুতর অসুস্থ রোগীদের চিকিৎসার প্রয়োজনে ব্যবহৃত হয় অথচ আমাদের দেশে উৎপাদন ও বাজারজাত হয় না এমন হার্বাল ঔষধ ও অত্যাবশ্যকীয় নিউট্রেশনাল সাপ্লিমেন্টসমূহ আমদানী করা সম্ভবপর হচ্ছে না। এর ফলে সংশ্লিষ্ট গুরুতর অসুস্থ রোগীদের যথার্থ চিকিৎসা ব্যহত হবে বলে তিনি আবেদনে উল্লেখ করেন।

বঙ্গবন্ধু শেখ মুজিব মেডিক্যাল বিশ্ববিদ্যালয়ের ফার্মাকোলজী বিভাগের অধ্যাপক মীর মিজবাহ উদ্দিন বলেন যে, বাংলাদেশে হার্বাল ঔষধ শিল্পকে আরও সমৃদ্ধ করা প্রয়োজন।

অধ্যাপক ড. মোঃ আনোয়ারুল ইসলাম বলেন যে, হার্বাল ঔষধের উপর গবেষণা করা প্রয়োজন রয়েছে, ক্লিনিক্যাল ট্রায়াল এর মাধ্যমে হার্বাল ঔষধের Safety efficacy নিশ্চিত করা আবশ্যক। তিনি ঔষধ উৎপাদনকারী প্রতিষ্ঠানের লাভের ১% ঔষধের উপর গবেষণার জন্য প্রদানের প্রস্তাব করেন।

ঔষধ প্রশাসন অধিদপ্তরের মহাপরিচালক মেজর জেনারেল মোঃ মোদ্ভাফিজুর রহমান বলেন যে, বাংলাদেশের হার্বাল ঔষধ শিল্পের ইতোমধ্যেই যথেষ্ট পরিমাণে উন্নতি সাধিত হয়েছে। সময়ের সাথে সাথে এ শিল্প সমৃদ্ধ হচ্ছে। বিভিন্ন অ্যালোপ্যাথিক ঔষধ উৎপাদনকারী প্রতিষ্ঠান হার্বাল ঔষধ উৎপাদনের কারখানা স্থাপন করছে। পৃথিবীর বিভিন্ন দেশে হার্বাল ঔষধ রপ্তানী করা হচ্ছে। দেশীয় ঔষধ শিল্পের বিকাশের জন্য আমদানী নির্ভরতা কমাতে হবে। ঔষধের গবেষণার জন্য কেউ এগিয়ে আসলে ঔষধ শিল্প হতে সহযোগিতা পাওয়া যাবে বলে তিনি অভিমত ব্যক্ত করেন।

অন্য কোন আলোচ্য বিষয় না থাকায় সভাপতি মহোদয় উপস্থিত সকলকে ধন্যবাদ জ্ঞাপন করে সভার সমাপ্তি ঘোষণা করেন।

মেজর জেনারেল মোঃ মোন্ডাফিজুর রহমান মহাপরিচালক ঔষধ প্রশাসন অধিদপ্তর ও সদস্য-সচিব ঔষধ নিয়ন্ত্রণ কমিটি। মোঃ সিরাজুল হক খান সচিব স্বাস্থ্য সেবা বিভাগ স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয় ও সভাপতি ঔষধ নিয়ন্ত্রণ কমিটি।

# Annex-A: Product for locally manufacture (Human)

| নং | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                               | সভার সিদ্ধান্ত   |
|----|--|---|---|---------------------|--|---|--|---|--|--|
| 1. | a) Aristopharma Ltd. Plot No.21, Road No.11, Shampur- Kadamtali I/A Dhaka-1204 b) Drug International Ltd 252, Tongi I/A Tongi, Gazipur | Linagliptin 5 mg + Metformin Hydrochloride 1000mg Extended Release Tablet               | Linagliptin INN 5 mg + Metformin Hydrochloride BP 1000 mg                         | Antidiabetic        | It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Extended Release is appropriate.   | Contraindication: It is contraindicated in patients with known hypersensitivity to Linagliptin , Metformin or any other components of this drug. This medicine is also contraindicated for following patients: Severe Renal impairment, acute or chronic metabolic acidosis including diabetic ketoacidosis.  Side effects: The most common side effects are nasopharyngitis and diarrhea. Other side effects are nausea, vomiting, allergic reactions, joint pain. Hypoglycemia is more common in patient treated with this combination and Sulfonylurea or Insulin. | Linagliptin 2.5mg + Metformin Hydrochloride 1000 mg Tablet | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |
| 2. | a) Beacon Pharmaceutical s Ltd, Kathali, Bhaluka, Mymensingh b)Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna               | Deflazacort 12mg<br>Tablet  | Deflazacort INN 12mg  | Glucocorticoid      | Asthma and other airway Diseases, Rheumatoid arthritis, juvenile chronic arthritis, pemphigus, uveitis, nephritic, syndrome,Immune suppression in transplantation, anaphylaxis, severe,hypersensitivity reactions, dermatomyositis, mixed connective, tissue disease, polyarteritis nodosa, bullous pemphigoid, ulcerative colitis, optic neuritis, autoimmune haemolytic anaemia, idiopathic, thrombocytopenic, purpura, acute and lymphatic leukaemia, malignant lymphoma. | Contraindications: Systemic infection; live virus vaccines in those receiving immunosuppressive doses.  Side Effects: Gl disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.   | 6mg, 24mg<br>Tablet<br>&<br>120mg/100ml<br>Suspention      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 3. | a) Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh  | Sofosbuvir 400<br>mg + Velpatasvir<br>100 mg +<br>Voxilaprevir 100<br>mg<br>Film Coated | Sofosbuvir INN 400 mg +<br>Velpatasvir INN 100 mg<br>+<br>Voxilaprevir INN 100 mg | Antiviral           | It is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have-  ◆ Genotype 1, 2, 3, 4, 5, or 6 infection  | Contraindications: Contraindications with rifampin.  Side Effects: The most common adverse reactions (incidence greater than or equal to 10%, all   | Sofosbuvir INN<br>400 mg +<br>Velpatasvir INN<br>100 mg    | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |

| নং | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |                           | সভার সিদ্ধান্ত     |
|----|--|---|--|---------------------|--|--|--|---|---------------------------|--------------------|
|    | b)Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka  c) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka  d) EVEREST Pharmaceutical s Ltd. Kanchpur BSCIC, Soanragon, Narayanagnj BANGLADESH | Tablet  |  |                     | and have previously been treated with an HCV regimen containing an NS5A inhibitor.  Genotype 1a or 3 infection and have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor.  Additional benefit over Sofosbuvir/ Velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infections previously treated with Sofosbuvir without an NS5A inhibitor. | grades) observed with treatment with Sofosbuvir, Velpatasvir and Voxilaprevir for 12 weeks were headache, fatigue, diarrhea, and nausea.  Warning: Risk of Hepatitis B virus reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.  Bradycardia with amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking amiodarone with Sofosbuvir, Velpatasvir and Voxilaprevir, a sofosbuvir-containing regimen, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of amiodarone with Sofosbuvir, Velpatasvir and Voxilaprevir is not recommended. In patients without alternative viable treatment options, cardiac monitoring is recommended. |  |   |                           |                    |
| 4. | a) Beacon Pharmaceutical s Ltd, Kathali, Bhaluka, Mymensingh b) Navana Pharmaceutical s Ltd. c) Square   | Diphenhydramine Hydrochloride 14mg + Guaifenesin 100mg + Levomenthol 1.10mg/5ml syrup | Diphenhydramine Hydrochloride BP 14mg + Guaifenesin BP 100mg + Levomenthol BP 1.10mg/5ml | Antitussive         | It is indicated for the night time relief of cough, associated congestive symptoms and aiding restful sleep.   | Contraindications:Known hypersensitivity to the product or any of its constituents.  This product should not be administered to patients currently receiving monoamine oxidase inhibitors (MAOIs) or those patients who have received treatment with MAOIs within the last two week  Not to be used in children under the age of 12 years.   | Dextromethorp<br>han<br>Hydrobromide<br>300mg +<br>Guaiphenesin<br>4gm + Menthol<br>300mg/100ml<br>Syrup | MHRA  | অনুমোদন করা যেতে<br>পারে। | অনুমোদন করা<br>হল। |

| নং | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                     | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত  |
|----|---|---|---|---------------------|--|--|--|---|---|---|
|    | Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna   |   |   |                     |  | Side effects: Common side effects may include:  • dizziness, drowsiness;  • sleep problems (insomnia);  • diarrhea; or  • feeling nervous, restless, anxious, or irritable.  |  |   |   |   |
| 5. | a) Beacon Pharmaceutical s Ltd, Kathali, Bhaluka, Mymensingh b) Square Pharmaceutical s Ltd., (Dhaka Unit) Kaliakoir, Gazipur | Doxofylline 400mg<br>+ Montelukast<br>10mg Tablet     | Doxofylline INN 400mg +<br>Montelukast Sodium<br>USP/BP 10.400mg eq. to<br>10mg of Montelukast  | Bronchodilator      | It is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: | Contraindication: Contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients. It should not be used if you have the following conditions:  | Doxophylline<br>400 mg Tablet,<br>Montelukast<br>10mg Tablet |   | প্রয়োজনীয় রেফারেপ<br>এবং পৃথকভাবে<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। | প্রয়োজনীয়<br>রেফারেন্স এবং<br>পৃথকভাবে<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 6. | a) Beacon Pharmaceutical s Ltd. b) Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna                                  | Escitalopram<br>10mg +<br>Clonazepam<br>0.50mg Tablet | Escitalopram oxalate<br>USP 12.774mg eqv. to<br>Escitalopram 10mg +<br>Clonazepam USP<br>0.50mg | Antidepressant      | Indicated for the treatment of patient with comorbid depression and anxiety disorder                                 | Contraindications: The most common set of undesirable effects observed with Escitalopram are dry mouth, increased sweating, headache, par aesthesia, dizziness, nausea, diarrhoea, constipation, indigestion, abdominal pain, vomiting, flatulence, influenza-like symptoms, fatigue, insomnia, somnolence, decreased appetite, decreased libido, yawning, rhinitis, sinusitis, ejaculation disorder, impotence, anorgasmia and menstrual disorders. | Escitalopram 5mg, 10mg Tablet  Clonazepan 0.5mg, 10mg Tablet |   | প্রয়োজনীয় রেফারেপ<br>এবং পৃথকভাবে<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। | প্রয়োজনীয়<br>রেফারেঙ্গ এবং<br>পৃথকভাবে<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                        | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|----|--|----------------------------------|---|---------------------|---|---|--|---|--|--------------------|
| 7. | a) Beximco Pharmaceutical s Ltd. b) GLOBE PHARMACEU TICALS LTD. Bscic Industrial estate Begumgonj, noakhali c) Healthcare Pharmaceutical s Ltd. d) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka e) The IBN SINA Pharmaceutical s Industries Ltd. | Delafloxacin 300 mg IV injection | Each vial contains Delafloxacin meglumine INN 433 mg equivalent to Delafloxacin 300 mg injection. | Antibiotic          | Delafloxacin is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. To reduce the development of drug-resistant bacteria and maintain the effectiveness of delafloxacin and other antibacterial drugs, delafloxacin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. | Contraindications: Known hypersensitivity to Delafloxacin or other fluoroquinolone. Side effects: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |
| 8. | a) Beximco Pharmaceutical s Ltd. b) Drug International Ltd 252, Tongi I/A Tongi, Gazipur c) Healthcare Pharmaceutical s Ltd.   | Delafloxacin 450<br>mg Tablet    | Delafloxacin Meglumine<br>INN 649mg eq. to 450mg<br>Delafloxacin                                  | Antibiotic          | Delafloxacin is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following: Gram-Positive Organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates),  | Contraindication: Delafloxacin is contraindicated in patients with known hypersensitivity to Delafloxacin or any other components of this drug.  Side effects:The most common adverse reactions are nausea, diarrhea, headache, transaminase elevations and vomiting. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং | প্রস্তৃতকারকে<br>নাম  | ঔষধের নাম                                    | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নির্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                                | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত  |
|----|---|--|---|----------------------|---|---|---|---|--|---|
|    | d) Incepta Pharmaceutical s e) The IBN SINA Pharmaceutical s Industries Ltd. f) M/s. Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka g) GLOBE PHARMACEU TICALS LTD. Bscic Industrial estate Begumgonj, noakhali |  |   |                      | Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis. Gram-Negative Organisms: Escherichia coli, Enterobacter cloacae, Klebsiella pneumonia and Pseudomonas aeruginosa. |   |   |   |  |   |
| 9. | a) Beximco Pharmaceutical s Ltd., Tongi, Gazipur b) Genral Pharmaceutical s Ltd., Gazipur c) Healthcare Pharmaceutical s Ltd.   | Nebivolol 5mg +<br>Valsartan 80 mg<br>Tablet | Nebivolol Hydrochloride<br>INN 5.45mg eq. to 5mg<br>Nebivolol + Valsartan<br>USP 80mg | Antihypertensiv<br>e | is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.   | Contra-indication Severe bradycardia  • Heart block greater than first degree  • Patients with cardiogenic shock  • Decompensated cardiac failure • Sick sinus syndrome (unless a permanent pacemaker is in place)  • Patients with severe hepatic impairment (Child-Pugh >B)  • Hypersensitivity to any component of this product Side effects: Hypotension & Hyperkalemia | Nebivolol 2.5mg and 5.0mg Tablet  Valsartan 40mg, 80mg and 160mg Tablet | USFDA   | পৃথকভাবে অনুমোদিত<br>রয়েছে বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | পৃথকভাবে<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম                                      | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত                                   |
|-----|--|---|--|---------------------|--|--|--|---|---|--|
| 10. | a) Healthcare Pharmaceutical Itd., Rajendrapur, Gazipur b) EVEREST Pharmaceutical s Ltd. Kanchpur BSCIC, Soanragon, Narayanagnj BANGLADESH | Glecaprevir<br>100mg +<br>Pibrentasvir 40mg<br>Tablet | Glecaprevir INN 100mg<br>+ Pibrentasvir INN 40mg | Antiviral           | It is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both | Contraindications: Patients with severe hepatic impairment (Child-Pugh C). Coadministration with atazanavir and rifampin Adverse Reactions: The most commonly reported adverse reactions (greater than 10%) are headache and fatigue.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল ।                              |
| 11. | a) Healthcare Pharmaceutical s Ltd. b) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka  | Lesinurad 200mg<br>+ Allopurinol<br>200mg Tablet      | Lesinurad INN 200mg +<br>Allopurinol USP 200mg   | Antigout            | A combination of lesinurad, a URAT1 inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.  Limitations of Use: Lesinurad 200mg + Allopurinol 200mg Tablet is not recommended for the treatment of asymptomatic hyperuricemia.   | Contraindication: Severe renal impairment, end stage renal disease, kidney transplant recipients, or patients on dialysis.  Tumor lysis syndrome or Lesch-Nyhan syndrome.  Known hypersensitivity to allopurinol, including previous occurrence of skin rash.  Side effects: Most common adverse reactions in 12-month controlled clinical trials (occurring in greater than or equal to 2% of patients treated with lesinurad in combination with a xanthine oxidase inhibitor and more frequently than on oxidase inhibitor alone) were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease.  The most frequently reported adverse reaction for allopurinol is skin rash. | Allopurinol<br>100mg and<br>300mg Tablet | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)            | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত                                   |
|-----|--|--|---|---------------------|---|--|---|---|---|--|
| 12. | a) Healthcare Pharmaceutical s Ltd. b) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka                                | Lesinurad 200mg<br>+ Allopurinol<br>300mg Tablet     | Lesinurad INN 200mg +<br>Allopurinol USP 300mg  | Anti-Gout<br>Agent  | A combination of lesinurad, a URAT1 inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone  Limitations of Use: Lesinurad 200mg + Allopurinol 200mg Tablet is not recommended for the treatment of asymptomatic hyperuricemia.   | Contra-indication: Severe renal impairment, end stage renal disease, kidney transplant recipients, or patients on dialysis.  Tumor lysis syndrome or Lesch-Nyhan syndrome.  Known hypersensitivity to allopurinol, including previous occurrence of skin rash.  Side effects: Most common adverse reactions in 12-month controlled clinical trials (occurring in greater than or equal to 2% of patients treated with lesinurad in combination with a xanthine oxidase inhibitor and more frequently than on oxidase inhibitor alone) were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease. The most frequently reported adverse reaction for allopurinol is skin rash. | Allopurinol<br>100mg and<br>300mg Tablet            | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 13. | a) Healthcare Pharmaceutical s Ltd. b) Ziska Pharmaceutical s Ltd. c) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Meropenem 1.0 gm + Vaborbactam 1.0 gm/Vial Injection | Meropenem Trihydrate<br>USP 1.14gm eq. to<br>Anhydrous Meropenem<br>1.0 gm + Vaborbactam<br>INN 1.0 gm/Vial | Antibiotic          | It is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.  To reduce the development of drugresistant bacteria and maintain the effectiveness of this injection and other antibacterial drugs, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria | Contraindication: Known hypersensitivity to the components of this injection (meropenem and vaborbactam) or anaphylactic reactions to beta-lactams.  Side effects: The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.   | Meropenem<br>250mg, 500mg<br>and 1.0gm<br>Injection | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস     | নিৰ্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)             | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত   |
|-----|--|---|--|-------------------------|---|--|--|---|---|--|
| 14. | a) Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka b) Beacon Pharmaceutical s Ltd, Kathali, Bhaluka, Mymensingh | Dupilumab<br>300mg/2ml<br>Injection                   | Each prefilled syringe<br>contains Dupilumab INN<br>300mg/2ml                | Dermatological<br>Agent | It is indicated for the treatment of adult patients with moderate-to- severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.   | Contraindications: It is contraindicated in patients who have known hypersensitivity to dupilumab or any of its excipients.  Side Effects:  injection site reactions, pink eye (conjunctivitis), swollen or puffy eyelids, oral herpes, inflammation of the cornea (keratitis), eye itching, other herpes simplex virus infection, and dry eye.      | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 15. | a) Navana Pharmaceutical s Ltd b) IBN Sina Pharmaceutical s Ltd.   | Cetirizine<br>0.240gm/100ml<br>Ophthalmic<br>Solution | Cetirizine Hydrochloride<br>BP 0.290gm eq. to<br>Cetirizine<br>0.240gm/100ml | Antihistamine           | It is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.   | Contraindications: None  Adverse Reactions: The most common adverse reactions (1–7%) were ocular hyperemia, instillation site pain, and visual acuity reduced.   | 10 mg Tablet 5mg/5ml Syrup 2.5mg/ml Paediatric Drops | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 16. | a) Navana Pharmaceutical s Ltd b) Beacon Pharmaceutical s Ltd.   | Montelukast<br>80mg/100ml<br>suspension               | Montelukast Sodium<br>USP 83.00 mg eq. to<br>Montelukast 80mg/100ml          | Antiasthmatic           | it is a leukotriene receptor antagonist indicated for:  • Prophylaxis and chronic treatment of asthma in patients 12 months of age and older  • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older  • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older | Contraindications:Hypersensitivity to any component of this product Side effect:o Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis | 4mg, 5mg & 10<br>mg Tablet                           |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেপ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                       | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস        | নির্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত                                   |
|-----|--|---------------------------------|---|----------------------------|--|--|--|---|---|--|
| 17. | a) Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna   | Linaclotide<br>145mcg Capsule   | 0.09% Blended Pellets of<br>Linaclotide Ph. Grade<br>161.111mg contains<br>Linaclotide INN 145mcg | Gastrointestina<br>I Agent | This is a guanylate cyclase-C agonist indicated in adults for treatment of:  • Irritable bowel syndrome with constipation. (IBS-C) (1)  • Chronic idiopathic constipation. (CIC) (1)                                       | Contraindications:  •Patients less than 6 years of age due to the risk of serious dehydration.  • Patients with known or suspected mechanical gastrointestinal obstruction.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |
|     | b) Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur<br>c) Ziska<br>Pharmaceutical<br>s Ltd. |                                 |   |                            |  | Adverse reactions: Most common adverse reactions (≥2%) reported in IBS-C or CIC patients are: diarrhea, abdominal pain, flatulence and abdominal distension.   |  |   |   |  |
| 18. | a) Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna b) Ziska Pharmaceutical   | Linaclotide<br>290mcg Capsule   | 0.09% Blended Pellets of<br>Linaclotide Ph. Grade<br>322.222mg contains<br>Linaclotide INN 290mcg | Gastrointestina<br>I Agent | This is a guanylate cyclase-C agonist indicated in adults for treatment of:  • Irritable bowel syndrome with constipation. (IBS-C) (1)  • Chronic idiopathic constipation. (CIC) (1)                                       | Contraindications:  •Patients less than 6 years of age due to the risk of serious dehydration.  • Patients with known or suspected mechanical gastrointestinal obstruction.  Adverse reactions: Most common adverse reactions (≥2%) reported in IBS-C or CIC                           | New                                      | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামপ্তুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
|     | s Ltd.   |                                 |   |                            |  | patients are: diarrhea, abdominal pain, flatulence and abdominal distension.   |  |   |   |  |
| 19. | a) Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna b) Drug International Ltd 252, Tongi I/A                            | Obeticholic Acid<br>10mg Tablet | Obeticholic Acid INN<br>10mg  | Bile acid<br>analogue      | It is indicated for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. | Contraindications: Patients with complete biliary obstruction.  Adverse Reaction: Most common adverse reactions (≥ 5%) are: pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তৃতকারকে<br>নাম  | ঔষধের নাম                   | জেনেরিক নাম              | থেরাপিউটিক<br>ক্লাস   | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | কমিটির সভার               | সভার সিদ্ধান্ত     |
|-----|---|-----------------------------|--------------------------|-----------------------|--|--|--|---|---------------------------|--------------------|
|     | c) Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh   |                             |                          |                       |  |  |  |   |                           |                    |
| 200 | a) Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna  b) Drug International Ltd 252, Tongi I/A Tongi, Gazipur  c) EVEREST Pharmaceuticals Ltd. Kanchpur BSCIC, Soanragon, Narayanagnj BANGLADESH  D) Beacon Pharmaceuticals Ltd, Kathali, Bhaluka, Mymensingh e) Pharmasia Limited Gojariapara, BhawalMirzapur, Gazipur Sadar, Gazipur | Obeticholic Acid 5mg Tablet | Obeticholic Acid INN 5mg | Bile acid<br>analogue | This is indicated for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. | Contraindications: Patients with complete biliary obstruction.  Adverse Reaction: Most common adverse reactions (≥ 5%) are: pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema. | New                                      | USFDA   | অনুমোদন করা থেতে<br>পারে। | অনুমোদন করা<br>হল। |
| 21  | . a) Square   | Sodium Alginate             | Sodium Alginate BP       | Antacid               | It is indicated for the treatment of gastro-   | Contraindications: Hypersensitivity to the active  | Potassium                                | MHRA  | প্রয়োজন নেই বিধায়       | প্রয়োজন নেই       |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |                                  |                                  |
|-----|---|---|---|---------------------|--|---|---|---|----------------------------------|----------------------------------|
|     | Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna<br>b) Beximco<br>Pharmaceutical<br>s Ltd.                         | 5.0 gm + Sodium<br>Bicarbonate<br>2.13gm +<br>Calcium<br>Carbonate (light)<br>3.25gm/100ml<br>Oral Suspension | 5.0gm + Sodium<br>Bicarbonate BP 2.13gm<br>+ Calcium Carbonate BP<br>3.25gm / 100ml |                     | oesophageal reflux i.e. acid regurgitation, heartburn, indigestion (for example following meals or during pregnancy) and for symptoms of excess stomach acid (hyperacidity)  It acts in a dual mechanism mood, quickly neutralizes excess stomach acid and also forms a protective layer over stomach content  | substances or to any of the excipients, including the esters of hydroxybenzoates (parabens).  Side effects: Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions  | Bicarbonate<br>100mg +<br>Sodium<br>Alginate<br>500mg/5ml |   | আবেদন নামঞ্জুর করা<br>যেতে পারে। | বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 22. | a) UniMed & UniHealth Mfg. Ltd. B.K, Bari Gazipur Sadar, Gazipur b) Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna | Deflazacort 30mg<br>Tablet  | Deflazacort INN 30mg  | Glucocorticoid      | Asthma and other airway Diseases, Rheumatoid arthritis, juvenile chronic arthritis, pemphigus, uveitis, nephritic, syndrome,Immune suppression in transplantation, anaphylaxis, severe,hypersensitivity reactions, dermatomyositis, mixed connective, tissue disease, polyarteritis nodosa, bullous pemphigoid, ulcerative colitis, optic neuritis, autoimmune haemolytic anaemia, idiopathic, thrombocytopenic, purpura, acute and lymphatic leukaemia, malignant lymphoma. | Contraindications: Systemic infection; live virus vaccines in those receiving immunosuppressive doses.  Side Effects: Gl disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.   | 6mg, 24mg<br>Tablet<br>&<br>120mg/100ml<br>Suspention     | USDFA   | অনুমোদন করা যেতে<br>পারে।        | অনুমোদন করা<br>হল।               |
| 23. | ACI Limited, 7<br>Hajeegonj<br>Road, Godnyl,<br>Narayangonj   | Beclomethasone<br>dipropionate 50<br>mcg / puff<br>200 metered dose<br>HFA Inhaler                            | Beclomethasone<br>dipropionate BP 50 mcg<br>/ puff (actuation)                      | Antiasthmatic       | It is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.Beclomethasone dipropionate is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone dipropionate may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is not indicated for the relief of acute bronchospasm.                                     | Contraindications: Hypersensitivity to Beclomethasone inhaler is a contraindication; and special care is necessary in patients with active or quiescent pulmonary tuberculosis. Side Effects: Beclomethasone dipropionate HFA inhalation aerosol has been found generally well tolerated in the extensive clinical development program. The adverse effects that occurred in a very few patients are headache, URTI, rhinitis, sinusitis, pain, back pain, nausea, dysphonia etc. No patients in the clinical development program developed symptomatic oropharyngeal candidiasis with HFA Beclomethasone. If it occurs, it can be treated with topical antifungal therapy whilst | 100mcg,<br>200mcg,<br>250mcg,<br>400mcg Inhaler           | BNF- 74<br>Page: 250                            | অনুমোদন করা যেতে<br>পারে।        | অনুমোদন করা<br>হল।               |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস    | নিৰ্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত      |
|-----|---|---|--|------------------------|---|--|--|---|--|---------------------|
|     |   |   |  |                        |   | still continuing with the Beclometasone dipropionate HFA inhaler. In some patients, inhaled Beclomethasone dipropionate may cause hoarseness or throat irritation. It may be helpful to rinse mouth with water immediately after inhalation.  As with other inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind.   |  |   |  |                     |
| 24. | ACI Limited, 7<br>Hajeegonj<br>Road, Godnyl,<br>Narayangonj | Methoxy polyethylene glycol-epoetin beta 100mcg /0.3 ml Prefilled syringe | Methoxy polyethylene glycol-epoetin beta ready to fill sterile solution Ph. Grade 0.300 ml eq. to 100mcg of Methoxy polyethylene glycol-epoetin beta INN | Hematopoietic<br>Agent | It is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. It is not indicated for the treatment of anemia due to cancer chemotherapy. | Contraindications: Uncontrolled hypertension, History of hypersensitivity to the drug.  Side Effects: The most common adverse reactions are hypertension, diarrhea, nasopharyngitis, headache, and upper respiratory tract infection.  Warnings and Precautions Hypertension: Do not treat patients with uncontrolled hypertension. Monitor blood pressure throughout course. Stop as necessary, Seizures: During the first several months of therapy. Adjust dose or therapy, closely monitor blood pressure and the presence of premonitory neurologic symptoms.  Pure Red Cell Aplasia (PRCA): If fantierythropoietin antiboardy associated anemia is suspected, discontinue this drug.  Serious allergic reactions: Discontinue treatment if serious reaction occur Predialysis patients may require lower maintenance doses than patients receiving dialysis. Marginally dialyzed patients may require adjustments in dialysis. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল । |
| 25. | ACI Limited, 7  | Methoxy   | Methoxy polyethylene   | Hematopoietic<br>Agent | It is an erythropoiesis-stimulating agent   | Contraindications:   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।  |

| নং  | প্রস্তুতকারকে<br>নাম                      | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস            | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|---|---|---|--------------------------------|---|---|--|---|---|--|
|     | Hajeegonj<br>Road, Godnyl,<br>Narayangonj | polyethylene<br>glycol-epoetin<br>beta 50mcg / 0.3<br>ml Prefilled<br>syringe | glycol-epoetin beta ready to fill sterile Solution Ph. Grade 0.300 ml eq. to 50 mcg of Methoxy polyethylene glycol-epoetin beta INN |                                | (ESA) indicated for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. It is not indicated for the treatment of anemia due to cancer chemotherapy. | Uncontrolled hypertension, History of hypersensitivity to the drug. Side Effects: The most common adverse reactions are hypertension, diarrhea, nasopharyngitis, headache, and upper respiratory tract infection. Warnings and Precautions Hypertension: Do not treat patients with uncontrolled hypertension. Monitor blood pressure throughout course. Stop as necessary, Seizures: During the first several months of therapy. Adjust dose or therapy, closely monitor blood pressure and the presence of premonitory neurologic symptoms. Pure Red Cell Aplasia (PRCA): If fantierythropoietin antiboardy associated anemia is suspected, discontinue this drug. Serious allergic reactions: Discontinue treatment if serious reaction occur Predialysis patients may require lower maintenance doses than patients receiving dialysis. Marginally dialyzed patients may require adjustments in dialysis. |  |   |   |  |
| 26. | Acme<br>Laboratorie                       | Codeine<br>Phosphate<br>(Anhydrous) 54.30                                     | Codeine Phosphate<br>(Anhydrous) USP 54.30<br>mg + Chlorpheniramine<br>Maleate USP 8 mg   | Antitussive +<br>Antihistamine | It is indicated for the relief of cough & symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age & older.  | Contraindication: It is contraindicated in postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. Patients with known   | Chlorphenira<br>mine Maleate<br>4.0mg    | USFDA<br>(Discontinue<br>d)                     | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
|     | s Ltd.,<br>Dhamrai,<br>Dhaka              | mg +<br>Chlorpheniramine<br>Maleate 8 mg<br>Extended Release<br>Tablet        | ivialeate USF of Hig  |                                | adults to years of age & older.   | hypersensitivity to codeine phosphate 54.3 mg/chlorpheniramine maleate 8 mg extended release tablet. Persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to it.  Side effects: Allergic reactions may be seen. Increased appetite, palpitations, hypoglycemia, nausea & vomiting etc. also may be seen.   |  |   |   |  |
| 27. | Aristopharma                              | Afatinib 40 mg  | Afatinib Dimaleate INN  | Anticancer                     | Afatinib is a kinase inhibitor indicated for:   | Contra-indication: None   | New                                      | USFDA,  | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|-----|---|--|--|---------------------|--|--|--|---|--|--|
|     | Ltd. Plot No.21, Road No.11, Shampur- Kadamtali I/A Dhaka-1204                                | Film Coated<br>Tablet  | 59.12mg Eqv.to Afatinib<br>40 mg   |                     | First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epiderma I growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have other EGFR mutations.  Treatment of patients with metasta tic, squamous NSCLC progressing after platinum-based chemotherapy. | Side-effect: Afatinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) that has spread (metastasized), whose tumors have a genetic mutation called epidermal growth factor receptor (EGFR). Common side effects of Afatinib include: diarrhea, rash, blisters or other skin lesions or reactions, inflammation of the mouth and lips, chapped lips, mouth sores, infection of the skin around fingernails or toenails, dry skin, acne, decreased appetite, weight loss, nausea, vomiting, itching, urinary tract or bladder infection, bloody nose, runny nose, fever, or pinkeye conjunctivitis).  |  | BNF-74<br>Page-892                              |  |  |
| 28. | Aristopharma<br>Ltd.<br>Plot No.21,<br>Road No.11,<br>Shampur-<br>Kadamtali I/A<br>Dhaka-1204 | Biotin 5 mg + Copper 2 mg + Manganese 5 mg + Selenium 40 mcg + Zinc 25 mg Film Coated Tablet | Biotin BP 5 mg + Cupric Oxide Ph. Gr. 2.505 mg Eqv.to Copper 2 mg + Manganese Sulphate Monohydrate BP 15.380 mg Eqv.to Manganese 5 mg + Sodium Selenate Ph. Gr. 96 mg Eqv.to Selenium 40 mcg + Zinc Oxide BP 31.120 mg Eqv.to Zinc 25 mg | Vitamin & Minerals  | It is indicated for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:  Hair loss Skin and hair growth Healthy nervous system and bone marrow maintenance Biotin deficiency in pregnancy Long-term tube feeding Malnutrition Rapid weight loss Copper deficiency Wound healing Osteoarthritis Brittle bones Manganese deficiency Osteoporosis Diseases of the heart and blood vessels Stroke                                    | Contra-indication: These tablets are contraindicated in patients with a history of hypersensitive reaction to Biotin, Cupric Oxide, Manganese Sulphate Monohydrate, Sodium Selenate and Zinc Oxide. In addition, the mentioned tablet should not be sued in the following conditions:  Fertility problems in men  High doses  Higher doses  Hypersensitivity  Inhalation by children  Large amounts Side-effect: The various reported side effects of the drug are  Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required  Nausea  Vomiting  Bloody diarrhea | New                                      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামজুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস          | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|-----|---|---|--|------------------------------|--|---|--|---|--|--|
|     |   |   |  |                              | <ul> <li>Hardening of the arteries</li> <li>Cancer of the prostate</li> <li>Stomach cancer</li> <li>Lung cancer</li> <li>Zinc deficiencies</li> <li>Diarrhea in malnutrition children</li> <li>Wilson's disease</li> </ul> | <ul><li>Fever</li><li>Stomach pain</li></ul>  |  |   |  |  |
| 29. | Aristopharma<br>Ltd.<br>Plot No.21,<br>Road No.11,<br>Shampur-<br>Kadamtali I/A<br>Dhaka-1204 | Carboxymethylcell<br>ulose Sodium<br>0.5gm + Glycerin<br>0.90gm + Sodium<br>Hyaluronate<br>0.1gm/100ml<br>Sterile Eye Drops | Carboxymethylcellulose<br>Sodium USP 0.5gm +<br>Glycerin BP 0.90gm +<br>Sodium Hyaluronate BP<br>0.1gm/100ml | Artificial tear<br>Lubricant | It is used for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or due to exposure to wind or sun. It may be used as a protectant against further irritation.                         | Contra-indication: It is contraindicated in patients with hypersensitivity to any ingredients in this product. Side-effect: Allergic reaction, Blurred vision, Eye discharge, Eye irritation, Eye itching, Eye pain, Foreign body sensation in eyes, Increased production of tears, Eye redness, Visual impairment.   | Carboxymethyl cellulose Sodium 0.5% + Glycerin 0.9% Sterile Eye Drops  Sodium Hyaluronate 0.1% Sterile Eye Drops |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।   |
| 30. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh                      | Acotiamide<br>Hydrochloride<br>100mg Tablet   | Acotiamide Hydrochloride Hydrate INN 111.097mg eq. to Acotiamide Hydrochloride 100 mg                        | Antiemetic                   | Acotiamide is indicaled for the treatment of bloating after meals. epigastricbloating and early satiety in functional dyspepsia  | Contra-indication: Acotiamide is contraindicated in individuals who have shown hypersensitivity to Acotiamide Hydrochloride hydrate & any of its inactive ingredients.  SIDE EFFECT: In clinical studies involving functional dyspepsia patients, the incidence of adverse events was comparable between Acotiamide and placebo. The most common adverse reactions reported are diarrhea (2.1%) and Constipation (1.6%), Nausea (.08%) and vomiting (.5%). If following adverse reactions are noted Acotiamide is indicated for the treatment of bloating after meals. epigastricbloating and early satiety in functional | New  |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস       | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|--|---|--|---------------------------|--|---|---|---|---|--|
|     |  |   |  |                           |  | dyspepsia, administration should be discontinued and appropriate measures must be taken according to symptoms.  |   |   |   |  |
| 31. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Butamirate Citrate<br>0.08gm<br>+Guaifenesin<br>2.00gm/100ml<br>syrup | Butamirate Citrate INN<br>0.08gm + Guaifenesin<br>USP 2.00gm/100ml               | Expectorant               | Symptomatic treatment of cough of various origins  | Contra-indication Hypersensitivity to Butamirate citrate or to any of the ingredients Side-effect Butamirate is usually well tolerated. The most common side include:  Central nervous system (CNS): dizziness (1%) Digestive system: nausea, diarrhea Allergic reactions: skin rash and itching(in rare cases)   | Butamirate citrate 50mg Tablet, 150mg/100ml syrup & Dextromethorp han Hydrobromide 300 mg + Guaiphenesin 4 gm + Menthol 300 mg/100 ml Syrup |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 32. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Elemental<br>Lanthanum 500<br>mg chewable<br>Tablet                   | Lanthanum Carbonate<br>Hydrate INN 945.00mg<br>eq. to Elemental<br>Lanthanum 500 | Antihyperphos<br>phatemia | It is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).  | Contraindications: Bowel obstruction, ileus, and fecal impaction  Side Effects: In controlled trials, the most common adverse reactions that were more frequent (> 5% difference vs. placebo) in FOSRENOL were nausea, vomiting and abdominal pain • The following adverse reactions have been identified during post-approval use of FOSRENOL: constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet | New   | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 33. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Fosaprepitant<br>150mg/Vial<br>Injection as<br>Lyophilized<br>Powder  | Fosaprepitant Dimeglumine INN 245.30mg eq. to Fosaprepitant 150mg/Vial           | Antiemetic                | This for injection is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of (1): • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose | Contraindications: Known hypersensitivity to any component of this drug. Concurrent use with pimozide  Side Effects: Most common adverse reactions (≥2%) are: fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy,  | Fosaprepitant<br>115mg/Vial<br>Sterile<br>Lyophilized<br>Powder for<br>Injection  | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                               | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস       | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত               |
|-----|--|---|---|---------------------------|---|---|--|---|--|------------------------------|
|     |  |   |   |                           | cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use (1) • EMEND has not been studied for treatment of established nausea and vomiting. | leukopenia, dyspepsia, urinary tract infection, pain in extremity   |  |   |  |                              |
| 34. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Lanthanum 1000<br>mg chewable<br>Tablet | Lanthanum Carbonate<br>Hydrate INN<br>1908.00mg eqv. to<br>Elemental Lanthanum<br>1000 mg | Antihyperphos<br>phatemia | It is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).   | Contraindications: Bowel obstruction, ileus, and fecal impaction Side Effects: In controlled trials, the most common adverse reactions that were more frequent (> 5% difference vs. placebo) in FOSRENOL were nausea, vomiting and abdominal pain • The following adverse reactions have been identified during post-approval use of FOSRENOL: constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।           |
| 35. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Lanthanum 750<br>mg chewable<br>Tablet  | Lanthanum Carbonate<br>Hydrate INN 1431.00mg<br>eq. to Elemental<br>Lanthanum 750 mg      | Antihyperphos<br>phatemia | It is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).   | Contraindications: Bowel obstruction, ileus, and fecal impaction  Side Effects: In controlled trials, the most common adverse reactions that were more frequent (> 5% difference vs. placebo) in FOSRENOL were nausea, vomiting and abdominal pain • The following adverse reactions have been identified during post-approval use of FOSRENOL: constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।           |
| 36. | Beacon<br>Pharmaceutical   | Methotrexate<br>1000mg/10ml             | Methotrexate BP 1000mg/10ml   | Anticancer                | Acute leukemias, non-hodgkin's lymphoma, soft-tissue and osteogenic sarcomas and  | Contra-indication: Pregnant psoriatic patients should not receive methotrexate. Psoriatic   | 2.5mg & 10mg<br>Tablet                   |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন  | প্রয়োজনীয়<br>রেফারেন্স নেই |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                              | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                                     | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |  |
|-----|--|--|---|---------------------|--|---|--|---|---|--|
|     | s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh                             | injection                              |   |                     | solid tumors particularly breast, lung, head and neck, bladder, cervical, ovarian and testicular carcinoma.  Methotrexate is also indicated in moderate to severe rheumatoid arthritis, psoriasis and effective in the treatment of advanced stages (III and IV Peters Staging System) of lymphosarcoma, particularly in those cases in children; and in advanced cases of mycosis fungoides | patients with severe renal or hepatic disorders should not receive methotrexate.  Psoriatic patients with pre-existing blood dyscrasias, such as marrow hypoplasia, leukopenia, thrombocytopenia or anaemia, should not receive methotrexate.  SIDE EFFECT: The most common adverse reactions include ulcerative stomatitis, leukopenia, nausea and abdominal distress. Others reported are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection. In general, the incidence and severity of side-effects are considered to be dose-related. Adverse reactions as reported for the various systems are as follows:  Skin Erythematous rashes, pruritus, urticaria, photosensitivity, depigmentation, alopecia, ecchymosis, telangiectasia, acne, furunculosis. Lesions of psoriasis may be aggravated by concomitant exposure to ultraviolet radiation.  Blood Bone marrow depression, leukopenia, thrombocytopenia, anaemia, hypogammaglobulinaemia, haemorrhage from various sites, septicaemia | 1% & 10% IV Infusion  2 mg/ml Injection  50mg/vial injection                 |   | নামজুর করা যেতে<br>পারে।  | বিধায় আবেদন<br>নামঞ্জুর করা হল।                                 |
| 37. | Beacon<br>Pharmaceutical<br>s Ltd,<br>Kathali,<br>Bhaluka,<br>Mymensingh | Palonosetron<br>0.005gm/100ml<br>Syrup | Palonosetron Hydrochloride INN 0.0056gm eqv to palonosetron 0.005gm/100ml | Antiemetic          | Indicated for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.  | Contra-indication: Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components Side-effect: The following adverse reactions were reported for palonosetron: Nervous System: <1%: headache, dizziness,   | 0.5mg Tablet &<br>Capsule<br>0.25 mg/vial<br>Injection<br>0.075 mg/1.5<br>ml |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| ন  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                               | সভার সিদ্ধান্ত   |
|----|---|---|---|---------------------|---|---|---|---|--|--|
|    |   |   |   |                     |   | dyskinesia.  General: <1%: infusion site pain.  Dermatological: <1%: allergic dermatitis, skin disorder.  |   |   |  |  |
| 38 | Beacon Pharmaceutical s Ltd, Kathali, Bhaluka, Mymensingh | Risperidone 3mg<br>+ Trihexyphenidyl<br>Hydrochloride<br>2mg Tablet | Risperidone USP 3mg + Trihexyphenidyl Hydrochloride USP 2mg | Antipsychotic       | It can be used in the treatment of schizophrenia, bipolar disorder and behavior problems associated with Aspergers syndrome in patients diagnosed with autism. Some patients may also use the medication in the treatment and management of Parkinson's disease | CONTRAINDICATION: Risperidone + Trihexyphenidyl and Pregnancy USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are in gestation or planning to have a baby during Risperidone + trihexyphenidyl treatment. Risperidone + Trihexyphenidyl and Lactation It is not known whether Risperidone + trihexyphenidyl can pass through the breast milk or not. Nursing mothers should avoid breastfeeding while taking Risperidone + trihexyphenidyl SIDE EFFECT A list of some side effects which have been reported by patients taking Risdone-Plus (Risperidone/Trihexyphenidyl HCL) is provided here:  Dry mouth Weight gain Dizzy sensation Skin discoloration Production of breastmilk Promptly inform your physician of any side effects that occur during treatment. Consult your physician straight away if you notice uncontrolled bodily movements, muscular stiffness, painful eyes, hallucinations, flu symptoms or any other symptoms that indicate you may be suffering from a severe reaction. | Trihexyphenidyl Hydrochloride 2mg, 5mg Tablet 40mg/100ml syrup Risperidone 1mg, 2mg, 4mg Tablet |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামপ্তুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেঙ্গ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 39 |   | Brodalumab  | Brodalumab INN  | Antipsoriatic       | It is a human interleukin-17 receptor A (IL-  | Contraindication: Crohn's disease   | New   | USFDA   | অনুমোদন করা যেতে   | অনুমোদন করা  |
|    | Pharmaceutical  | 210mg/1.5ml Pre-  | 210mg/1.5ml   |                     | 17RA) antagonist indicated for the  | Side effect: Most common adverse reactions  |   |   | পারে।  | হল।  |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম                                       | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                       | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | কমিটির সভার   | সভার সিদ্ধান্ত                                   |
|-----|---|---|--|---------------------|--|---|--|---|---|--|
|     | s Ltd, Kathali,<br>Bhaluka,<br>Mymensingh                             | Filled syringe                                  |  |                     | treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies  | (incidence ≥1%) were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections   |  |   |   |  |
| 40. | Beacon<br>Pharmaceutical<br>s Ltd, Kathali,<br>Bhaluka,<br>Mymensingh | Elemental Iron<br>1000mg/10ml<br>vial           | Iron Isomaltoside<br>1000 INN 3846.00mg<br>eqv. to Elemental<br>Iron 1000mg/10ml<br>vial | Mineral             | Iron isomaltoside is indicated for the treatment of iron deficiency in the following conditions:  • When oral iron preparations are ineffective or cannot be used  • Where there is a clinical need to deliver iron rapidly  | CONTRAINDICATIONS  Non-iron deficiency anaemia, Iron overload or disturbances in utilisation of iron, Hypersensitivity to any of the ingredients, Decompensated liver cirrhosis and hepatitis, or known serious hypersensitivity to other parental iron product  SIDE EFFECT  The severe or irreversible adverse effects of Iron isomaltoside, which give rise to further complications include Hypersensitivity reactions. The symptomatic adverse reactions produced by Iron isomaltoside are more or less tolerable and if they become severe, they can be treated symptomatically, these include Difficulty to swallow, swollen face, tongue or pharynx, difficulty to swallow, hives and difficulties to breath. | Elemental iron 50mg/2.5 ml , 100mg/5ml, 27.2 mg/5 ml Injection | BNF-74<br>Page:<br>932                          | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 41. | Beacon<br>Pharmaceutical<br>s Ltd, Kathali,<br>Bhaluka,<br>Mymensingh | Sarilumab<br>150mg/1.14ml<br>Pre-filled Syringe | Sarilumab INN<br>150 mg/1.14 ml  | Antirheumatic       | It is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs) | Contraindication:it is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients Side effect: Most common adverse reactions (incidence at least 3%) are neutropenia, increased ALT, injection site erythema, upper respiratory infections and urinary tract infections  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |
| 42. | Beacon<br>Pharmaceutical<br>s Ltd, Kathali,                           | Sarilumab<br>200mg/1.14ml<br>Pre-filled Syringe | Sarilumab INN<br>200mg/1.14 ml   | Antirheumatic       | It is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of adult patients with moderately to severely  | Contraindication:it is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients Side effect: Most  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস                       | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                            | সভার সিদ্ধান্ত   |
|-----|-------------------------------------|--|---|---|---|--|---|---|---|--|
|     | Bhaluka,<br>Mymensingh              |  |   |   | active rheumatoid arthritis who have had<br>an inadequate response or intolerance to<br>one or more disease-modifying<br>antirheumatic drugs (DMARDs)   | common adverse reactions (incidence at least 3%) are neutropenia, increased ALT, injection site erythema, upper respiratory infections and urinary tract infections  |   |   |   |  |
| 43. | Beximco<br>Pharmaceutical<br>s Ltd. | Aspirin 100mg +<br>glycine 45 mg<br>Tablet                   | Aspirin USP 100 mg +<br>Glycine BP 45 mg                        | Antiplatelet and<br>Fibrinolytic<br>agent | Prophylaxis against strokes and heart attacks.  | Special Precautions: Avoid taking Aspirin/Glycine 100 if hypersensitive to aspirin or using medications eg, anticoagulants or gastric irritants. Discontinue taking any form of aspirin 1 week before surgery. Use in children: The combination is not recommended for children and adolescents.   | Aspirin 75mg,<br>100mg & 300<br>mg tablet |   | প্রয়োজনীয় রেফারেস<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 44. | Beximco<br>Pharmaceutical<br>s Ltd. | Empagliflozin 12.5mg + Metformin Hydrochloride 1000mg Tablet | Empagliflozin INN 12.5mg + Metformin Hydrochloride BP 1000mg    | Antidiabetic                              | It is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of SYNJARDY on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.  Limitations of Use: Not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis | Hypersensitivity to the active substances or to any of the excipients.  • Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)  • Diabetic pre-coma.  • Severe renal failure (GFR <30 ml/min).  • Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.  • Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.  • Hepatic impairment, acute alcohol intoxication, alcoholismAdverse reactions: Most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache | Empagliflozin<br>10mg & 25 mg<br>Tablet   | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামপ্তুর করা<br>যেতে পারে।               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।               |
| 45. | Beximco<br>Pharmaceutical<br>s Ltd. | Empagliflozin 5mg<br>+ Metformin<br>Hydrochloride            | Empagliflozin INN 5mg +<br>Metformin Hydrochloride<br>BP 1000mg | Antidiabetic                              | It is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride, a  | Hypersensitivity to the active substances or to any of the excipients.  • Any type of acute metabolic acidosis (such as  | Empagliflozin<br>10mg & 25 mg<br>Tablet   | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।               |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম                                 | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|-------------------------------------|---|---|----------------------|--|---|--|---|---|--|
|     |                                     | 1000mg Tablet                             |   |                      | biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of SYNJARDY on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.  Limitations of Use: Not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis | lactic acidosis, diabetic ketoacidosis)  Diabetic pre-coma.  Severe renal failure (GFR <30 ml/min).  Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.  Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.  Hepatic impairment, acute alcohol intoxication, alcoholism  Adverse reactions: Most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections.  Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache |  |   |   |  |
| 46. | Beximco<br>Pharmaceutical<br>s Ltd. | Nebivolol 20 mg<br>Tablet                 | Nebivolol Hydrochloride<br>INN 21.780mg eq. to 20<br>mg Nebivolol | Antihypertensiv<br>e | It is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.   |   | 2.5mg & 5mg<br>Tablet                    | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 47. | a) Beximco<br>Pharmace<br>uticals   | Nebivolol 5mg +<br>Hydrochlorthiazid<br>e | Nebivolol Hydrochloride<br>INN 5.450mg eq. to 5mg<br>Nebivolol +  | Antihypertensiv<br>e | Treatment of essential hypertension.<br>Nebivolol / Hydrochlorothiazide 5 mg/12.5<br>mg fixed dose combination is indicated in   | Contraindications: - Hypersensitivity to the active substances or to any of the excipients  | Nebivolol<br>2.5mg, 5mg<br>Tablet,       | MHRA  | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম      | জেনেরিক নাম                     | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | সভার সিদ্ধান্ত |
|----|--|----------------|---------------------------------|---------------------|--|---|---|---|----------------|
|    | Ltd.  b) Square Pharmace uticals Ltd., Pabna Unit, Salgaria, Pabna | 12.5 mg Tablet | Hydrochlorothiazide BP 12.50 mg |                     | patients whose blood pressure is adequately controlled on nebivolol 5 mg and hydrochlorothiazide 12.5 mg given concurrently. | - Hypersensitivity to other sulphonamide-derived substances - Liver insufficiency or liver function impairment Anuria, severe renal insufficiency (creatinine clearance < 30 ml/min.) Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy Sick sinus syndrome, including sino-atrial block Second and third degree atrioventricular block (without a pacemaker) Bradycardia (heart rate < 60 bpm prior to start therapy) Hypotension (systolic blood pressure < 90 mmHg) Severe peripheral circulatory disturbances History of bronchospasm and bronchial asthma Untreated phaeochromocytoma Metabolic acidosis Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia  Undesirable effects:  Nebivolol The adverse reactions reported following administration of nebivolol alone, the common are- headache, dizziness, paraesthesia, dyspnoea, constipation, nausea, diarrhoea, tiredness, oedema. | Hydrochlorothia zide 12.5mg, 25 mg Tablet | / WITHA RET.                                    |                |
|    |  |                |                                 |                     |  | Hydrochlorothiazide: The adverse events that have been reported with the use of hydrochlorothiazide alone include the following: Blood and lymphatic system disorders: leukopenia, neutropenia, agranulocytosis, thrombocytopenia, aplastic anaemia,  |   |   |                |

| নং | প্রস্তুতকারকে<br>নাম | ঔষধের নাম | জেনেরিক নাম | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|----|----------------------|-----------|-------------|---------------------|-----------|--|--|---|--|----------------|
|    |                      |           |             |                     |           | haemolytic anaemia, bone marrow failure. Immune system disorders: anaphylactic reaction. Metabolism and nutritional disorders: anorexia, dehydration, gout, diabetes mellitus, metabolic alkalosis, hyperuricaemia, electrolyte imbalance (including hyponatraemia, hypokalaemia, hypomagnesaemia, hypochloraemia, hypercalcaemia), hyperglycaemia, hyperamylasaemia. Psychiatric disorders: apathy, confusional state, depression, nervousness, restlessness, sleep disorder. Nervous system disorders: convulsions, depressed level of consciousness, coma, headache, dizziness, paraesthesia, paresis. Eye disorders: xanthopsia, blurred vision, myopia (aggravated), lacrimation decreased. Ear and labyrinth disorders: vertigo. Cardiac disorders: cardiac arrhythmias, palpitations. Vascular disorders: orthostatic hypotension, thrombosis, embolism, shock Respiratory, thoracic and mediastinal disorders: respiratory distress, pneumonitis, interstitial lung disease, pulmonary oedema. Gastrointestinal disorders: dry mouth, nausea, vomiting, stomach discomfort, diarrhoea, constipation, abdominal pain, ileus paralytic, flatulence, sialoadenitis, pancreatitis. Hepatobiliary disorders: jaundice cholestatic, cholecystitis. Skin and subcutaneous tissue disorders: pruritus, purpura, urticaria, photosensitivity reaction, rash, cutaneous lupus erythematosus, vasculitis necrotising, toxic epidermal necrolysis. Musculoskeletal, connective tissue and bone disorders: muscle spasms, myalgia. Renal and urinary disorders: | Existing)                                | / MHRA Ref.                                     |  |                |
|    |                      |           |             |                     |           | renal impairment, renal failure acute, nephritis interstitial, glycosuria. Reproductive system and breast disorders: erectile dysfunction.   |  |   |  |                |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                                | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত                                   |
|-----|-------------------------------------|---|--|----------------------|---|---|---|---|---|--|
|     |                                     |   |  |                      |   | General disorders and administration site conditions: asthenia, pyrexia, fatigue, thirst. Investigations: electrocardiogram change, blood cholesterol increased, blood triglycerides increased.   |   |   |   |  |
| 48. | Beximco<br>Pharmaceutical<br>s Ltd. | Nebivolol 10 mg<br>Tablet                             | Nebivolol Hydrochloride<br>INN 10.890mg eq. to<br>10mg Nebivolol                           | Antihypertensiv<br>e | It is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.      | Contraindications:     Severe bradycardia   | 2.5mg & 5mg<br>Tablet   | USFDA<br>MHRA                                   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |
| 49. | Beximco<br>Pharmaceutical<br>s Ltd. | Nebivolol 5mg +<br>Hydrochlorthiazid<br>e 25mg Tablet | Nebivolol Hydrochloride INN 5.445mg eq. to 5mg Nebivolol + Hydrochlorothiazide BP 25.00 mg | Antihypertensiv e    | Treatment of essential hypertension. Nebivolol / Hydrochlorothiazide 5 mg/12.5 mg fixed dose combination is indicated in patients whose blood pressure is adequately controlled on nebivolol 5 mg and hydrochlorothiazide 12.5 mg given concurrently. | Contraindications: - Hypersensitivity to the active substances or to any of the excipients - Hypersensitivity to other sulphonamidederived substances - Liver insufficiency or liver function impairment Anuria, severe renal insufficiency (creatinine clearance < 30 ml/min.) Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy Sick sinus syndrome, including sino-atrial block Second and third degree atrioventricular block (without a pacemaker) Bradycardia (heart rate < 60 bpm prior to start therapy) Hypotension (systolic blood pressure < 90 mmHg) Severe peripheral circulatory disturbances History of bronchospasm and bronchial asthma Untreated phaeochromocytoma. | Nebivolol 2.5mg, 5mg Tablet,  Hydrochlorothia zide 12.5mg, 25 mg Tablet | MHRA  | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং | প্রস্তুতকারকে ঔষধের | নাম জেনেরিক নাম | থেরাপিউটিক | নির্দেশনা | Contra-indication &                              | Status    |             | টেকনিক্যাল সাব | সভার সিদ্ধান্ত |
|----|---------------------|-----------------|------------|-----------|--|-----------|-------------|----------------|----------------|
|    | নাম                 |                 | ক্লাস      |           | Side-effect                                      | (New      | কর্তৃক      | কমিটির সভার    |                |
|    |                     |                 |            |           |  | Molecule/ | USFDA/BNF   | সিদ্ধান্ত      |                |
|    |                     |                 |            |           |  | Existing) | / MHRA Ref. |                |                |
|    |                     |                 |            |           | - Refractory hypokalaemia, hypercalcaemia,       | <u></u>   |             |                |                |
|    |                     |                 |            |           | hyponatraemia and symptomatic                    |           |             |                |                |
|    |                     |                 |            |           | hyperuricaemia                                   |           |             |                |                |
|    |                     |                 |            |           | ,  |           |             |                |                |
|    |                     |                 |            |           | Undesirable effects:                             |           |             |                |                |
|    |                     |                 |            |           |  |           |             |                |                |
|    |                     |                 |            |           | Nebivolol The adverse reactions reported         |           |             |                |                |
|    |                     |                 |            |           | following administration of nebivolol alone, the |           |             |                |                |
|    |                     |                 |            |           | common are- headache, dizziness,                 |           |             |                |                |
|    |                     |                 |            |           | paraesthesia, dyspnoea, constipation, nausea,    |           |             |                |                |
|    |                     |                 |            |           | diarrhoea, tiredness, oedema.                    |           |             |                |                |
|    |                     |                 |            |           |  |           |             |                |                |
|    |                     |                 |            |           | Hydrochlorothiazide: The adverse events that     |           |             |                |                |
|    |                     |                 |            |           | have been reported with the use of               |           |             |                |                |
|    |                     |                 |            |           | hydrochlorothiazide alone include the following: |           |             |                |                |
|    |                     |                 |            |           | Blood and lymphatic system disorders:            |           |             |                |                |
|    |                     |                 |            |           | leukopenia, neutropenia, agranulocytosis,        |           |             |                |                |
|    |                     |                 |            |           | thrombocytopenia, aplastic anaemia,              |           |             |                |                |
|    |                     |                 |            |           | haemolytic anaemia, bone marrow failure.         |           |             |                |                |
|    |                     |                 |            |           | Immune system disorders: anaphylactic            |           |             |                |                |
|    |                     |                 |            |           | reaction. Metabolism and nutritional disorders:  |           |             |                |                |
|    |                     |                 |            |           | anorexia, dehydration, gout, diabetes mellitus,  |           |             |                |                |
|    |                     |                 |            |           | metabolic alkalosis, hyperuricaemia, electrolyte |           |             |                |                |
|    |                     |                 |            |           | imbalance (including hyponatraemia,              |           |             |                |                |
|    |                     |                 |            |           | hypokalaemia, hypomagnesaemia,                   |           |             |                |                |
|    |                     |                 |            |           | hypochloraemia, hypercalcaemia),                 |           |             |                |                |
|    |                     |                 |            |           | hyperglycaemia, hyperamylasaemia.                |           |             |                |                |
|    |                     |                 |            |           | Psychiatric disorders: apathy, confusional       |           |             |                |                |
|    |                     |                 |            |           | state, depression, nervousness, restlessness,    |           |             |                |                |
|    |                     |                 |            |           | sleep disorder. Nervous system disorders:        |           |             |                |                |
|    |                     |                 |            |           | convulsions, depressed level of consciousness,   |           |             |                |                |
|    |                     |                 |            |           | coma, headache, dizziness, paraesthesia,         |           |             |                |                |
|    |                     |                 |            |           | paresis. Eye disorders: xanthopsia, blurred      |           |             |                |                |
|    |                     |                 |            |           | vision, myopia (aggravated), lacrimation         |           |             |                |                |
|    |                     |                 |            |           | decreased. Ear and labyrinth disorders: vertigo. |           |             |                |                |
|    |                     |                 |            |           | Cardiac disorders: cardiac arrhythmias,          |           |             |                |                |
|    |                     |                 |            |           | palpitations. Vascular disorders: orthostatic    |           |             |                |                |
|    |                     |                 |            |           | hypotension, thrombosis, embolism, shock         |           |             |                | ,              |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম  | জেনেরিক নাম                                  | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                                 | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|-------------------------------------|--|--|---------------------|--|---|--|---|---|--|
|     |                                     |  |  |                     |  | Respiratory, thoracic and mediastinal disorders: respiratory distress, pneumonitis, interstitial lung disease, pulmonary oedema. Gastrointestinal disorders: dry mouth, nausea, vomiting, stomach discomfort, diarrhoea, constipation, abdominal pain, ileus paralytic, flatulence, sialoadenitis, pancreatitis. Hepatobiliary disorders: jaundice cholestatic, cholecystitis. Skin and subcutaneous tissue disorders: pruritus, purpura, urticaria, photosensitivity reaction, rash, cutaneous lupus erythematosus, vasculitis necrotising, toxic epidermal necrolysis. Musculoskeletal, connective tissue and bone disorders: muscle spasms, myalgia. Renal and urinary disorders: renal impairment, renal failure acute, nephritis interstitial, glycosuria. Reproductive system and breast disorders: erectile dysfunction. General disorders and administration site conditions: asthenia, pyrexia, fatigue, thirst. Investigations: electrocardiogram change, blood cholesterol increased, blood triglycerides increased. |  |   |   |  |
| 50. | Beximco<br>Pharmaceutical<br>s Ltd. | Paracetamol 500<br>mg + Ibuprofen<br>150 mg Tablet | Paracetamol BP 500mg<br>+ Ibuprofen BP 150mg | Analgesic           | For temporary relief of pain associated with: headache, migraine, backache, period pain, dental pain, muscular pain, cold and flu symptoms, sore throat and fever. | Contraindications: This product is contraindicated: In patients with a known hypersensitivity to ibuprofen, paracetamol or any other excipients, In patients with a history of hypersensitivity reactions (e.g. bronchospasm, angioedema, asthma, rhinitis, or urticaria) associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). In patients with a history of, or an existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs.   | Paracetamol<br>500 mg &<br>1000mg.<br>Ibuprofen<br>200mg,300mg&<br>400mg | MHRA  | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম  | জেনেরিক নাম                                   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                                 | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|-------------------------------------|--|---|---------------------|---|---|--|---|---|--|
|     |                                     |  |   |                     |   | Patients with defects in coagulation. In patients with severe hepatic failure, severe renal failure or severe heart failure (NYHA Class IV)     In concomitant use with other NSAID containing products, including cyclooxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above 75 mg daily – increased risk of adverse reactions     In concomitant use with other paracetamol-containing products – increased risk of serious adverse effects     During the last trimester of pregnancy due to risk of premature closure of the foetal ductus arteriosus with possible pulmonary hypertension  Adverse reactions: Common undesirable effects Abdominal pain, diarrhoea, dyspepsia, nausea, stomach discomfort and vomiting and Alanine aminotransferase increased, gammaglutamyltransferase increased and liver function tests abnormal with paracetamol. Blood creatinine increased and blood urea increased. |  |   |   |  |
| 51. | Beximco<br>Pharmaceutical<br>s Ltd. | Paracetamol 500<br>mg + Ibuprofen<br>200 mg Tablet | Paracetamol BP 500 mg<br>+ Ibuprofen BP 200mg | Analgesic           | For the temporary relief of mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic and muscular pain, pain of nonserious arthritis, cold and flu symptoms, sore throat and fever. This product is especially suitable for pain which requires stronger analgesia than ibuprofen or paracetamol alone.  Ibuprofen and Paracetamol 200mg/500mg tablets is indicated in adults aged 18 years. | Contraindications: This product is contraindicated: In patients with a known hypersensitivity to ibuprofen, paracetamol or any other excipients, In patients with a history of hypersensitivity reactions (e.g. bronchospasm, angioedema, asthma, rhinitis, or urticaria) associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). In patients with a history of, or an existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs.   | Paracetamol<br>500 mg &<br>1000mg.<br>Ibuprofen<br>200mg,300mg&<br>400mg | MHRA  | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম | ঔষধের নাম                                    | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত      |
|-----|----------------------|--|--|----------------------|--|--|--|---|--|---------------------|
|     |                      |  |  |                      |  | <ul> <li>Patients with defects in coagulation. In patients with severe hepatic failure, severe renal failure or severe heart failure (NYHA Class IV)</li> <li>In concomitant use with other NSAID containing products, including cyclooxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above 75 mg daily – increased risk of adverse reactions</li> <li>In concomitant use with other paracetamol-containing products – increased risk of serious adverse effects</li> <li>During the last trimester of pregnancy due to risk of premature closure of the foetal ductus arteriosus with possible pulmonary hypertension</li> <li>Adverse reactions: Common undesirable effects Abdominal pain, diarrhoea, dyspepsia, nausea, stomach discomfort and vomiting and Alanine aminotransferase increased and liver function tests abnormal with paracetamol. Blood creatinine increased and blood urea increased.</li> </ul> |  |   |  |                     |
| 52. | Delta Pharma<br>Ltd. | Bedaquiline 100<br>mg film coated<br>Tablets | Bedaquiline Fumrate INN 100.890 mg eq. to Bedaquiline 100 mg | Antituberculosi<br>s | It is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (18 years and older) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve Bedaquiline for use when an effective treatment regimen cannot otherwise be provided. Administer Bedaquiline by directly observed therapy (DOT). | Contra-indications: None Side-effects: The most common adverse reactions reported in 10% or more of patients treated with Bedaquiline were nausea, arthralgia, headache, hemoptysis and chest pain.  Warning and Precautions:  •QT prolongation can occur with Bedaquiline. Monitor ECGs and discontinue Bedaquiline if significant ventricular arrhythmia or QTcF   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে ।                 | অনুমোদন করা<br>হল । |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                          | জেনেরিক নাম         | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----|------------------------|------------------------------------|---------------------|---------------------|--|--|--|---|--|--------------------|
|     |                        |                                    |                     |                     |  | interval > 500 ms evelops.   |  |   |  |                    |
|     |                        |                                    |                     |                     |  | Hepatotoxicity may occur with use of Bedaquiline. Monitor liver related laboratory tests. Discontinue if evidence of liver injury. |  |   |  |                    |
| 53. | . Delta Pharma<br>Ltd. | Delamanid 50 mg film coated Tablet | Delanamid INN 50 mg | Antituberculosi     | It is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. | ●Hypersensitivity to the active substance.     ●Serum albumin < 2.8 g/dL     ●Taking medicinal products that are strong            | New                                      | BNF-74<br>Page: 554                             | অনুমোদন করা থেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং | প্রস্তুতকারকে<br>নাম | ঔষধের নাম | জেনেরিক নাম | থেরাপিউটিক<br>ক্লাস | নির্দেশনা | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|----|----------------------|-----------|-------------|---------------------|-----------|---|--|---|--|----------------|
|    |                      |           |             |                     |           | hypotension, Bruising, Hot flushes, Shortness of breath, Cough, Pain in the mouth or throat, Throat irritation, Dry throat, Runny nose, Chest pain, Gastritis, Constipation, Indigestion, Dermatitis, Hives, Itching, Papules, Rash, Acne, Increased sweating, A bone disease called osteochondrosis, Muscular weakness, Pain in bones, Flank pain, Pain in arms or legs, Blood in urine, Fever, Chest pain, Feeling unwell, Chest discomfort, Foot, leg or ankle swelling,Increased values for blood investigations for the hormone cortisol. Uncommon: may affect up to 1 in 100 people. Shingles, Oral thrush, Yeast infection of the skin, Low white blood cell count, Low blood platelets count, Dehydration, Low blood calcium level, High blood cholesterol level, Aggression, Paranoia, Panic attacks, Adjustment disorder with depressed mood, Neurosis, Feeling of emotional and mental discomfort, Mental aberration, Problems with sleeping, Increase of libido, Lethargy, Balance disorder, Regional pain, Allergic conjunctivitis, Heart rhythm problems, Swallowing problems, Abnormal feeling in the mouth, Tenderness in the abdomen, Hair loss, Itchy or red skin including around the hair roots, Urine retention, Painful urination, Increased need to urinate at night, Feeling hot, Abnormal values for blood investigations related to coagulation (prolonged APPT), Abnormal blood values related to the function of the liver, biliary system or pancreas, Decreased values for blood investigations for the hormone cortisol, Increased blood pressure.  Warning and Precautions: |  |   |  |                |
|    |                      | 1         |             |                     |           | THEIR AIR HU GALA OH LIRALIHEHL WILH GEIGHIGHIG   |  |   |  |                |

| নং  | প্রস্তুতকারকে<br>নাম | ঔষধের নাম                                   | জেনেরিক নাম            | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----|----------------------|---|------------------------|---------------------|---|--|--|---|--|--------------------|
|     |                      |   |                        |                     |   | for more than 24 consecutive weeks.  There are no clinical data on the use of delamanid to treat  - extra pulmonary tuberculosis (e.g. central nervous system, bone)  - infections due to Mycobacterial species other than those of the <i>M. tuberculosis</i> complex  - latent infection with <i>M. tuberculosis</i> There are no clinical data on the use of delamanid as part of combination regimens used to treat drug susceptible <i>M. tuberculosis</i> .  Delamanid must only be used in an appropriate combination regimen for MDR-TB treatment as recommended by WHO to prevent development of resistance to delamanid.  Resistance to delamanid has occurred during treatment. The risk of selecting for resistance to delamanid appears to be increased when it is used with few agents predicted to be active and/or when these additional agents were not among those deemed to be most effective against <i>M. tuberculosis</i> . In addition, limited clinical data indicate that the addition of delamanid to regimens for treating MDR-TB that were resistant to rifampicin and isoniazid but otherwise susceptible, gave the highest efficacy whereas use of delamanid as part of the best available regimens that could be constructed for treating XDR-TB was associated with the lowest efficacy. |  |   |  |                    |
| 54. | Delta Pharma<br>Ltd. | Praziquantel<br>600mg film coated<br>Tablet | Praziquantel USP 600mg | Anthelmintic        | Praziquantel is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opistho | Contra-indications: Praziquantel is contraindicated in patients who previously have shown hypersensitivity to the drug or any of the excipients. Since parasite destruction within the eye may cause   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং | প্রস্তুতকারকে<br>নাম | ঔষধের নাম | জেনেরিক নাম | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|----|----------------------|-----------|-------------|---------------------|--|---|--|---|--|----------------|
|    |                      |           |             |                     | rchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). | not be treated with this compound. Concomitant administration with strong Cytochrome P450 (P450) inducers, such as rifampin, is contraindicated since therapeutically effective blood levels of praziquantel may not be achieved. In patients receiving rifampin who need immediate treatment for schistosomiasis, alternative agents for schistosomiasis should be considered.  However, if treatment with praziquantel is necessary, rifampin should be discontinued 4 weeks before administration of praziquantel. Treatment with rifampin can then be restarted one day after completion of praziquantel treatment.  Side-effects: In general Praziquantel is very well tolerated. Side effects are usually mild and transient and do not require treatment. The following side effects were observed generally in order of severity: malaise, headache, dizziness, abdominal discomfort with or without nausea, rise in temperature and, rarely, urticaria. Such symptoms can, however, also result from the infection itself. Such side effects may be more frequent and/or serious in patients with a heavy worm burden.  Warning and Precautions: | Existing)                                | / MHRA Ref.                                     |  |                |
|    |                      |           |             |                     |  | Therapeutically effective levels of Praziquantel IDE may not be achieved when administered concomitantly with strong P450 inducers, such as rifampin.  Approximately 80% of a dose of praziquantel is excreted in the kidneys, almost exclusively   |  |   |  |                |

| নং  | প্রস্তুতকারকে<br>নাম         | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|------------------------------|--|--|---------------------|---|---|--|---|---|--|
|     |                              |  |  |                     |   | (>99%) in the form of metabolites. Excretion might be delayed in patients with impaired renal function, but accumulation of unchanged drug would not be expected. Therefore, dose adjustment for renal impairment is not considered necessary. Nephrotoxic effects of praziquantel or its metabolites are not known. Caution should be exercised in the administration of the usual recommended dose of praziquantel to hepatosplenic schistosomiasis patients with moderate to severe liver impairment (Child-Pugh class B and C). Reduced metabolism of praziquantel by the liver in these patients may lead to considerably higher and longer lasting plasma concentrations of unmetabolized praziquantel. Minimal increases in liver enzymes have been reported in some patients. Patients suffering from cardiac irregularities should be monitored during treatment. As praziquantel can exacerbate central nervous system pathology due to schistosomiasis, as a general rule this drug should not be administered to individuals reporting a history of epilepsy and/or other signs of potential central nervous systems involvement such as subcutaneous nodules suggestive of cysticercosis. When schistosomiasis or fluke infection is found to be associated with cerebral cysticercosis it is advised to hospitalize the patient for the duration of treatment Patients should be warned not to drive a car and not to operate machinery on the day of praziquantel treatment and the following day. |  |   |   |  |
| 55. | Drug<br>International<br>Ltd | Sodium Alginate<br>5.00gm+ Sodium<br>Bicarbonate | Sodium Alginate BP<br>5.00gm+ Sodium<br>Bicarbonate BP 2.67gm+ | Antacid             | It is indicated for the management of gastric reflux, reflux oesophagitis, hiatus hernia, heartburn (including heartburn of | Contraindication: It is   | New                                      | BNF-74<br>Page No-81                            | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----|--|---|---|---------------------|--|---|--|---|--|--------------------|
|     | 252, Tongi I/A<br>Tongi, Gazipur   | 2.67gm + Calcium<br>Carbonate<br>1.60gm/100ml<br>Oral suspension    | Calcium Carbonate BP<br>1.60gm /100ml                       |                     | pregnancy) and similar gastric distress.   | contraindicated in patients with known to have hypersensitivity to  |  |   |  |                    |
|     |  |   |   |                     |  | the drug.   |  |   |  |                    |
|     |  |   |   |                     |  | As with all medicines, it is recommended to limit the treatment duration as much as possible. If symptoms do not improve after seven days, the clinical situation should be reviewed  |  |   |  |                    |
|     |  |   |   |                     |  | Side effects: The most common side effects are constipation; diarrhea, Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.  |  |   |  |                    |
| 56. | Drug<br>International<br>Ltd (Unit-2)<br>Plot # 13A &<br>14A, Tongi I/A,<br>Tongi, Gazipur | Enasidenib<br>100mg Tablet  | Enasidenib Mesylate INN<br>120mg eq. to 100mg<br>Enasidenib | Anticancer          | It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.   | Contraindication: Enasidenib is contraindicated in patients with known hypersensitivity to Enasidenib or any other components of this product.  Side effects:The most common adverse reactions included nausea, vomiting, diarrhea, elevated bilirubin, decreased appetite, respiratory, thoracic and mediastinal disorder. Serious adverse reactions are reported such as leukocytosis and differentiating syndrome. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |
| 57. | Drug<br>International<br>Ltd (Unit-2)<br>Plot # 13A &<br>14A, Tongi I/A,<br>Tongi, Gazipur | Gemtuzumab Ozogamicin 4.5mg/Vial Lyophilized powder for IV infusion | Gemtuzumab<br>Ozogamicin 4.5mg/Vial                         | Anticancer          | It is indicated for the treatment of newly-<br>diagnosed CD33-positive acute myeloid<br>leukemia in adults.<br>Relapsed Or Refractory CD33-positive<br>AML: It is indicated for the treatment of<br>relapsed or refractory CD33-positive acute | Contraindication:It is contraindicated in patients with known hypersensitivity to gemtuzumab or any other components of this product. Caution should be exercised when using gemtuzumab in patients with the risk of Hepatotoxicity, Infusion related reactions, Hemorrhage.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                                      | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                 | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত               |
|-----|--|--|---|---------------------|---|---|--|---|--|------------------------------|
|     |  |  |   |                     | myeloid leukemia in adults and in pediatric patients 2 years and older.   | Side effects:The most common adverse are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.  |  |   |  |                              |
| 58. | Drug<br>International<br>Ltd (Unit-2)<br>Plot # 13A &<br>14A, Tongi I/A,<br>Tongi, Gazipur | Neratinib 40mg<br>Tablet                       | Neratinib Maleate INN<br>48.30mg eq. to 40mg<br>Neratinib | Anticancer          | Neratinib is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy. | Contraindication: There are no data available. Side effects:The most common adverse reactions are diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।           |
| 59. | Eskayef<br>Pharmaceutical<br>s Limited,<br>Tongi,Gazipur                                   | Azelastine HCI<br>0.05% Ophthalmic<br>Solution | Azelastine HCI BP<br>0.05gm/100ml                         | Antihistamine       | It is indicated for the treatment of itching of the eye associated with allergic conjunctivitis  Limitation of use: It is for ocular use only and not for injection or oral use.        | Contraindications: It is contraindicated in persons with known or suspected hypersensitivity to any of its components.  Side effects: In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%), and bitter taste (approximately 10%). The occurrence of these events was generally mild. The following events were reported in 1-10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied. | Azelastine HCI<br>125mcg/Metere<br>d Dose Nasal<br>Spray | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।           |
| 60. | Eskayef<br>Pharmaceutical<br>s Limited,<br>Tongi,Gazipur                                   | Dapsone 5% Gel                                 | Dapsone BP 5%   | Antiacne            | It is indicated for the topical treatment of acne vulgaris.   | Contraindications: None  Side effects: Most common adverse effects are oiliness /peeling, dryness and erythema at the application site.   | 50mg & 100mg<br>Tablet                                   | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।           |
| 61. | Eskayef  | Dextromethorpha                                | Dextromethorphan HBr                                      | Antitussive         | It is used to relieves-   | Contraindications: Hypersensitivity   | 10mg/5ml   | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা  | প্রয়োজন নেই<br>বিধায় আবেদন |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |   |
|-----|---|--|---|----------------------|--|---|--|---|---|---|
|     | Pharmaceutical<br>s Limited,<br>Tongi,Gazipur                           | n HBr 30mg/5ml<br>Extended Release<br>Suspension                                 | USP 30mg/5ml  |                      | <ul> <li>Cough due to minor throat and bronchial irritation as many occur with the common cold or inhaled irritants.</li> <li>The impulse to cough to help patient to sleep.</li> </ul>                  | Side effects: Sedative effects  | Syrup  | (Dextrometh orphan Polistirex)                  | যেতে পারে।  | নামঞ্জুর করা হল।  |
| 62. | GLOBE PHARMACEU TICALS LTD. Bscic Industrial estate Begumgonj, noakhali | Diphenhydramin<br>e hydrochloride 7<br>mg + L-menthol<br>0.55 mg / 5 ml<br>Syrup | Diphenhydramine hydrochloride USP 7 mg + L-menthol USP 0.55 mg / 5 ml                         | Expectorant          | It is indicated for the relief of cough and associated congestive symptoms (runny nose and sneezing), in the treatment of hay fever and other allergic conditions affecting the upper respiratory tract. | Contraindications: It is contraindicated in individuals with known hypersensitivity to the product or any of its constituents and also contraindicated in patients with chronic or persistent cough, such as occurs with asthma, or where cough is accompanied by excessive secretions, unless directed by the physician. It should not be administered to patients currently receiving monoamine oxidase inhibitors (MAOI) or those patients who have received treatment with MAOIs within the last two weeks Side effects: Side effects associated with the use of this syrup are uncommon. Diphenhydramine may cause drowsiness, dizziness, gastrointestinal disturbance, dry mouth, nose and throat; difficulty in urination or blurred vision. | Diphenhydrami<br>ne<br>hydrochloride<br>USP 14 mg +<br>L-menthol USP<br>2mg/5 ml Syrup | MHRA (BENYLIN Children Night Cough Syrup)       | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                           | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।  |
| 63. | Healthcare<br>Pharmaceutical<br>s Ltd.                                  | Bisoprolol<br>Fumarate 2.5mg<br>+ Amlodipine<br>10mg Tablet                      | Bisoprolol Fumarate USP 2.5 mg + Amlodipine Besilate BP 13.87mg eq to Amlodipine 10 mg        | Antihypertensiv<br>e | Indicated in adults for the treatment of mild to moderate hypertension.  | Contra-indication: Cardiogenic shock, second or third degree AV block, and marked sinus bradycardia and known sensitivity to amlodipine/ bisoprolol.  Side effects: Most common adverse reactions are Edema feet, headache, fatigue, leg cramps, dry mouth  | Bisoprolol<br>2.5mg, 5mg &<br>10mg Tablet<br>Amlodipine<br>5mg, 10 mg<br>Tablet        |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে ।            | প্রয়োজনীয়<br>রেফারেপ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                            |
| 64. | Healthcare<br>Pharmaceutical<br>s Ltd.                                  | Bisoprolol<br>Fumarate 5mg +<br>Amlodipine 10mg<br>Tablet                        | Bisoprolol Fumarate<br>USP 5 mg + Amlodipine<br>Besilate BP 13.87mg eq<br>to Amlodipine 10 mg | Antihypertensiv<br>e | Indicated in adults for the treatment of mild to moderate hypertension.  | Contra-indication: Cardiogenic shock, second or third degree AV block, and marked sinus bradycardia and known sensitivity to amlodipine/ bisoprolol.  Side effects: Most common adverse reactions are Edema feet, headache, fatigue, leg cramps, dry mouth  | Bisoprolol 2.5mg, 5mg & 10mg Tablet  Amlodipine 5mg, 10 mg Tablet                      |   | প্রয়োজন রেফারেন্স নেই এবং পৃথকভাবে অনুমোদিত বিধায় আবেদন নামঞ্জুর করা যেতে পারে। | প্রয়োজন রেফারেন্স<br>নেই এবং<br>পৃথকভাবে<br>অনুমোদিত বিধায়<br>আবেদন নামঞ্জুর<br>করা হল। |
| 65. | Healthcare  | Elemental Iron   | Sucroferric Oxyhydroxide  | Elemental Iron       | It is is a phosphate binder indicated for the  | Contra-indications: None  | Elemental Iron   | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা   | প্রয়োজন নেই<br>বিধায় আবেদন  |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |  |
|-----|---|--|---|---------------------|---|---|--|---|---|--|
|     | Pharmaceutical s Ltd.                                     | 500 mg (as<br>Sucroferric<br>Oxyhydroxide)<br>Chewable Tablet                  | INN 2500 mg eq. to<br>Elemental Iron 500mg  |                     | control of serum phosphorus levels in patients with chronic kidney disease on dialysis.   | Side effects: Discolored feces and diarrhea   | 100 mg/5 ml,<br>200mg/10ml<br>and 27.2 mg/5<br>ml Injection  |   | যেতে পারে।  | নামঞ্জুর করা হল।   |
| 66. | Incepta Pharmaceutical s Ltd (Dhamrai Unit)               | Clindamycin Phosphate 100 mg + Clotrimazole 100 mg + Tinidazole 100 mg Capsule | Clindamycin Phosphate<br>BP 100 mg +<br>Clotrimazole BP 100mg<br>+ Tinidazole BP 100 mg | Antibiotic          | Clindamycin is used in the treatment of bacterial infections. Clotrimazole is used in the treatment of fungal infections. Tinidazole is used in the treatment of bacterial infections. It is used in infections of the brain, reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body. | Contra-indication: This medicine are contraindicated for patients who are having these following conditions: Blood dyscrasias, Decreased neutrophils, Epileptic seizure, First trimester of pregnancy, Hypersensitivity, Hypersensitivity to clindamycin or lincomycin Side-effect: Vomiting, Nausea, Joint pain, Difficulty in swallowing, Heartburn, Vaginal discharge, Vaginal irritation, Vaginal swelling, Vaginal itching, White spots in the mouth, White patches on the tongue, White spots in the throat. Abdominal pain, Skin rash, Increased liver enzymes Headache, Dry mouth, Metallic taste | Clindamycin Phosphate 1.2% + Tretinoin 0.025% Gel Clotrimazole 200mg Vaginal Tablet Clotrimazole 200mg Vaginal Suppository Clotrimazole 2% Cream |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 67. | Incepta<br>Pharmaceutical<br>s Ltd (Dhamrai<br>Unit)      | Eucalyptus oil BP<br>0.5 ml and<br>Menthol BP 100<br>mg inhalation<br>vapour   | Eucalyptus oil BP 0.5 ml<br>+ Menthol BP 100 mg   | Antitussive         | For the relief of the symptoms of coughs, colds and nasal congestion  | Contra-indication: Hypersensitivity to menthol or any of the other ingredients.  Side-effect: Menthol may give rise to hypersensitivity reactions including contact dermatitis. There have been reports of apnoea and instant collapse in infants following local application of menthol to their nostrils.   |  |   | প্রয়োজনীত রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।  | প্রয়োজনীঢ<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।  |
| 68. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka | Abaloparatide<br>3120 mcg/1.56<br>ml Pre Filled Pen<br>for injection           | Abaloparatide INN<br>3120mcg/1.56 ml  | Hormone<br>Analog   | It is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.   | Contra-indication : None.  Side-effect: Hyper calciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 69. | Incepta<br>Pharmaceutics                                  | Cefoperazone   | Cefoperazone Sodium   | Antibiotic          | It is indicated for the treatment of  | Contraindication:   | 500mg/Vial &   | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম                             | ঔষধের নাম                                | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)               | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                             | সভার সিদ্ধান্ত   |
|-----|--|--|--|---------------------|--|---|--|---|--|--|
|     | Ltd.; Zirabo,<br>Savar, Dhaka                    | Sodium USP 2gm<br>Injection              | USP 2.0gm  |                     | respiratory tract infections, urinary tract infections, peritonitis and other intra- abdominal infections, bacterial septicemia, infections of the skin and skin structures, enterococcal infections caused by susceptible organisms. Cefoperazone is also used to treat pelvic inflammatory disease, endometritis, and other infections of the female genital tract.  | Hypersensitivity to cephalosporin Side effects: Skin rash, hives, eosinophilia, diarrhea, nausea, vomiting, eye inflammation, blood clotting problem and super infection  | 1.0 gm/Vial  |   |  |  |
| 70. | Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Dexamethasone<br>6.0mg/Vial<br>Injection | Dexamethasone Sodium<br>Phosphate USP<br>7.8940mg eq. to<br>Dexamethasone 6 mg | Corticosteroid      | Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness.  Dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome).  Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.  Gastrointestinal diseases: to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.  Hematologic disorders: acquired | Contraindications: Systemic fungal infections  Side-effects: No severe side effects found.  Allergic reactions: anaphylactic reaction, anaphylaxis, angioedema. cardiovascular: bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see warnings, cardio-renal), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. dermatologic: acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. endocrine: decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, | 0.5mg, 2 mg,<br>4mg Tablet<br>&<br>5mg/ml<br>Injection |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামজুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং | প্রস্তুতকারকে<br>নাম | ঔষধের নাম | জেনেরিক নাম | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|----|----------------------|-----------|-------------|---------------------|--|---|--|---|--|----------------|
|    |                      |           |             |                     | (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia.  Miscellaneous: diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: for the palliative management of leukemias and lymphomas.  nervous system: acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.  Ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.  Renal diseases: to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.  Respiratory diseases: berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.  Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, | menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and electrolyte disturbances: congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. gastrointestinal: abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.  Metabolic: negative nitrogen balance due to protein catabolism. musculoskeletal: aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures. neurological/psychiatric: convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo.  Ophthalmic: exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts. |  |   |  |                |

| নং  | প্রস্তুতকারকে<br>নাম                             | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)           | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                             | সভার সিদ্ধান্ত   |
|-----|--|---|--|----------------------|---|--|--|---|--|--|
|     |  |   |  |                      | psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.   |  |  |   |  |  |
| 71. | Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Linagliptin INN 5<br>mg + Metformin<br>HCI BP 1000mg<br>SR tablet | Linagliptin INN 5 mg + Metformin HCI BP 1000mg                                     | Antidiabetes         | It is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment withboth linagliptin and metformin is appropriate.   | Contra-indication: Severe renal impairment (eGFR below 30 mL/min/1.73 m2 Metabolic acidosis, including diabetic ketoacidosis History of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative ski conditions, urticaria, or bronchial hyperreactivity Hypersensitivity to metformin  Side effect: Adverse reactions reported in ≥5% of patients treated with LINAGLIPTIN + METFORMIN HCL and more commonly than in patients treated withplacebo are nasopharyngitis and diarrhea. | Linagliptin 2.5mg + Metformin Hydrochloride 1000mg | USFDA   | অনুমোদন করা যেতে<br>পারে ।   | অনুমোদন করা<br>হল।   |
| 72. | Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Mebeverine Hydrochloride 50 mg/10ml Oral Suspension               | Mebeverine Pamoate<br>INN 88.00mg eq. to<br>50mg Mebeverine<br>Hydrochloride/100ml | Spasmolytic<br>agent | For the symptomatic treatment of irritable bowel syndrome and other conditions usually included in this grouping, such as chronic irritable colon, spastic constipation, mucous colitis, spastic colitis. Colofac is effectively used to treat the symptoms of these conditions, such as colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.  For the symptomatic treatment of gastrointestinal spasm secondary to organic diseases. | Contraindications: Hypersensitivity to any component of the product.  Side effects: Immune system disorders Very rare: hypersensitivity skin and subcutaneous tissue disorders Very rare: urticaria, angioedema, face oedema, exanthema/rash Reporting of suspected adverse reactions  | 135 mg, 200<br>mg Capsule                          |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 73. | Incepta<br>Pharmaceutics                         | Meropenem 2.0<br>gm +   | Meropenem USP 2 .0<br>gm + Vaborbactam INN   | Antibiotic           | It is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-   | Contraindication: Known hypersensitivity to the components of this injection (meropenem and  | Meropenem<br>250mg, 500mg                          |   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)            | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|---|---|--|---------------------|---|--|---|---|---|--|
|     | Ltd.; Zirabo,<br>Savar, Dhaka                             | Vaborbactam 2.0<br>gm / Vial Powder<br>for Injection                          | 2.0 gm   |                     | lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.  To reduce the development of drugresistant bacteria and maintain the effectiveness of this injection and other antibacterial drugs, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria  | vaborbactam) or anaphylactic reactions to beta-lactams.  Side effects: The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.   | and 1.0gm<br>Injection                              |   |   |  |
| 74. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka | Meropenem 500<br>mg +<br>Vaborbactam 500<br>mg / Vial Powder<br>for Injection | Meropenem USP<br>500mg + Vaborbactam<br>INN 500 mg | Antibiotic          | It is a combination of meropenem, a penem antibacterial, and vaborbactam, a betalactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. To reduce the development of drugresistant bacteria and maintain the effectiveness of this injection and other antibacterial drugs, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria | Contraindication: Known hypersensitivity to the components of this injection (meropenem and vaborbactam) or anaphylactic reactions to beta-lactams.  Side effects: The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea. | Meropenem<br>250mg, 500mg<br>and 1.0gm<br>Injection |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 75. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka | Peginesatide 2<br>mg/ 0.5 ml pre-<br>filled syringe<br>injection              | Peginesatide INN 2 mg                              | Hematopoietic       | It is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  Limitations of Use: It is not indicated and is not recommended for use: In patients with CKD not on dialysis. In patients receiving treatment for cancer and whose anemia is not due to CKD. As a substitute for RBC transfusions in patients   | Contraindication: Uncontrolled hypertension. Serious allergic reactions to Peginesatide. Side-Effect: The most common adverse events (≥ 10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication   | New   | USFDA   | অনুমোদন করা থেতে<br>পারে।   | অনুমোদন করা<br>হল ।  |

| নং  | প্রস্তুতকারকে<br>নাম                             | ঔষধের নাম  | জেনেরিক নাম                               | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত           | সভার সিদ্ধান্ত                                |
|-----|--|--|---|---------------------|---|--|--|---|--|---|
|     |  |  |   |                     | who require immediate correction of anemia. It has not been shown to improve symptoms, physical, functioning or health-related quality of life.   |  |  |   |  |   |
| 76. | Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Peginesatide 3<br>mg/ 0.5 ml pre-<br>filled syringe<br>injection | Peginesatide INN 3 mg                     | Hematopoietic       | It is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  Limitations of Use: It is not indicated and is not recommended for use: In patients with CKD not on dialysis. In patients receiving treatment for cancer and whose anemia is not due to CKD. As a substitute for RBC transfusions in patients who require immediate correction of anemia. It has not been shown to improve symptoms, physical, functioning or health-related quality of life. | Contraindication: Uncontrolled hypertension. Serious allergic reactions to Peginesatide. Side-Effect: The most common adverse events (≥ 10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication | New                                      | USFDA   | High dose বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | High dose<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 77. | Incepta Pharmaceutics Ltd.; Zirabo, Savar, Dhaka | Peginesatide 4<br>mg/ 0.5 ml pre-<br>filled syringe<br>injection | Peginesatide INN 4 mg                     | Hematopoietic       | It is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  Limitations of Use: It is not indicated and is not recommended for use: In patients with CKD not on dialysis. In patients receiving treatment for cancer and whose anemia is not due to CKD. As a substitute for RBC transfusions in patients who require immediate correction of anemia. It has not been shown to improve symptoms, physical, functioning or health-related quality of life. | Contraindication: Uncontrolled hypertension. Serious allergic reactions to Peginesatide. Side-Effect: The most common adverse events (≥ 10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication | New                                      | USFDA   | High dose বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | High dose<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 78. | Incepta<br>Pharmaceutics                         | Pentosan<br>Polysulfate  | Pentosan Polysulfate<br>Sodium INN 100 mg | Cystitis Agent      | It is indicated for the relief of bladder pain or discomfort associated with interstitial   | Contraindication: It is contraindicated in patients with known hypersensitivity to the   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                            | অনুমোদন করা<br>হল।                            |

| নং  | প্রস্তৃতকারকে<br>নাম                      | ঔষধের নাম   | জেনেরিক নাম                       | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                            | সভার সিদ্ধান্ত   |
|-----|---|---|-----------------------------------|---------------------|--|---|--|---|---|--|
|     | Ltd.; Zirabo,<br>Savar, Dhaka             | Sodium100 mg<br>Capsule                               |                                   |                     | cystitis   | drug, structurally related compounds, or excipients. This monograph has been modified to include the generic and brand name in many instances.  Side effects: It was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3-month trial and the remaining 2499 patients were in a long-term, unblinded trial. Deaths occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months. The deaths appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known. Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe abdominal pain or diarrhea and dehydration that required hospitalization. Because there was not a control group of patients with interstitial cystitis who were concurrently evaluated, it is difficult to determine which events are associated with PENTOSAN POLYSULFATE SODIUM and which events are associated with concurrent illness, medicine, or other factors. |  |   |   |  |
| 79. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo, | Posaconazole<br>0.300 gm/ Vial<br>Injectable Solution | Posaconazole INN<br>0.300 gm/Vial | Antifungal          | It is indicated for Prophylaxis of invasive<br>Aspergillus and Candida infections in<br>patients who are at high risk of | Do not administer to persons with known   | New                                      |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম                                   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|---|---|---|---------------------|--|--|--|---|---|--|
|     | Savar, Dhaka  |   |   |                     | developingthese infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy Oral suspension  Treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole.   | antifungal agents.  Do not coadminister posaconazole with the following drugs; This drug increases concentrations of:  Sirolimus: can result in sirolimus toxicity CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of TdP  HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4: can lead to rhabdomyolysis, Ergot alkaloids: can result in ergotism  Side-effects: Common treatment-emergent adverse reactions in studies with posaconazole are diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia.   |  |   |   |  |
| 80. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka | Posaconazole<br>100mg DR Tablet             | Posaconazole INN 100 mg   | Antifungal          | It is indicated for Prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developingthese infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy Oral suspension Treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole. | Contraindication: Do not administer to persons with known hypersensitivity toposaconazole or other azole antifungal agents. Do not coadminister posaconazole with the following drugs; This drug increases concentrations of: Sirolimus: can result in sirolimus toxicity CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of TdP HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4: can lead to rhabdomyolysis Ergot alkaloids: can result in ergotism Side-effects: Common treatment-emergent adverse reactions in studies with posaconazole are diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 81. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,                 | Pyrantel<br>0.50gm/100ml<br>Oral Suspension | Pyrantel Paomate USP<br>14.40gm eq. to Pyrantel<br>0.50gm/100ml | Anthelmintics       | It is used to treat intestinal worm infections such as pinworm, roundworm, and hookworm. Pyrantel belongs to a class of  | Side Effects:Nausea, vomiting, diarrhea, stomach/abdominal cramps, headache, drowsiness, dizziness, trouble sleeping, or loss  | 500 mg/10 ml<br>Suspension               |   | প্রয়োজনীয় রেফারেঙ্গ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস   | নিৰ্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)       | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|-----|---|---|--|-----------------------|--|--|--|---|--|--|
|     | Savar, Dhaka  |   |  |                       | drugs known as anthelmintics. It works by making the worms unable to move (paralyzed) so that the body can remove them naturally in the stool.   | of appetite may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.  Precautions: Before taking pyrantel, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.  Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, severe lack of nutrition (malnutrition), anemia. |  |   |  |  |
| 82. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka | Sodium<br>Hyaluronate<br>4.0mg + Glycerin<br>9.0mg/100 ml<br>Ophthalmic Gel<br>drop | Sodium Hyaluronate BP<br>4.0 mg + Glycerin BP<br>9.0mg/ 100 ml | Eye lubricant         | Sodium Hyaluronate provides protective layer which prevent further water loss and lubricates & reduces friction during blinking and relief from eye irritation. Sodium Hyaluronate also adhere to mucin layer and it retain aqueous layer and total relief from dry eye.  Directions for use Adults and children (12+)  1. Wash hands thoroughly before use.  2. Tilt your head backwards and gently squeeze 1-2 drops into each eye before going to sleep or use as directed by your doctor or eye practitioner.  3. Blink a few times to ensure the whole eye is covered.  4. Replace the bottle top tightly after use. Children must be supervised by an adult. | Contraindications: not found Side-effects/Toxicity: All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with sodium hyaluronate gel. Seek medical attention right away if any of these SEVERE side effects occur: Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).  | 0.1 gm/ 100 ml,<br>0.2 gm/ 100 ml<br>Eye Drops |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 83. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,                 | Tacrolimus 0.75<br>mg ER Tablet   | Tacrolimus USP 0.75mg  | Immune<br>Suppressant | It is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney   | Contraindication: Known hypersensitivity to tacrolimus.  | 0.03% & 0.1%<br>as Ointment                    | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম                                       | ঔষধের নাম                    | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস   | নির্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|--|------------------------------|--|-----------------------|--|---|--|---|---|--|
|     | Savar, Dhaka   |                              |  |                       | transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants.  Limitation of use: Not interchangeable or substitutable with other tacrolimus products.  | Side- Effects: Most common adverse reactions (incidence ≥10 %) include: diarrhea and blood creatinine increased.  |  |   |   |  |
| 84. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka  | Tacrolimus 1 mg<br>ER Tablet | Tacrolimus USP 1 mg                                | Immune<br>Suppressant | It is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants.  Limitation of use: Not interchangeable or substitutable with other tacrolimus products. | Contraindication: Known hypersensitivity to tacrolimus.  Side- Effects: Most common adverse reactions (incidence ≥10 %) include: diarrhea and blood creatinine increased.   | 0.03% & 0.1%<br>as Ointment              | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 85. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka  | Valbenazine 40<br>mg capsule | Valbenazine Tosylate<br>INN 73.00mg eq. to<br>40mg | CNS Agent             | It is indicated for the treatment of adults with tardive dyskinesia.   | Contra-indication: None.  Side effect: Most common adverse reaction (≥5% and twice the rate of placebo): somnolence.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |
| 86. | Incepta<br>Pharmaceutics<br>Ltd.; Zirabo,<br>Savar, Dhaka. | Naldemedine 0.2<br>mg Tablet | Naldemedine INN<br>0.20mg                          | Analgesic             | It is an opioid antagonist indicated for the treatment of opioidinduced constipation (OIC) in adult patients with chronic noncancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.                                   | Contraindication: 1. Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction. 2. Patients with a history of a hypersensitivity reaction to naldemedine. Side-effects: 1. Gastrointestinal perforation | New                                      | USFDA   | অনুমোদন করা থেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তুতকারকে<br>নাম                                   | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|--|--|---|---------------------|---|--|--|---|---|--|
|     |  |  |   |                     |   | Opioid Withdrawal  |  |   |   |  |
| 87. | Pharmaceuti<br>cs Ltd.;<br>Zirabo,<br>Savar,<br>Dhaka. | Promethazine Hydrochloride 0.1250gm + Phenylephrine Hydrochloride 0.10gm/100ml Syrup | Promethazine Hydrochloride USP 0.1250gm + Phenylephrine Hydrochloride USP 0.10 gm/100ml | Antihistamine       | Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.   | Contraindications: Promethazine is contraindicated in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. Phenylephrine is contraindicated in patients with hypertension or with peripheral vascular insufficiency (ischemia may result with risk of gangrene or thrombosis of compromised vascular beds). Phenylephrine should not be used in patients known to be hypersensitive to the drug or in those receiving a monoamine oxidase inhibitor (MAOI). Side-effects/Toxicity: Most common adverse reactions (≥ 5% and > placebo) were asthenia, nausea, dizziness, and somnolence. These reactions appear to be dose-related. | Promethazine 10mg & 25mg Tablet; 5 mg/5 ml Syrup 50 mg/2 ml Injection  Dextromethorpha n Hydrobromide 400mg + Phenylephrine Hydrochloride 200mg+ Triprolidine Hydrochloride 50mg/100ml | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                 | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |
| 88. | Navana<br>Pharmaceutical<br>s Ltd                      | Cefteram Pivoxil<br>50mg Tablets   | Cefteram Pivoxil INN<br>50mg  | Antibiotic          | Cefteram-susceptible bacteria; Streptococcus sp., Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, Citrobacter sp., Klebsiella sp., Enterobacter sp., Serratia sp., Proteus sp., Morganella morganii, Providencia sp., Haemophilus influenzae, and Peptostreptococcus sp. • Pharyngitis/laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, and secondary infections in chronic respiratory | Contraindications: Patients with a history of shock due to any of the ingredients of the product.  Side Effects: Shock and anaphylactoid reactions, Toxic epidermal necrolysis (Lyell syndrome) and Mucocutaneous ocular syndrome (Stevens-Johnson syndrome), Serious nephropathy such as acute renal failure, Serious colitis with bloody stool such as pseudomembranous colitis, Hepatic function disorder and jaundice, Agranulocytosis and   | New  |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামপ্তুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম              | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস  | নির্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত   |
|-----|-----------------------------------|---|--|----------------------|--|---|---|---|---|--|
|     |                                   |   |  |                      | lesion     Cystitis, pyelonephritis and urethritis    Bartholinitis, intrauterine infection and uterine adnexitis   Otitis media and sinusitis    Periodontitis, pericoronitis and gnathitis | thrombocytopenia may develop  |   |   |   |  |
| 89. | Navana<br>Pharmaceutical<br>s Ltd | Diphenhydramine<br>hydrochloride 280<br>mg +<br>Dextromethorpha<br>n hydrobromide<br>130 mg +<br>Levomenthol 40<br>mg/ 100 ml Syrup | Diphenhydramine hydrochloride BP 280 mg + Dextromethorphan hydrobromide BP 130 mg + Levomenthol BP 40 mg/ 100 ml Syrup | Antitussive          | It is indicated as an antitussive, for the night time relief of persistent, dry, irritating cough, and aiding restful sleep.   | Contraindications: Contraindicated in individuals with known hypersensitivity to the product or any of its components. It is contraindicated in individuals who are taking, or have taken, monoamine oxidase inhibitors within the preceding two weeks. The concomitant use of a dextromethorphan-containing product and monoamine oxidase inhibitors can occasionally result in symptoms such as hyperpyrexia, hallucinations, gross excitation or coma. Dextromethorphan, in common with other centrally acting antitussive agents, should not be given to subjects in, or at risk of developing respiratory failure  Not to be used in children under the age of 12 years.  Side Effects: Diphenhydramine may cause: drowsiness; dizziness; gastrointestinal disturbance; dry mouth, nose and throat; difficulty in urination or blurred vision.  Dextromethorphan: dizziness, nausea, vomiting, or gastro-intestinal disturbance may occur. | Guaifenesin 4.0gm+ Dextromethorp han Hydrobromide 0.30gm + Menthol 0.30gm/100ml | MHRA (BENYLIN Dry Coughs Night Syrup)           | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 90. | Navana<br>Pharmaceutical<br>s Ltd | Itopride<br>Hydrochloride<br>50mg Tablet  | Itopride Hydrochloride<br>INN 50mg   | Gastroprokineti<br>c | Gastrointestinal Symptoms in chronic gastritis (bloated feeling, upper abdominal pain, anorexia, heartburn, nausea and vomiting)   | Contraindications: Hypersensitivity to any of its ingredients. Side Effects: The most common side-effects of itopride include mild to moderate abdominal  | New   |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম                | থেরাপিউটিক<br>ক্লাস       | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)           | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত  | সভার সিদ্ধান্ত  |
|-----|--|---|----------------------------|---------------------------|--|--|--|---|---|---|
|     |  |   |                            |                           |  | pain and diarrhoea. Some other side effects that may occur include: rash, giddiness, exhaustion, back or chest pain, increased salivation, constipation, headache, sleeping disorders, dizziness, galactorrhea, and gynecomastia   |  |   |   |   |
| 91. | a) Navana Pharmace uticals Ltd  c) Square Formulatio ns Ltd., Gorai, Tangail | Pregabalin 165mg<br>Extended Release<br>Tablet      | Pregabalin INN<br>165.00mg | Neuropathic<br>Pain Agent | It is indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy (DPN), Postherpetic neuralgia (PHN)  Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. | Contraindications: Contraindicated in patients with known hypersensitivity to pregabalin or any of its components.  Side Effects: Most common adverse reactions reported in greater than or equal to 4% of patients treated with Pregabalin CR are dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain. | 25 mg, 50mg,<br>75mg, 100mg &<br>150 mg<br>Capsule | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                                  |
| 92. | Navana<br>Pharmaceutical<br>s Ltd  | Pregabalin 330.00<br>mg Extended<br>Release Tablet  | Pregabalin INN<br>330.00mg | Neuropathic<br>Pain Agent | It is indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy (DPN), Postherpetic neuralgia (PHN)  Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. | Contraindications: Contraindicated in patients with known hypersensitivity to pregabalin or any of its components.  Side Effects: Most common adverse reactions reported in greater than or equal to 4% of patients treated with Pregabalin CR are dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain. | 25 mg, 50mg,<br>75mg, 100mg &<br>150 mg<br>Capsule | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                                  |
| 93. | a) Navana Pharmaceu ticals Ltd  b) Square Formulatio ns Ltd., Gorai, Tangail | Pregabalin<br>82.50mg<br>Extended Release<br>Tablet | Pregabalin INN 82.50mg     | Neuropathic<br>Pain Agent | It is indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy (DPN), Postherpetic neuralgia (PHN)  Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. | Contraindications: Contraindicated in patients with known hypersensitivity to pregabalin or any of its components.  Side Effects: Most common adverse reactions reported in greater than or equal to 4% of patients treated with Pregabalin CR are dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain. | 25 mg, 50mg,<br>75mg, 100mg &<br>150 mg<br>Capsule | USFDA   | Extended<br>Release Tablet<br>প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | Extended<br>Release<br>Tablet<br>প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  |  |
|-----|---|--|---|---------------------|---|---|--|---|--|--|
| 94. | Navana<br>Pharmaceutical<br>s Ltd   | Rebamipide 100<br>mg Tablet  | Rebamipide INN 100mg  | Antacid             | Treatment of gastric mucosal lesions (erosions, bleeding, redness and edema) in the following conditions:  • Acute gastritis and acute exacerbation of chronic gastritis. Gastric ulcers (In combination with offensive factor inhibitors (proton pump inhibitors, anticholinergic, H <sub>2</sub> antagonist). | Contraindications: Patient with a history of hypersensitivity to any ingredient of this drug. Side Effects: <i>Hypersensitivity:</i> Rash, pruritus and eczematous drug eruption may rarely occur. <i>Gastrointestinal:</i> Dry mouth, constipation, sensation of abdominal enlargement, diarrhea, nausea, vomiting, heartburn, abdominal pain and belching may rarely occur. <i>Hepatic:</i> Signs of hepatic function disorder including increased GOT, GPT, γ-GTP and alkaline phosphatase levels may rarely occur. <i>Hematologic:</i> Leukopenia may rarely occur. <i>Others:</i> Mammary gland expansion, nonpuerperal lactation, menstrual disorder, dizziness may rarely occur. | New                                      |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেপ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 95. | Navana<br>Pharmaceutical<br>s Ltd.  | Zinc oxide 15.250<br>gm + Benzyl<br>alcohol 0.39gm +<br>Benzyl benzoate<br>1.01gm + Benzyl<br>Cinnamate 0.15<br>gm + Lanolin<br>(hypoallergenic)<br>4.00gm/100 gm<br>cream | Zinc oxide USP 15.25gm<br>+Benzyl alcohol BP<br>0.39gm+<br>Benzyl benzoate BP<br>1.01gm + Benzyl<br>Cinnamate BP 0.15gm +<br>Lanolin (hypoallergenic)<br>BP 4.00gm/100 gm | Antiseptic          | In the treatment of: 1. Napkin rash 2. Eczema 3. Bedsores 4. Acne 5. Minor burns 6. Surface wounds 7. Sunburn 8. Chilblains   | Contraindications: Hypersensitivity to any of the ingredients, side effects include local hypersensitivity occasionally.  Undesirable effects: Side effects include local hypersensitivity occasionally.  | New                                      | BNF-74,<br>Page-1129<br>MHRA<br>(Sudocrem)      | অনুমোদন করা থেতে<br>পারে।  | অনুমোদন করা<br>হল।   |
| 96. | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Droxidopa INN<br>100 mg Capsule  | Droxidopa INN 100 mg  | Vasopressor         | Droxidopa is used to treat neurogenic orthostatic hypotension (lightheadedness, dizziness, or fainting) caused by primary autonomic failure (eg, Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine betahydroxylase deficiency, and non-diabetic autonomic neuropathy.         | Contraindication: None Side-effects: The following side-effect with droxidopa are included in more detail in the Warnings and Precautions section of the label: Supine Hypertension, Hyperpyrexia and Confusion, May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |
| 97. | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu                                 | Edoxaban 30 mg<br>Tablet   | Edoxaban INN 30 mg  | Anticoagulant       | It is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).   | Contraindication: Active pathological bleeding.  Side-effect/Toxicity: Treatment of NVAF: The most common   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম                      | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস    | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|---|--------------------------------|--|------------------------|---|--|--|---|---|--|
|     | r, Gazipur<br>Sadar, Gazipur  |                                |  |                        | Limitation of Use: for Edoxaban 30 mg Tablet should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg. Edoxaban 30 mg Tablet is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant | adverse reactions (≥ 5%) are bleeding and anemia.  Treatment of DVT and PE: The most common adverse reactions (≥ 1%) are bleeding, rash, abnormal.   |  |   |   |  |
| 98. | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Ezogabine 200<br>mg Tablet     | Ezogabine INN 200 mg   | Anticonvulsant<br>s    | Indicated as adjunctive treatment of – Partial-onset seizures in patients aged 18 years and older.  | Contraindication: Ezogabine should not be given to individuals with known hypersensitivity to Ezogabine.  Side-effects: Commonly reported side effects of ezogabine include: ataxia, blurred vision, confusion, dizziness, drowsiness, fatigue, tremor, hallucination, and skin discoloration. | New                                      | USFDA<br>(Discontinue<br>d)                     | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                 | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |
| 99. | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Ilaprazole INN 10<br>mg Tablet | llaprazole INN 10 mg   | Antiulcerant           | Indicated for the treatment of-  Dyspepsia  Peptic ulcer disease (PUD)  Gastroesophageal reflux disease (GERD)  Duodenal ulcer  | Contraindication: Ilaprazole should not be prescribed to individuals who are allergic to other PPIs.  Side-effects: Nausea, Abdominal pain, Constipation, Diarrhoea, Flatulence.   | New                                      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 100 | Pharmasia Limited Gojariapara, BhawalMirzapu r, Gazipur Sadar, Gazipur                | Lomitapide 5.0mg<br>Capsule    | Lomitapide Mesylate INN<br>5.695 mg eq. to 5.0mg<br>Lomitapide | Antihyperlipide<br>mic | It is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC),   | Contraindication: Pregnancy. Concomitant use with strong or moderate CYP3A4 inhibitors. Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.  | New                                      | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                 | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম                                 | থেরাপিউটিক<br>ক্লাস   | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত      |
|-----|---|---|---|---|---|---|--|---|--|---------------------|
|     |   |   |   |   | apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).  Limitations of Use: The safety and effectiveness of Lomitapide 5.0mg Capsule have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH). • The effect of Lomitapide 5.0mg Capsule on cardiovascular morbidity and mortality has not been determined  | Side-effects: Most common adverse reactions (incidence ≥28%) are diarrhea, nausea, vomiting, dyspepsia, and abdominal pain.   |  |   |  |                     |
| 101 | . Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Lumacaftor 200<br>mg + Ivacaftor<br>125 mg Tablet | Lumacaftor INN 200mg + Ivacaftor INN 125 mg | CFTR (cystic fibrosis transmembran e regulator) channel activator | It is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.  Limitations of Use: The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation. | Side-effects: The most common adverse reactions to Lumacaftor 200 mg/lvacaftor 125 mgTablet (occurring in ≥5% of patients with CF homozygous for the <i>F508del</i> mutation in the <i>CFTR</i> gene) were dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, respiration abnormal, blood creatine phosphokinase increased, rash, flatulence, rhinorrhea, influenza. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল।  |
| 102 | . Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Macitentan 10mg<br>Tablet                         | Macitentan INN 10 mg                        | Vasodilator   | It is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or  | Contraindication: Macitentan may cause fetal harm when administered to a pregnant woman. macitentanis contraindicated in females who are pregnant. macitentan was consistently shown to have teratogenic effects when administered to animals. If macitentan is used  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল । |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----|---|---|---|----------------------|--|--|--|---|--|--------------------|
|     |   |   |   |                      | subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH   | during pregnancy, apprise the patient of the potential hazard to a fetus.  Side-effect: Common side effects of Macitentan include low red blood cell count (anemia), nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection.  |  |   |  |                    |
| 103 | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Patiromer 8.40<br>gm/ Sachet for<br>Oral Suspension                     | PatiromerSorbitex<br>Calcium INN 16.80 gm<br>eq. to Patiromer 8.40<br>gm/Sachet                                 | Exchange<br>Resins   | It is a potassium binder indicated for the treatment of hyperkalemia.  Limitation of Use: It should not be used as an emergency treatment for lifethreatening hyperkalemia because of its delayed onset of action  | Contraindication: Known hypersensitivity to Patiromer or any of its components.  Side-effects: Most common adverse reactions (incidence ≥2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence.  | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |
| 104 | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Riociguat 1.0mg<br>Tablet   | Riociguat INN 1 mg  | Antihypertensiv<br>e | It is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening | Contraindication: Pregnancy  • Use with nitrates or nitric oxide donors in any form  • Use with PDE inhibitors  • Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)  Side-effects: Adverse reactions occurring more frequently (≥3%) on Adempas compared to placebo are headache, dyspepsia/gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation. | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |
| 105 | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Sodium Picosulfate 0.010gm + Magnesium Oxide 3.50 gm + Anhydrous Citric | Sodium Picosulfate BP<br>0.010 gm + Magnesium<br>Oxide BP 3.50 gm +<br>Anhydrous Citric Acid BP<br>12 gm/Sachet | Laxatives            | It is a combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid which form magnesium citrate, an osmotic laxative, indicated for cleansing of the colon as a preparation for colonoscopy in adults.   | Contraindication: Sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution is contraindicated in the following conditions:  • Patients with severely reduced renal function (creatinine clearance less than 30 mL/minute)   | New                                      | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম                                 | জেনেরিক নাম                  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|-----|---|---|------------------------------|---------------------|---|---|--|---|---|--|
|     |   | Acid 12<br>gm/Sachet for<br>Oral Solution |                              |                     |   | which may result in accumulation of magnesium.  Gastrointestinal obstruction or ileus. Bowel perforation Toxic colitis or toxic megacolon Gastric retention An allergy to any of the ingredients in sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution  Side-effects: Most common adverse reactions (>1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected).   |  |   |   |  |
| 106 | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Solithromycin<br>200mg Capsule            | Solithromycin INN 200        | Antibacterial       | Indicated for the treatment of- Community-Acquired Bacterial Pneumonia, caused by susceptible isolates of the following Gram-positive and Gram-negative bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus and the atypical bacterial pathogens Legionella pneumophila and Mycoplasma pneumoniae. | Contraindication: Contraindicate or recommend against use of Solithromcyin in patients with severe renal insufficiency because of reduced clearance effects of the drug and rising exposure levels that may be toxic.  Side-effects: The most common treatment-emergent adverse events in both treatment arms were diarrhea, nausea, vomiting, headache and dizziness. In 856 Solithromycintreated patients in the phase 3 trials, approximately 95% completed treatment. The incidence of study drug discontinuation was similar for Solithromycin and placebo in the oral study, CE01-300. Higher rates of discontinuation in the Solithromycin arm (4.9%) compared to moxifloxacin (3.7%) occurred in the IV-to-oral trial CE01-301, largely due to infusion site reactions. | New                                      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেঙ্গ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 107 | Pharmasia<br>Limited<br>Gojariapara,  | Telotristat Ethyl<br>250mg Tablet         | Telotristat Ethyl INN 250 mg | Antidiarrheal       | Indicated for the treatment of-<br>Carcinoid syndrome diarrhea in<br>combination with somatostatin analog   | Contraindication: None Side-effects: Most common adverse reactions  | New                                      | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                 | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |

| নং   | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস                  | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              | সভার সিদ্ধান্ত   |
|------|---|--|---|--------------------------------------|---|---|--|---|---|--|
|      | BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur   |  |   |                                      | (SSA) therapy in adults inadequately controlled by SSA therapy.   | (≥5%) are nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.   |  |   |   |  |
| 108. | Pharmasia<br>Limited<br>Gojariapara,<br>BhawalMirzapu<br>r, Gazipur<br>Sadar, Gazipur | Vorapaxar 2.08<br>mg Tablet  | Vorapaxar INN 2.08 mg   | Platelet<br>Aggregation<br>Inhibitor | It is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization   | Contraindication:  • History of stroke, TIA, or ICH. • Active pathologic bleeding.  Side-effects: Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction.  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |
| 109. | Popular Pharmaceutical s Limited, 164 Tongi Industrial Area, Tongi, Gazipur           | Azithromycin 250mg + Ambroxol Hydrochloride BP 75mg Extended Release Bi-Layer Film Coated Tablet | Azithromycin USP 262mg eq. to Azithromycin 250mg + Ambroxol Hydrochloride BP 75mg             | Antibiotic + Mucolytic agent         | It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.  • Upper Respiratory Tract Infections Pharyngitis/Tonsillitis Acute Bacterial Sinusitis Otitis Media  • Lower Respiratory Tract Infections Acute Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease Community-Acquired Pneumonia [CAP] | Contraindications Azithromycin Plus is contraindicated in patients with known hypersensitivity to ambroxol, azithromycin, erythromycin, or any macrolide antibiotic.  Side effects: In clinical trials, most of the reported side effects with azithromycin were mild to moderate in severity and were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. Rarely but potentially serious side effects were angioedema and cholestatic jaundice. Ambroxol: The side effects on account of ambroxol include gastrointestinal side effects, skin rashes, headache, dizziness and sweating | Azithromycin<br>250mg &<br>500mg Tablet<br>Ambroxol<br>Hydrochloride<br>75mg Capsule |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে ।  | প্রয়োজনীয়<br>রেফারেঙ্গ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 110. | Popular Pharmaceutical s Limited, 164 Tongi Industrial Area, Tongi, Gazipur           | Azithromycin 500mg + Ambroxol Hydrochloride 75mg Extended Release Bi-Layer                       | Azithromycin USP<br>524mg eq. to<br>Azithromycin 500mg +<br>Ambroxol Hydrochloride<br>BP 75mg | Antibiotic +<br>Mucolytic<br>agent   | It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.  • Upper Respiratory Tract Infections  | Contraindications: Azithromycin Plus is contraindicated in patients with known hypersensitivity to ambroxol, azithromycin, erythromycin, or any macrolide antibiotic.  Side effects: In clinical trials, most of the  | Azithromycin<br>250mg &<br>500mg Tablet<br>Ambroxol                                  |   | প্রয়োজনীয় রেফারেঙ্গ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।   |

| নং   | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)             | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|------|---|---|---|---------------------|---|--|--|---|--|--|
|      |   | Film Coated<br>Tablet   |   |                     | Pharyngitis/Tonsillitis Acute Bacterial Sinusitis Otitis Media  • Lower Respiratory Tract Infections Acute Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease Community-Acquired Pneumonia [CAP]  | reported side effects with azithromycin were mild to moderate in severity and were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. Rarely but potentially serious side effects were angioedema and cholestatic jaundice.  Ambroxol: The side effects on account of ambroxol include gastrointestinal side effects, skin rashes, headache, dizziness and sweating   | Hydrochloride<br>75mg Capsule                        |   |  |  |
| 111. | Popular Pharmaceutical s Limited, 164 Tongi Industrial Area, Tongi, Gazipur | Follicle Stimulating Hormone (FSH) (Urofollitropin) 150 IU/Vial Lyophilized Injection | Follicle Stimulating Hormone (FSH) (Urofollitropin) BP 150IU/Vial | Hormone             | FSH administered IM or SC with HCG in a sequential manner, which is indicated for ovulation indication in patients who have previously received pituitary suppression. Multi-follicular Development During ART FSH administered IM in conjunction with HCG is indicated for multiple follicular developments (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. Polycystic Ovarian Syndrome (OCOS). Used to treat Polycystic Ovarian Syndrome (PCOS) related infertility. IN Women; Starting dose of 150 to 225 international units (IU) of FSH is administered intramuscularly for at least the first 4 days of treatment. Subsequent doses are adjusted based upon ovarian response as determined by ultrasound evaluation of follicular growth and serum estradiol levels. Final Oocyte (egg) retrieval is performed 34 to 36 hours later Polycystic Ovarian Hyperstimulation (PCOS). FSH injections are therefore given each morning as an intramuscular injection. It is best to start with the lowest dose of FSH per day (using 75 IU) per day). There doses | Contraindications: Tumours of the ovary, breast, uterus, pituitary or hypothalamus. Pregnancy or lactation. Undiagnosed vaginal bleeding. Hypersensitivity to the active substance or to any of the excipients. Primary ovarian failure. Fibroid tumors of the uterus incompatible with pregnancy. Primary testicular failure.  Side effects: FSH sometimes excites the ovaries too much. This may cause pelvic pain or breathing problems. It may also make you urinate less. In rare cases, patients with this problem have had serious lung problems, including fluid in the lungs, troublebreathing, and worsening of asthma blood clots and strokes, severe pelvic pain, chest pain, or abdominal pain, Nausea, Vomiting, Sudden weight gain, Bloating, Trouble, breathing. FSH may cause twins or multiple births.  The most common side effects with FSH are headache, vaginal bleeding, nausea, and hot flashes. Sometimes there is a reaction at the spot where you give yourself the injection. This can include bruising, pain, or redness. | Follicle Stimulating Hormone (Urofollitrophin) 75 IU |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|---|---|--|----------------------|--|--|--|---|---|--|
| 112 | Popular Pharmaceuticals Limited, 164 Tongi Industrial Area, Tongi, Gazipur      | Olmesartan<br>Medoxomil 40 mg<br>+ Amlodipine<br>10mg Film Coated<br>Tablet | Olmesartan Medoxomil<br>BP 40mg + Amlodipine<br>Besilate BP 13.860mg<br>eq. to Amlodipine 10mg | Antihypertensiv<br>e | are used for 4 to 6 days at a time. The ovarian response is determined by measuring oestrogen levels in the blood. When the oestrogen beings to rise, the FSH is successfully growing an egg or eggs. If there is no response to a dose of FSH in 5-6 days of FSH 5-6 days of injections the dose will be increased. The normal dose increments are 75 units, 112 units, 150 units and 225 units per day. Most patients respond with 50 to 150 IU per day. However it is very important that increments are only made cautiously.  It is indicated for the treatment of hypertension, alone or with other antihypertensive agents.  Amlodipine+Olmesartan may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. | Contraindications: Combination of Amlodipine and Olmesartan is contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients.  Side effects: The overall incidence of side effects on therapy with Amlodipine and Olmesartan combination was similar to that  | Amlodipine 5mg + Olmesartan Medoxomil 20mg | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 113 | . Popular   | Sulindac 150mg  | Sulindac BP 150mg  | NSAIDS               | It is indicated for acute or long-term use in  | seen with corresponding doses of the individual components and to placebo. The common side effects include edema, hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia.  Contraindications: Patients known to be allergic  | 5mg + Olmesartan Medoxomil 40mg            | USFDA   | প্রয়োজন নেই বিধায়                                     | थ्राङ्ग त्नर                                     |
|     | Pharmaceutical<br>s Limited, 164<br>Tongi Industrial<br>Area, Tongi,<br>Gazipur | Tablet  |  |                      | the relief of signs and symptoms of the following:  1. Osteoarthritis  2. Rheumatoid arthritis  3. Ankylosing spondylitis  4. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis)  5. Acute gouty arthritis   | to Sulindac and those in whom acute asthmatic attacks, urticaria or rhinitis have been precipitated by Aspirin or other non-steroidal anti-inflammatory agents. Sulindac is also contraindicated in patients with a history of active gastro-intestinal bleeding or peptic ulceration. It should not be given to children, pregnant or lactating women.  Side effects: Gastrointestinal side effects are |  |   | আবেদন নামঞ্জুর করা<br>যেতে পারে।                        | বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |

| নং  | প্রস্তুতকারকে<br>নাম            | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)     | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----|---------------------------------|---|--|---------------------|--|--|--|---|--|--------------------|
|     |                                 |   |  |                     |  | the most common and consist of abdominal pain, nausea and constipation. Gastrointestinal ulceration and bleeding may also occur. The most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. Other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. A hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. Leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. There have also been reports of hepatitis and jaundice or renal failure. |  |   |  |                    |
| 114 | Renata Limited<br>Mirpur, Dhaka | Hydroxyethyl<br>Cellulose BP 1gm<br>+ Glycerin USP<br>1.30gm/50gm | Hydroxyethyl Cellulose<br>BP 1.0gm + Glycerin<br>USP 1.30gm/50gm | Lubricant           | Personal Lubricating Jelly is used for penile and/or vaginal application intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity | This product is not a contraceptive and does not contain a spermicide to any of the excipients.  | Glycerin 1.15<br>gm, 2.3 gm<br>Suppositories | USFDA   | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

| নং  | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম                       | জেনেরিক নাম                | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত   |
|-----|--|---------------------------------|----------------------------|---------------------|--|---|--|---|---|--|
|     |  | Personal<br>Lubricating Gel     |                            |                     | and supplement the body's natural lubrication.  Personal Lubricating Jelly is also used clinically to perform prostate examinations in men and gynecological examinations in women.  |   | 1.5gm/100 ml<br>Irrigation<br>Solution   |   |   |  |
| 115 | Renata Limited<br>Mirpur, Dhaka  | Levonorgestrel<br>0.03mg Tablet | Levonorgestrel BP<br>30mcg | Hormone             | The contraceptive action of Levonorgestrel may be explained as follows: it changes the cervical mucus so that a barrier is formed against the migration of sperm into the uterine cavity; nidation is impeded because of changes in the structure of the endometrium. As a rule there is no inhibition of ovulation. Evidence suggests that a reduction in corpus luteum function may also contribute to the contraceptive action. | Contra-indication: Known or suspected pregnancy, presence or history of severe hepatic disease, history of or existing thromboembolic processes (e.g. stroke, myocardial infarction), presence or history of liver tumours, known or suspected sex- steroid influenced malignancies (e.g. current or history of breast cancer), undiagnosed abnormal vaginal bleeding, severe diabetes with vascular changes, hypersensitivity to the active substance or to any of the excipients. If any of the conditions appear during the use of Levonorgestrel, the use of the preparation must be discontinued immediately.  Side-effect: The most commonly reported adverse reactions with progestogen-only pills including Levonorgestrel are uterine/vaginal bleeding including spotting, menorrhagia and/or metrorrhagia and amenorrhea. | 1500mcg and<br>750mcg Tablet             | MHRA  | পদটি বিষয়ে The<br>President<br>OGSB এর<br>মতামতের গ্রহণ করা<br>যেতে পারে।  | অধ্যাপক ডাঃ লায়লা আরজুমান্দ বানু, সভাপতি, ওজিএসবি Levonorges trel 0.03mg Tablet-Gi Safety, Efficacy & Usefulness মূল্যায়নপূর্বক অনুমোদনের মুপারিশ করেন। তাঁর মুপারিশের ভিত্তিতে পদটি অনুমোদন করা হল। |
| 116 | Sonear Laboratories Itd.  11/3-4, Toynbee circular road, motijheel commercial area, Dhaka. | Aspartame 25mg<br>Tablet        | Aspartame USP 25mg         | Sweetening agent    | As a non-nutritive sweetening agent.   | Contraindication: People with genetic disorder of phenylketonuria are advised to avoid aspartame. Also person allergic to aspartic acid, phenylalanine are also advised to avoid aspartame.  Side effects: Rarely causes headache, insomnia. No direct documentary evidence of carcinogenicity.   | 18mg Tablet                              |   | প্রয়োজনীয় রেফারেন্স<br>নেই এবং ১৮মিঃগ্রাঃ<br>ট্যাবলেট অনুমোদিত<br>বিধায় এই উচ্চ ডোজ<br>এর আবেদন নামঞ্জুর<br>করা যেতে পারে। | প্রয়োজনীয় রেফারেন্স<br>নেই এবং ১৮মিগ্রগ্রাঃ<br>ট্যাবলেট অনুদোদিত<br>বিধায় এই উচ্চ ডোজ<br>এর আবেদন নামঞ্জুর<br>করা হল।   |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |  |
|-----|---|---|--|---------------------|---|--|--|---|---|--|
| 117 | - Sonear<br>Laboratorie   | Sucralose 8.5mg<br>Tablet   | Sucralose USP 8.5mg  | Sweetening<br>agent | As a non-nutritive sweetening agent.  | Contraindication: Sucralose was found to affect glycemic and insulin responses, leading to an increase in peak plasma glucose concentration and insulin secretion rat.   | 8mg, 6.5mg &<br>12mg Tablet              |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
|     | s ltd.  |   |  |                     |   | Side effects: Rarely causes headache, dizziness, rash, intestinal cramping, sucralose has not shown any DNA damaging properties in DNA repair assays at normal consumption levels, and no evidence of carcinogenicity.   |  |   |   |  |
|     | 11/3-4,<br>Toynbee circu<br>road, motijhe<br>commercial are<br>Dhaka. |   |  |                     |   |  |  |   |   |  |
|     | . Square<br>Formulations<br>Ltd., Gorai,<br>Tangail                   | Amylase 1,20,000<br>USP Units +<br>Lipase 24000<br>USP Units +<br>Protease 76,000<br>USP Units<br>Capsule | Pancrelipase EC Pellets Ph. Grade 669.36mg (contains Amylase 1,20,000 USP Units + Lipase 24,000 USP Units + Protease 76,000 USP Units) | Enzymes             | It is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. | Contraindication: None.  Warnnigns: Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth Exercise caution when prescribing PANCREAZE to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE. | New                                      | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।               |
| 119 | . Square<br>Formulations<br>Ltd., Gorai,<br>Tangail                   | Amylase 15,000<br>USP Units +<br>Lipase 3000 USP<br>Units + Protease<br>9,500 USP Units<br>Capsule        | Pancrelipase EC Pellets Ph. Grade 83.67mg contains Amylase 15,000 USP Units + Lipase 3000 USP Units + Protease 9,500 USP Units         | Enzymes             | It is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. | Contraindication: None.  Warnnigns: Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE exceed 2,500 lipase  | New                                      | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।               | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।               |

| নং   | প্রস্তুতকারকে<br>নাম                              | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|------|---|--|---|---------------------|---|--|--|---|--|--|
|      |   |  |   |                     |   | units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth Exercise caution when prescribing PANCREAZE to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE. |  |   |  |  |
| 120. | Square<br>Formulations<br>Ltd., Gorai,<br>Tangail | Calcium L-5<br>Methyltetrahydrof<br>olate 1.00mg<br>Tablet       | Calcium L-5<br>Methyltetrahydrofolate<br>USP 1.00mg             | Mineral             | Folic acid is the man-made form of folate. Folate is a B-vitamin naturally found in some foods. It is needed to form healthy cells, especially red blood cells. Folic acid supplements may come in different forms (such as L-methylfolate, levomefolate, methyltetrahydrofolate). They are used to treat or prevent low folate levels. Low folate levels can lead to certain types of anemia. Conditions that can cause low folate levels include poor diet, pregnancy, alcoholism, liver disease, certain stomach/intestinal problems, kidney dialysis, among others. Women of childbearing age should receive adequate amounts of folic acid either through their diet or supplements to prevent infant spinal cord birth defects. | Contraindications: This product is contraindicated in patients with a known hypersensitivity to pregabalin or any of it's component.   | New  |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 121. | Square<br>Formulations<br>Ltd., Gorai,<br>Tangail | Canagliflozin 50mg + Metformin HCI 500mg Extended Release Tablet | Canagliflozin INN 50mg<br>+ Metformin<br>Hydrochloride BP 500mg | Antidiabetic        | This is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate  | Contraindications: Moderate to severe renal impairment (eGFR below 45 mL/min/1.73 m <sup>2</sup> ), end stage renal disease or dialysis. Metabolic acidosis, including diabetic ketoacidosis History of serious hypersensitivity reaction to canagliflozin or metformin  Adverse Effect: Most common adverse reactions associated with canagliflozin (5% or  | Metformin<br>500mg, 850mg<br>& 1000mg<br>Tablet<br>Canagliflozin<br>100mg Tablet | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।               |

| নং   | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস          | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                                  | সভার সিদ্ধান্ত   |
|------|--|--|--|------------------------------|---|--|---|---|---|--|
|      |  |  |  |                              |   | greater incidence): female genital mycotic infections, urinary tract infection, and increased urination  Most common adverse reactions associated with metformin (5% or greater incidence) are diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache   |   |   |   |  |
| 122. | Square<br>Formulations<br>Ltd., Gorai,<br>Tangail              | Dexrabeprazole<br>Sodium 10 mg<br>Tablet                       | Dexrabeprazole Sodium INN 10mg   | Proton pump<br>inhibitor     | GERD, Gastric and duodenal ulcer  | Hypersensitivty to any of the components of the formulation. Caution to be excercised when it is administerd to patients with severe hepatic dysfunction.  | Rabeprazole<br>10mg & 20mg<br>Tablet/Capsule  |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।     | প্রয়োজনীয়<br>রেফারেঙ্গ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।     |
| 123. | Square<br>Formulations<br>Ltd., Gorai,<br>Tangail              | Diphenhydramine<br>Citrate 38mg +<br>Ibuprofen 200mg<br>Tablet | Diphenhydramine Citrate USP 38mg + Ibuprofen DC 85 Ph. Grade 235.3mg contains Ibuprofen BP 200mg | Antihistamine +<br>Analgesic | Indicated for the sleeplessness due to minor aches and pains.Diphenhydramin is an antihistamine that causes drowsiness and ibuprofen reduces the inflammation and helps relieve inor aches and pains in adults and children not over than 12 years. | Contraindications: Aspirin allergy. Immediately before or after cardiac surgery. Side Effects: Upset stomach, nausea, vomiting, headache, diarrhea, constipation, dizziness, or drowsiness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. If your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. This medication may raise your blood pressure. | Diphenhydrami<br>ne 50mg Tablet<br>Ibuprofen<br>200mg, 300mg<br>& 400mg<br>Tablet;<br>100mg/5ml<br>Suspension | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                     | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                     |
| 124. | Square<br>Formulations<br>Ltd., Gorai,<br>Tangail              | Heme Iron Polypeptide contains elemental Iron 12.00mg          | Ph. Grade 666.67mg eq. to elemental Iron INN   | Mineral                      | It is used as iron supplement to prevent or<br>to treat low levels of iron in the blood (e.g.<br>due to anaemia or during pregnancy). It is<br>also indicated for anemia associated with<br>chronic Renal Failur                                    | Contraindication: Individual with known allergies to meat products or any ingredients of Hene Iron Polypeptide should not consume heme iron polypeptide. Also contraindicated to patients with hemochromatosis.  | Elemental Iron<br>100 mg/5 ml<br>Injection  |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে ।      | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।     |
| 125. | Square<br>Pharmaceutical<br>s Ltd., (Dhaka<br>Unit) Kaliakoir, | Dextrose<br>Anhydrous<br>400gm +<br>Potassium                  | Dextrose Anhydrous USP 4.00gm + Potassium Chloride BP 0.150gm + Sodium                           | Electrolytes                 | The Potassium Chloride, Sodium Chloride and Glucose intravenous infusion is indicated for  • Electrolyte imbalance  | Contraindication: The level of sodium and potassium in the Potassium Chloride, Sodium Chloride and Glucose is relatively low. Nevertheless it is contraindicated   | Dextrose 5gm +<br>225mg Sodium<br>Chloride/100ml,<br>Dextrose 5gm +   | BNF-74<br>Page: 952<br>[Glucose                 | একই জাতীয় পদ<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। | একই জাতীয় পদ<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref.  | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                                  | সভার সিদ্ধান্ত   |
|-----|---|---|--|---------------------|---|---|--|--|---|--|
|     | Gazipur   | Chloride 0.150gm<br>+ Sodium<br>Chloride 0.180gm<br>+/100ml IV<br>infusion                          | Chloride BP 0.180gm<br>/100ml  |                     | Replenishing fluid losses as a energy source Restoration and maintenance of sodium, potassiumand chloride ions in body fluids. It may be used as a vehicle of drug delivery (where intravenous delivery is appropriate and the drug is compatible with this solution.   | <ul> <li>In patients who has known hypersensitivity to the product</li> <li>In patients suffering from conditionin which the administration of either sodium chloride or potassium chloride alone is contraindicated</li> <li>In patien with hypernatraemia, hyperchloraemia and/or hyperkalaemia that are not related to the concentrationeffect associated to a volume depletion, severe renal insufficiency, uncompensated cardiac failure, Addison's disease and patients whi ha had a head trauma within 24 hours.</li> <li>This solution is also contraindicated in patients with uncompensated diabetes, other known glucose intolerances, hyperglycemia and hyperlactataemia</li> </ul>   | 450mg Sodium<br>Chloride/100ml,  | 4.00gm + Potassium Chloride 0.150gm + Sodium Chloride 0.180gm /100ml]                            |   |  |
| 126 | . Square<br>Pharmaceutical<br>s Ltd., (Dhaka<br>Unit) Kaliakoir,<br>Gazipur | Dextrose Anhydrous 400gm + Potassium Chloride 0.300gm + Sodium Chloride 0.180gm +/100ml IV infusion | Dextrose Anhydrous<br>USP 4.00gm +<br>Potassium Chloride BP<br>0.300gm + Sodium<br>Chloride BP 0.180gm<br>/100ml | Electrolytes        | The Potassium Chloride, Sodium Chloride and Glucose intravenous infusion is indicated for  • Electrolyte imbalance • Replenishing fluid losses • as a energy source • Restoration and maintenance of sodium, potassiumand chloride ions in body fluids. •It may be used as a vehicle of drug delivery (where intravenous delivery is appropriate and the drug is compatible with this solution. | Contraindication: The level of sodium and potassium in the Potassium Chloride, Sodium Chloride and Glucose is relatively low. Nevertheless it is contraindicated  In patients who has known hypersensitivity to the product  In patients suffering from conditionin which the administration of either sodium chloride or potassium chloride alone is contraindicated  In patien with hypernatraemia, hyperchloraemia and/or hyperkalaemia that are not related to the concentrationeffect associated to a volume depletion, severe renal insufficiency, uncompensated cardiac failure, Addison's disease and patients whi ha had a head trauma within 24 hours.  This solution is also contraindicated in patients with uncompensated diabetes, other known glucose intolerances, hyperglycemia and hyperlactataemia | Dextrose 5gm + 225mg Sodium Chloride/100ml,  Dextrose 5gm + 450mg Sodium Chloride/100ml, | BNF-74 Page: 952  [Glucose 4.00gm + Potassium Chloride 0.300gm + Sodium Chloride 0.180gm /100ml] | একই জাতীয় পদ<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। | একই জাতীয় পদ<br>অনুমোদিত রয়েছে<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম                                   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                                  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |                           | সভার সিদ্ধান্ত      |
|-----|---|---|---|---------------------|--|---|---|---|---------------------------|---------------------|
| 127 | Square<br>Pharmaceutical<br>s Ltd., (Dhaka<br>Unit) Kaliakoir,<br>Gazipur | Phenylephrine<br>Hydrochloride<br>10mg/ml Injection | Phenylephrine<br>Hydrochloride USP<br>10mg/ml | Vasopressor         | It is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, or hypersensitivity. It is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. | Contraindication: None  Side effect: Most common adverse reactions during treatment: nausea, vomiting, and headache.  | 2.5% Eye<br>Drops  Phenylepherine HCI 50mg + Tropicamide 8mg/ml Eye Drops | USFDA<br>+<br>BNF-74<br>Page: 183               | অনুমোদন করা যেতে<br>পারে। | অনুমোদন করা<br>হল।  |
| 128 | Square Pharmaceutical s Ltd., (Dhaka Unit) Kaliakoir, Gazipur             | Sodium Chloride<br>3gm/100ml IV<br>Infusion         | Sodium Chloride BP<br>3gm/100ml               | Electrolytes        | 3% sodium chloride is indicated as a source of water and electrolytes. It is used in the management of severe sodium chloride depletion when electrolyte restoration is required. It is also used to treat cerebral Oedema, raised ICP and Hyponatraemic seizures.   | Contraindication: None Known Adverse Reactions: Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.  Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a well-placed small bore needle is recommended.  The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted.  Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. | Sodium<br>Chloride 0.9%<br>IV Infusion                                    | USFDA,<br>Bangladesh<br>Govt.                   | অনুমোদন করা যেতে<br>পারে। | অনুমোদন করা<br>হল । |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নির্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|---|---|---|----------------------|--|--|---|---|---|--|
|     |   |   |   |                      |  | Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume.  |   |   |   |  |
|     |   |   |   |                      |  | If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.  |   |   |   |  |
|     |   |   |   |                      |  | If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.  |   |   |   |  |
| 129 | . Square<br>Pharmaceuticals<br>Ltd., Pabna Unit,<br>Salgaria, Pabna | mg +  | Amlodipine Besilate BP 7mg eqv. to 5mg Amlodipine + Valsartan 160 mg + Hydrochlorothiazide 12.5 mg Tablet | Antihypertensiv<br>e | Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. This combination is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes, and myocardial infarctions | Anuria, Hypersensitivity to Contraindications: sulfonamide-derived drugs, Known hypersensitivity to any component, Do not coadminister aliskiren with this product in patients with diabetes.  Side-effect: Most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis | Amlodipine 10mg + Hydrochlorothia zide 25mg + Valsartan 160mg Tablet                | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামপ্তুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 130 | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna           | Aspirin 250mg +<br>Acetaminophen<br>250mg + Caffeine<br>65mg Tablet | Aspirin BP 250mg + Acetaminophen USP 250mg + Caffeine BP 65mg   | NSAID                | Treatment of acute migraine attacks with or without aura in adults   | Contraindications: Contraindicated in the patients with salicylate hypersensitivity. Patient with aspirin-induced allergic reaction (e.g. allergic induced urticarial) are at risk of developing bronchoconstriction or anaphylaxis. Should not be used in patients with cardiac disease. Caffeine can stimulate the force of contraction and can increase heart rate.     | Caffeine 65 mg<br>+ Paracetamol<br>500 mg Tablet,<br>Aspirin 75 mg,<br>300mg Tablet | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম         | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                              |  |
|-----|---|-------------------|---------------|---------------------|--|---|--|---|---|--|
| 131 | . Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna | Biotin 3mg Tablet | Biotin BP 3mg | Vitamin             | It is indicated for prevention and treatment of vitamin B deficiency. Vitamin B deficiency may occur as a result of inadequate nutrition or intestinal malabsorption but does not occur in healthy individuals receiving an adequate balanced diet. Simple nutritional deficiency of individual B vitamins is rare since dietary inadequacy usually results in multiple deficiencies. For prophylaxis of biotin deficiency, dietary improvement, rather than supplementation, is advisable. For treatment of biotin deficiency, supplementation is preferred. Biotin deficiency may lead to dermatitis, alopecia, hypercholesterolemia, and cardiac abnormalities.  Requirements may be increased and/or supplementation may be necessary in the following conditions (based on documented biotin deficiency):  Biotinidase deficiency, Gastrectomy  Seborrheic dermatitis of infancy  Administration of large amounts of the biotin antagonist, avidin, which is found in raw egg whites, has also been found to cause biotin deficiency.  Some unusual diets (e.g., reducing diets that drastically restrict food  selection) may not supply minimum daily requirements of biotin  Supplementation may be necessary in patients receiving total parenteral nutrition (TPN) or undergoing rapid weight loss or in those with malnutrition, because of inadequate dietary intake.  Unaccepted Biotin has not been proven effective in the treatment of acne, seborrheic eczema, or alopecia. | Contraindications: None known.  Side Effects: Biotin may not have any known side effects through normal use, but that does not mean that an excess use of the vitamin does not have its drawbacks. Even with using too much of the vitamin, there aren't many side effects reported. Even in cases where extremely high doses were given (either by mouth or IV) there aren't many instances of side effects. These few instances have arisen over the years:  One documented case involved a very high dose of vitamin B7 (biotin) along with vitamin B5 that caused a lifethreatening condition called eosinophilic pleuropericardial effusion. The condition promptly subsided once the treatment with vitamin B7 and vitamin B5 was stopped. There is a possibility that the combination of the two vitamins in high doses caused the condition, but it could have also been something completely unrelated. In animal studies, pregnant rats were given high doses of biotin. The test results showed that the placenta of the fetal rats decreased in size which increased the possibility of miscarriage. It is not known why or how this occurred and is unknown if the same problem could happen in human mothers. | New                                      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম         | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |  |
|-----|---|-------------------|---------------|---------------------|---|---|--|---|---|--|
| 132 | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna | Biotin 5mg Tablet | Biotin BP 5mg | Vitamin             | Biotin deficiency (prophylaxis and treatment)  The B vitamins are indicated for prevention and treatment of vitamin B deficiency.  Vitamin B deficiency may occur as a result of inadequate nutrition or intestinal malabsorption but does not occur in healthy individuals receiving an adequate balanced diet. Simple nutritional deficiency of individual B vitamins is rare since dietary inadequacy usually results in multiple deficiencies.  For prophylaxis of biotin deficiency, dietary improvement, rather than supplementation, is advisable. For treatment of biotin deficiency, supplementation is preferred. Biotin deficiency may lead to dermatitis, alopecia, hypercholesterolemia, and cardiac abnormalities. Requirements may be increased and/or supplementation may be necessary in the following conditions (based on documented biotin deficiency):  Biotinidase deficiency, Gastrectomy  Biotinidase deficiency, Gastrectomy  Administration of large amounts of the biotin antagonist, avidin, which is found in raw egg whites, has also been found to cause biotin deficiency.  Some unusual diets (e.g., reducing diets that drastically restrict food  selection) may not supply minimum daily requirements of biotin, Supplementation may be necessary in patients receiving total parenteral nutrition (TPN) or undergoing rapid weight loss or in those with malnutrition, because of inadequate dietary intake. Unaccepted Biotin has not been proven effective in the treatment of acne, seborrheic eczema, or alopecia. | Contraindications: None known.  Side Effects: Biotin may not have any known side effects through normal use, but that does not mean that an excess use of the vitamin does not have its drawbacks. Even with using too much of the vitamin, there aren't many side effects reported. Even in cases where extremely high doses were given (either by mouth or IV) there aren't many instances of side effects. These few instances have arisen over the years:  One documented case involved a very high dose of vitamin B7 (biotin) along with vitamin B5 that caused a lifethreatening condition called eosinophilic pleuropericardial effusion. The condition promptly subsided once the treatment with vitamin B7 and vitamin B5 was stopped. There is a possibility that the combination of the two vitamins in high doses caused the condition, but it could have also been something completely unrelated. In animal studies, pregnant rats were given high doses of biotin. The test results showed that the placenta of the fetal rats decreased in size which increased the possibility of miscarriage. It is not known why or how this occurred and is unknown if the same problem could happen in human mothers. | New                                      |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং   | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম                                       | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                             | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  | সভার সিদ্ধান্ত   |
|------|---|---|---|---------------------|--|---|--|---|--|--|
| 133. | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna             | Canagliflozin 50mg + Metformin HCI 500mg Tablet | Canagliflozin INN 50mg + Metformin Hydrochloride BP 500mg         | Antidiabetic        | This is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate   | Contraindications: Moderate to severe renal impairment (eGFR below 45 mL/min/1.73 m²), end stage renal disease or dialysis. Metabolic acidosis, including diabetic ketoacidosis History of serious hypersensitivity reaction to canagliflozin or metformin  Adverse Effect: Most common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination  Most common adverse reactions associated with metformin (5% or greater incidence) are diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache | Metformin Hydrochloride BP 1000mg Tablet  Canagliflozin 100mg Tablet | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                 |
| 134. | Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna | Chlorhexidine<br>Gluconate<br>71mg/gm Gel       | Chlorhexidine Gluconate<br>Solution 20% (W/V) BP<br>35.50gm/100gm | Antiseptic          | It is indicated for prophylaxis of omphalitis (infection of the umbilical cord) in newborn infants.  | Contraindications: For the caregiver - This product should not be handled by anyone with a known history of hypersensitivity to chlorhexidine.  | 4% Solution<br>1% Gel &<br>Cream                                     | EMA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।   |
| 135. | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna             | Deflazacort 1mg<br>Tablet                       | Deflazacort INN 1mg   | Glucocorticoid      | Asthma and other airway Diseases, Rheumatoid arthritis, juvenile chronic arthritis, pemphigus, uveitis, nephritic, syndrome,Immune suppression in transplantation, anaphylaxis, severe,hypersensitivity reactions, dermatomyositis, mixed connective, tissue disease, polyarteritis nodosa, bullous pemphigoid, ulcerative colitis, optic neuritis, autoimmune haemolytic anaemia, idiopathic, thrombocytopenic, purpura, acute and lymphatic leukaemia, malignant lymphoma. | Contraindications: Systemic infection; live virus vaccines in those receiving immunosuppressive doses.  Side Effects: GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.   | 6mg, 24mg<br>Tablet<br>&<br>120mg/100ml<br>Suspention                |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীয়<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস      | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)         | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |  |  |
|-----|---|--|---|--------------------------|--|---|--|---|--|--|
| 136 | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna               | Diclofenac<br>Potassium<br>50mg/Sachet   | Diclofenac Potassium<br>USP 50mg/Sachet   | NSAID                    | Diclofenac Potassium for Oral Solution is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Important Limitations  1. Diclofenac Potassium for Oral Solution is not indicated for the prophylactic therapy of migraine.  2. The safety and effectiveness of Diclofenac Potassium for Oral Solution have not been established for cluster headache, which is present in an older, predominantly male population. | Contraindications: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.  BOXED WARNING WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk Diclofenac Potassium for Oral Solution is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery Gastrointestinal Risk NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. | Diclofenac<br>Potassium<br>25mg, 50 mg<br>Tablet | USFDA   | Diclofenac Potassium এর কারনে serious cardiovascular and gastrointestinal events (Esophagitis) এর ঝুকি রয়েছে বিধায় আবেদন নামপ্তুর করা যেতে পারে। | Diclofenac Potassium এর কারনে serious cardiovascula r and gastrointestin al events (Esophagitis ) এর ঝুকি রয়েছে বিধায় আবেদন নামঞ্জুর করা হল। |
| 137 | . Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna | Elemental Calcium 800mg + Colecalciferol 10mg + Vitamin k <sub>2</sub> 180mcg Tablet | Calcium Carbonate CS 90 Ph. Grade 2222.22mg eq. to 800mg of Elemental Calcium + Colecalciferol (1 lac IU/gm) BP 10mg (Dry Vitamin D <sub>3</sub> 1000 IU) + | Vitamin<br>&<br>Minerals | It is indicated to support healthy bones, Vitamin D, Vitamin K or Calcium Deficiency in adults and postmenopausal women.  Moreover inerali Calcium Delivery.Vitamin D is required for optimal calcium and phosphorous absorption. Vitamin D is required to maintain normal blood levels of   | Contraindications: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.  Side effects: Allergic sensitization has been reported following administration of folic acid.   | Calcium 500mg<br>+ Vitamin D3<br>200 IU          |   | প্রয়োজনীয় রেচারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।  | প্রয়োজনীয়<br>রেঢারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।   |

| নং | প্রস্তুতকারকে<br>নাম | ঔষধের নাম | জেনেরিক নাম                   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication & Side-effect | Status<br>(New | আবেদনকারী<br>কর্তৃক | টেকনিক্যাল সাব<br>কমিটির সভার | সভার সিদ্ধান্ত |
|----|----------------------|-----------|-------------------------------|---------------------|--|---------------------------------|----------------|---------------------|-------------------------------|----------------|
|    |                      |           |                               |                     |  | Olde-Cheet                      | Molecule/      | USFDA/BNF           | সিদ্ধান্ত                     |                |
|    |                      |           | 100                           |                     |  |                                 | Existing)      | / MHRA Ref.         |                               |                |
|    |                      |           | Vitamin K <sub>2</sub>        |                     | calcium and phosphate, which are in turn                             |                                 |                |                     |                               |                |
|    |                      |           | (menaquinone-7) Ph.           |                     | needed for the normal ineralization of                               |                                 |                |                     |                               |                |
|    |                      |           | Grade 90mg eq. to             |                     | bone, muscle contraction, nerve                                      |                                 |                |                     |                               |                |
|    |                      |           | Vitamin k <sub>2</sub> 180mcg |                     | conduction, and general cellular function in                         |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | all cells of the body as well as bone growth                         |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | and maintenance of bone density. Vitamin                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | K is responsible for the carboxylation of the                        |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | bone protein, osteocalcin, to its active form.                       |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | Osteocalcin regulates the function of calcium in bone turnover /bone |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | ineralization/bone development. MK-7 may                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | play a role in bone health.; MK-7 may be                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | involved in (bone health/maintenance of                              |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | healthy bone/normal bone/bone health).                               |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | May help to increase bone mineral density.                           |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | For optimal delivery of calcium into the                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | bones. More than 99% of total body                                   |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | calcium is stored in the bones and teeth.                            |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | Clinically trialled dose of Vitamin K2 (MK-7)                        |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | which may help decrease bone loss in                                 |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | postmenopausal women Supplementation                                 |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | of K2 (MK-7) may help decrease bone loss                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | in postmenopausal women; Maintaining                                 |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | adequate Vitamin K2 (MK-7) levels may                                |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | help decrease bone loss in post-                                     |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | menopausal women. Calcium is essential                               |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | for bone mineralisation. D3 is the preferred                         |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | form of vitamin D/ the form found in the                             |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | human body. Vitamin D is required for                                |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | optimal calcium and phosphorous                                      |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | absorption. Adequate serum vitamin D                                 |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | level is required for bone and muscle                                |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | health. Vitamin D is important for                                   |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | absorption of calcium and phosphorous                                |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | from the small intestine, extracellular                              |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | calcium homeostasis and mineralisation of                            |                                 |                |                     |                               |                |
|    |                      |           |                               |                     | the skeleton.  |                                 |                |                     |                               |                |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস            | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)  | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   |   |
|-----|---|---|---|--------------------------------|--|--|---|---|---|---|
| 138 | . Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna             | Fluticasone Propionate 0.005gm + Mupirocin 2gm/100gm Ointment   | Fluticasone Propionate<br>BP 0.005gm + Mupirocin<br>USP 2gm/100gm   | Corticosteroid<br>+ Antibiotic | It is indicated for the treatment, control, prevention and improvement of the following diseases, conditions and symptoms of  Wounds  Skin Infection caused by bacteria Impetigo Seasonal and year round allergic Stuffy/runny nose Itching and sneezing Itchy and watery eyes | Contraindications: This combination is contraindicated in patients who are hypersensitive to fluticasone Propionate and Mupirocin.  Side effects: The possible side effects that may occur include reddening of the skin, Rash of round, red welts on the skin, swelling of the eye lips, allergy and itching on skin. | Fluticasone 5 mg/100 gm Cream; 50 mg/100 gm Cream 2 mg/2 ml Respirator Suspension  Mupirocin 100 mg/5 gm Ointment |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে ।  | প্রয়োজনীয়<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।  |
| 139 | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna               | Fusidic Acid<br>2.00gm +<br>Halobetasol<br>Propionate<br>0.05gm/100gm<br>Cream  | Fusidic Acid BP 2.00gm<br>+ Halobetasol<br>Propionate USP<br>0.05gm/100gm   | Anti-Dermatitis                | It is indicated for dermatitis with infections caused by Staphylococci, Streptococci, Corynebacterium and other organism sensitive to Fusidic Acid.  | Contraindications: Known hypersensitivity to the product or any of its constituents.   | Fusidic Acid 2% + Hydrocortisone Acetate 1% Cream  Halobetasol Propionate 0.05% Cream                             |   | প্রয়োজনীট রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।  | প্রয়োজনীত<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 140 | . Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna | Halobetasol Propionate 0.050gm + Miconazole Nitrate 2.00gm + Gentamycin Sulfate 0.156gm eq. to 0.10gm Gentamycin/100g m Cream | Halobetasol Propionate USP 0.05gm + Miconazole Nitrate BP 2.0gm + Gentamycin Sulfate BP 0.156gm eqv. to 0.10gm Gentamycin/100gm               | Anti-Fungal +<br>Antibiotic    | It is indicated for  1. Dermatitises complicated with secondary bacterial infections  2. Wounds  3. Impetigo  4. Itching and sneezing  | Contraindications:  Known hypersensitivity to the product or any of its constituents.  | Halobetasol<br>Propionate<br>0.05% Cream  |   | প্রয়োজনীয় রেফারেন্স<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজনীট<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 141 | . Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria,<br>Pabna | L-Lysine 2.0gm + Vitamin A + Vitamin A 40,000 IU & vitamin D3 8000 IU + Vitamin A Palmitate                                   | L –Lysine Hydrochloride<br>USP 2.499 gm<br>Equivalent to 2.0 gm of L<br>–Lysine + Vitamin A +<br>D3, Type 100/20 Dried<br>Vitamin D Ph. Grade | Multivitamin                   | It is indicated for dietary supplement for children of growing age. It contains, Vitamin B1, B2, B6 which are necessary for the normal processes in protein, fat and carbohydrate metabolism. The presence of Vitamin C helps to   | Contraindication Hypersensitivity to any of the active ingredients.  |   |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।   | প্রয়োজনীঢ<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং   | প্রস্তুতকারকে<br>নাম   | ঔষধের নাম   | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing)                       | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                             | সভার সিদ্ধান্ত  |
|------|--|---|---|---------------------|--|--|--|---|--|---|
|      |  | 35.300mg Equivalent to 60,000 IU of Vitamin A + Vitamin E 200 IU + Thiamine 40 mg + Riboflavin 20 mg + Pyridoxine 20 mg + Vitamin C 600.000 mg + Nicotinamide 400.000 mg + Dex Panthenol 200.000 mg/100ml Syrup | 0.400 ml Equivalent to 40,000 IU of Vitamin A & 8000 IU vitamin D3 + Vitamin A Palmitate BP 35.300 mg Equivalent to 60,000 IU of Vitamin A + Vitamin E Acetate Oily BP 400.000 mg Equivalent to 200 IU of Vitamin E, as DL Alpha Tocopherol 50% Acetate + Vitamin B1 BP 50.840 mg Equivalent to 40 mg Thiamine as Thiamine Hydrochloride + Vitamin B2 BP 25.420 mg Equivalent to 20 mg Riboflavin as Riboflavin sodium 5- phosphate + Vitamin B6 BP 24.300 mg Equivalent to 20 mg Pyridoxine as Pyridoxine Hydrochloride + Vitamin C BP 600.000 mg + Nicotinamide BP 400.000 mg + Dex Panthenol BP 200.000 mg/100ml |                     | maintain healthy teeth and gums. The fat soluble Vitamin! and D3 ensure the maintenance of proper level of calcium in the body fluids. The latter ensures healthy growth of bones and teeth. Vitamin E is required for proper cell function. Nicotinamide is essential for healthy skin and nervous system. L-lysine improves health and growth. |  |  |   |  |   |
| 142. | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna    | Myo-inositol 2000mg + Melatonin 1mg + Folic 0.20mg/Sachet   | Myo-inositol BP 2000mg<br>+ Melatonin BP 1mg +<br>Folic BP 0.20mg/Sachet  | Vitamin             | It is indicated for the treatment of women suffers from PCOS (Polycystic Ovary Syndrome) and to improve fertility.   | Contraindications: This combination is contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients.                                       | Inositol 500mg,<br>700mg Tablet<br>Melatonin 3 mg<br>Tablet    |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীঢ<br>রেফারেন্স নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 143. | Square<br>Pharmaceutical<br>s Ltd., Pabna<br>Unit, Salgaria, | Sodium Alginate<br>250mg + Sodium<br>Bicarbonate<br>106.50mg +<br>Calcium   | Sodium Alginate USP<br>250mg + Sodium<br>Bicarbonate BP<br>106.50mg + Calcium<br>Carbonate (Heavy) BP   | Antacid             | It is indicated for the treatment of gastro-<br>oesophageal reflux i.e. acid regurgitation,<br>heartburn, indigestion (for example following<br>meals or during pregnancy) and for symptoms<br>of excess stomach acid (hyperacidity)   | Contraindications: Hypersensitivity to the active substances or to any of the excipients, including the esters of hydroxybenzoates (parabens).  Side effects: Very rarely (<1/10,000) patients | Potassium<br>Bicarbonate<br>100 mg +<br>Sodium<br>Alginate 500 | MHRA  | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।                |

| নং  | প্রস্তুতকারকে<br>নাম                                      | ঔষধের নাম  | জেনেরিক নাম                                   | থেরাপিউটিক<br>ক্লাস | নির্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                         | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                             | সভার সিদ্ধান্ত  |
|-----|---|--|---|---------------------|--|--|--|---|--|---|
|     | Pabna   | Carbonate<br>(Heavy) 187.50mg<br>Tablet                            | 187.50mg                                      |                     | It acts in a dual mechanism mood, quickly neutralizes excess stomach acid and also forms a protective layer over stomach content   | sensitive to the ingredients may develop<br>allergic manifestations such as urticaria or<br>bronchospasm, anaphylactic or anaphylactoid<br>reactions   | mg Tablet  |   |  |   |
| 144 | Square Pharmaceutical s Ltd., Pabna Unit, Salgaria, Pabna | Sucralfate<br>10gm/100ml Oral<br>Suspension                        | Sucralfate USP<br>10gm/100ml                  | Antiulcerant        | It is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer   | Contraindications: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.  Side Effects: the following signs or symptoms that may be related to a very bad side effect:  Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.  Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit. | 500mg<br>and<br>1.0gm Tablet<br>20gm/100ml<br>Oral<br>Suspension | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে।                | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।              |
| 145 | The IBN SINA Pharmaceutical s Industries Ltd.             | Abaloparatide<br>INN 2000 mcg/<br>1ml<br>Subcutaneous<br>Injection | Abaloparatide INN 2000 mcg/ml                 | Hormone<br>Analog   | It is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.  | Contra-indication: None. Side-effect: Hyper calciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.   | New  |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীঢ<br>রেফারেপ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 146 | The IBN SINA Pharmaceutical s Industries Ltd.             | Elbasvir INN 50<br>mg + Grazoprevir<br>INN 100 mg<br>Tablet        | Elbasvir INN 50 mg +<br>Grazoprevir INN 100mg | Antiviral           | It is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without r bavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. | Contra-indication: Patients with moderate or severe hepatic impairment (Child-Pugh B or C). OATP1B1/3 inhibitors, strong CYP3A inducers, and efavirenz. If ZEPATIER is administered with ribavirin, the contraindications to r bavirin also apply.  Side-effect: the most commonly reported adverse reactions of all intensity (greater than or equal to 5% in placebo-controlled trials) were fatigue, headache, and nausea. In subjects receiving it with ribavirin for 16 weeks,  | New  | USFDA   | অনুমোদন করা যেতে<br>পারে ।   | অনুমোদন করা<br>হল।  |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা  | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing)   | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                             | সভার সিদ্ধান্ত  |
|-----|---|--|--|---------------------|--|---|--|---|--|---|
|     |   |  |  |                     |  | the most commonly reported adverse reactions of moderate or severe intensity (greater than or equal to 5%) were anemia and headache.  |  |   |  |   |
| 147 | The IBN SINA Pharmaceutical s Industries Ltd.                               | Sumatriptan<br>Succinate 11.0<br>mg Nasal powder<br>for Inhalation | Sumatriptan Succinate USP 15.4 mg eq. to Sumatriptan 11 mg | Antimigraine        | It is a serotonin 5-HT1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults.  Limitations of Use: Use only if a clear diagnosis of migraine headache has been established  Not indicated for the prophylactic therapy of migraine attacks  Not indicated for the treatment of cluster headache | Contra-indication: History of coronary artery disease (CAD) or coronary vasospasm, Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders, History of stroke, transient ischemic attack, or hemiplegic or basilar, migraine, Peripheral vascular disease, Ischemic bowel disease, Uncontrolled hypertension. Recent (within 24 hours) use of another 5-HT1 agonist (e.g., another triptan) or of an ergotamine-containing medication, Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen), Severe hepatic impairment. Side-effect: the most common adverse reactions (incidence of ≥ 2% and greater than placebo) were abnormal taste, nasal discomfort, rhinorrhea, and rhinitis. | 50 & 100 mg<br>Tablet  | USFDA   | অনুমোদন করা যেতে<br>পারে।  | অনুমোদন করা<br>হল।  |
| 148 | . UniMed &<br>UniHealth Mfg.<br>Ltd. B.K, Bari<br>Gazipur Sadar,<br>Gazipur | Acetylcystein<br>2.0gm/100 ml<br>Syrup                             | Acetylcystein BP 2.0gm/100 ml                              | Mucolytic           | Fluimucil Mucolytic is used for the treatment of respiratory disorders characterized by hyper-dense and sticky.  | Contra-indications: Hypersensitivity to the active substance or to any of the excipients. The drug is contraindicated in children less than 2 years.  Side effects: Like all medicines, Fluimucil Mucolytic can cause side effects, although not everybody gets them. The following is a table showing the frequency of adverse reactions reported after taking N-acetylcysteine by mouth: System Organ Class Adverse Reactions uncommon (> / = 1 / 1,000, / = 1 / 10,000,  | 100mg & 200mg Effervescant Granules 600 mg Tablet 100mg/ml & 200mg/ml Resperitory Solution |   | প্রয়োজনীয় রেফারেপ<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে । | প্রয়োজনীত<br>রেফারেপ নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং   | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম                                    | জেনেরিক নাম                              | থেরাপিউটিক<br>ক্লাস  | নিৰ্দেশনা  | Contra-indication & Side-effect   | Status<br>(New<br>Molecule/<br>Existing)              | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত                                   |
|------|---|--|--|----------------------|--|---|---|---|---|--|
| 149. | UniMed &<br>UniHealth Mfg.<br>Ltd. B.K, Bari<br>Gazipur Sadar,<br>Gazipur | Deflazacort 18 mg<br>Tablet                  | Deflazacort INN 18 mg                    | Glucocorticoid       | Asthma and other airway Diseases, Rheumatoid arthritis, juvenile chronic arthritis, pemphigus, uveitis, nephritic, syndrome,Immune suppression in transplantation, anaphylaxis, severe,hypersensitivity reactions, dermatomyositis, mixed connective, tissue disease, polyarteritis nodosa, bullous pemphigoid, ulcerative colitis, optic neuritis, autoimmune haemolytic anaemia, idiopathic, thrombocytopenic, purpura, acute and lymphatic leukaemia, malignant lymphoma. | Contraindications: Systemic infection; live virus vaccines in those receiving immunosuppressive doses.  Side Effects: GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.                         | 6mg, 24mg<br>Tablet<br>&<br>120mg/100ml<br>Suspention | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 150  | UniMed &<br>UniHealth Mfg.<br>Ltd. B.K, Bari<br>Gazipur Sadar,<br>Gazipur | Minocycline<br>Hydrochloride<br>50mg Capsule | Minocycline<br>Hydrochloride USP<br>50mg | Antibiotic           | It is Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)   | Cautions: Systemic lupus erythematosus I Side-effects:  ► Rare Acute renal failure . alopecia . anorexia . hyperaesthesia . impaired hearing . paraesthesia . pigmentation (sometimes irreversible).tinnitus  ► Very rare Discoloration of conjunctiva . discoloration of sweat. discoloration of tears . systemic lupus erythematosus  ► Frequency not known Dizziness (more common in women) . vertigo (more common in women) | 100mg Tablet  | BNF-74<br>Page: 535                             | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |
| 151. | UniMed &<br>UniHealth Mfg.<br>Ltd. B.K, Bari<br>Gazipur Sadar,<br>Gazipur | Pirfenidone<br>801mg Tablet                  | Pirfenidone BP 801 mg                    | Respiratory<br>Agent | It is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF)  | Contra-indication: None Adverse Reactions: The most common adverse reactions (≥10%) are nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastro-esophageal reflux disease, sinusitis, insomnia, weight decreased, and arthralgia Warnings and Precautions: Elevated liver enzymes: ALT, AST, and   | 267 mg<br>Capsule                                     | USFDA   | অনুমোদন করা থেতে<br>পারে।                               | অনুমোদন করা<br>হল।                               |

| নং  | প্রস্তুতকারকে<br>নাম  | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস   | নিৰ্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing)                             | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত   |
|-----|---|--|---|-----------------------|--|--|--|---|---|--|
|     |   |  |   |                       |  | bilirubin elevations have occurred with Pirfenidone. Monitor ALT, AST, and bilirubin before and during treatment. Temporary dosage reductions or discontinuations may be required.  Photosensitivity and rash: Photosensitivity and rash have been noted with Pirfenidone. Avoid exposure to sunlight and sunlamps. Wear sunscreen and protective clothing daily. Temporary dosage reductions or discontinuations may be required. Gastrointestinal disorders: Nausea, vomiting, diarrhea, dyspepsia, gastroesophageal reflux disease, and abdominal pain have occurred with Pirfenidone. Temporary dosage reductions or discontinuations may be required. |  |   |   |  |
| 152 | UniMed &<br>UniHealth Mfg.<br>Ltd. B.K, Bari<br>Gazipur Sadar,<br>Gazipur | Salicylic Acid<br>12.00gm +Lactic<br>Acid<br>4.00gm/100gm<br>Gel   | Salicylic Acid BP<br>12.00gm + Lactic Acid<br>BP 4.00gm/100gm | Keratolytic<br>Agents | It is a treatment for calluses, corns, verrucas and warts.   | Side-effects: While the gel is working you may feel a slight tingling sensation and/or some mild tenderness at the treated area. This is usually temporary, and in rare cases may appear as a temporary blemish on the skin.   | Clobetasol<br>Propionate<br>0.05% +<br>Salicylic Acid<br>3% Ointment | BNF-74<br>Page:1182                             | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।   |
| 153 | Ziska<br>Pharmaceutical<br>s Ltd.   | Dapsone 7.5%<br>Gel  | Dapsone USP<br>7.5gm/100gm                                    | Antiacne              | It is a sulfone indicated for the topical treatment of acne vulgaris in patients 12 years of age and older                     | Contraindications: None. Side effects: Most common (incidence ≥ 0.9%) adverse reactions are application site dryness and pruritus.   | Dapsone 50 mg<br>& 100 mg tablet                                     | USFDA   | অনুমোদন করা যেতে<br>পারে।                               | অনুমোদন করা<br>হল।   |
|     | Ziska<br>Pharmaceutical<br>s Ltd.   | Dexlansoprazole 30mg Delayed- Release Orally Disintegrating Tablet | Dexlansoprazole INN<br>30mg                                   | Antiulcerant          | It is indicated in adults for: • Maintaining healing of EE and relief of heartburn. • Treating heartburn associated with GERD. | Contraindications: Patients with known hypersensitivity to any component of the formulation. • Patients receiving rilpivirine-containing products.  Side-effects: Most commonly reported adverse reactions (≥2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.   | Dexlansoprazol<br>e delayed-<br>release capsule<br>30 mg & 60 mg     | USFDA   | বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে।                 | Antiulcerant<br>হিসাবে<br>Disintegrating<br>Tablet প্রয়োজন<br>নেই বিধায়<br>আবেদন নামপ্তুর<br>করা হল। |
| 155 | Ziska<br>Pharmaceutical<br>s Ltd.   | Eprosartan<br>Mesylate 600mg +<br>Hydrochlorothiazi                | Eprosartan Mesylate INN<br>600mg +<br>Hydrochlorothiazide BP  | Antihypertensiv<br>e  | Eprosartan & Hydrochlorothiazide is indicated for the treatment of hypertension. It may be used alone or in combination with   | Contraindications: Eprosartan & Hydrochlorothiazide is contraindicated in patients who are hypersensitive to this product  | Eprosartan 400<br>mg & 600 mg<br>Tablet                              | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল।   |

| নং  | প্রস্তুতকারকে<br>নাম              | ঔষধের নাম  | জেনেরিক নাম   | থেরাপিউটিক<br>ক্লাস  | নির্দেশনা  | Contra-indication & Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|-----------------------------------|--|---|----------------------|--|--|--|---|---|--|
|     |                                   | de 12.5 mg Tablet  | 12.5 mg   |                      | other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy.  | or any of its components. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. Do not co-administer aliskiren with Eprosartan & Hydrochlorothiazide in patients with diabetes Side effects: Eprosartan/hydrochlorothiazide combination therapy was well tolerated. Most adverse events were of mild or moderate severity and did not require discontinuation of therapy. Adverse experiences were similar in patients regardless of age, gender, or race. In the controlled clinical trials, about 3% of the 268 patients treated with Eprosartan/hydrochlorothiazide 600/12.5 mg discontinued therapy due to clinical adverse experiences.   |  |   |   |  |
| 156 | Ziska<br>Pharmaceutical<br>s Ltd. | Eprosartan<br>Mesylate 600mg +<br>Hydrochlorothiazi<br>de 25 mg Tablet | Eprosartan Mesylate INN<br>600 mg+<br>Hydrochlorothiazide BP<br>25 mg | Antihypertensiv<br>e | Eprosartan & Hydrochlorothiazide is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy. | Contraindications: Eprosartan & Hydrochlorothiazide is contraindicated in patients who are hypersensitive to this product or any of its components. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. Do not co-administer aliskiren with Eprosartan & Hydrochlorothiazide in patients with diabetes Side effects: prosartan/hydrochlorothiazide combination therapy was well tolerated. Most adverse events were of mild or moderate severity and did not require discontinuation of therapy. Adverse experiences were similar in patients regardless of age, gender, or race. In the controlled clinical trials, about 3% of the 268 patients treated with prosartan/hydrochlorothiazide 600/12.5 mg discontinued therapy due to clinical adverse experiences. | Eprosartan 400<br>mg & 600 mg<br>Tablet  | USFDA   | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং  | প্রস্তুতকারকে<br>নাম        | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস                    | নির্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | কমিটির সভার<br>সিদ্ধান্ত  | সভার সিদ্ধান্ত   |
|-----|-----------------------------|--|--|--|---|--|--|---|---|--|
| 157 | Ziska Pharmaceutical s Ltd. | Hydrocortisone Acetate 0.25gm + Benzyl Benzoate 1.25gm + Bismuth Subgallate 2.25gm + Bismuth Oxide 0.875gm + Balsam Peru 1.875gm + Zinc Oxide 10.75gm/100gm Ointment | 2.25gm + Bismuth Oxide<br>Ph. Gr 0.875gm +<br>Balsam Peru Ph. Gr | anti-<br>inflammatories<br>(steroidal) | Indicated for Symptomatic treatment of internal and external haemorrhoids and pruritus ani. | Contraindications: Hypersensitivity to the active substance(s) or to any of the excipients.  Side-effects: Possible side effect includes: Burning, Itching, Irritation, Dryness, Hypertrichosis, Acneiform, eruptions, Hypopigmentation. | New                                      | BNF-74, page-90                                 | প্তমধটির Safety, efficacy and usefulness এর বিষয়ে একজন colorectal surgeon এর মতামত নেওয়া যেতে পারে। | অধ্যাপক ডাঃ এ জেড এম মোল্ডাক হোসেন, বিভাগীয় প্রধান (সার্জারী বিভাগ), ঢাকা মেডিকেল কলেজ হাসপাতাল মূল্যায়নপূর্বক মতামত প্রদান করেন যে, ঔষধটিতে Anti- inflammator y, Moisturizer, Hemostatic and Antibacterial effect রয়েছে এবং গুরুতর কোন পার্শ্বপ্রতিক্রিয়া নেই। তাছাড়া ঔষধটি Internal Hemorrhoids , anal fissure & Pruritis ani - এ ঔষধটি ব্যবহার করা নিরাপদ, কার্যকরী এবং উপযোগী। তাঁর সুপারিশের ভিত্তিতে পদটি অনুমোদন করা হল। |
| 158 | Ziska<br>Pharmaceutical     | Lomitapide 10 mg<br>Capsule  | Lomitapide INN 10 mg   | Antihyperlipide mic                    | It is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a     | Contraindications: • Pregnancy • Concomitant use with strong or  | New                                      | USFDA/<br>BNF-74                                | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।   |

| নং  | প্রস্তুতকারকে<br>নাম                | ঔষধের নাম                   | জেনেরিক নাম          | থেরাপিউটিক<br>ক্লাস | নিৰ্দেশনা   | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত              | সভার সিদ্ধান্ত                                   |
|-----|-------------------------------------|-----------------------------|----------------------|---------------------|---|--|--|---|---|--|
|     | s Ltd.                              |                             |                      |                     | low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Limitations of Use • The safety and effectiveness have not been established in patients with hypercholesterolemia who do not have HoFH. • The effect on cardiovascular morbidity and mortality has not been determined.   | moderate CYP3A4 inhibitors. • Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.  Side effects:  Most common adverse reactions (incidence ≥28%) are diarrhea, nausea, vomiting, dyspepsia, and abdominal pain.  |  | Page-201  |   |  |
| 159 | Ziska<br>Pharmaceutical<br>s Ltd.   | Lomitapide 20 mg<br>Capsule | Lomitapide INN 20 mg | Antihyperlipide mic | It is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Limitations of Use • The safety and effectiveness have not been established in patients with hypercholesterolemia who do not have HoFH. • The effect on cardiovascular morbidity and mortality has not been determined. | Contraindications: • Pregnancy • Concomitant use with strong or moderate CYP3A4 inhibitors. • Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.  Side effects: Most common adverse reactions (incidence ≥28%) are diarrhea, nausea, vomiting, dyspepsia, and abdominal pain. | New                                      | USFDA/<br>BNF-74<br>Page-201                    | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 160 | . Ziska<br>Pharmaceutical<br>s Ltd. | Lomitapide 5 mg<br>Capsule  | Lomitapide INN 5 mg  | Antihyperlipide mic | It is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-  | Contraindications: • Pregnancy • Concomitant use with strong or moderate CYP3A4 inhibitors. • Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.  Side effects:   | New                                      | USFDA/<br>BNF-74<br>Page-201                    | প্রয়োজন নেই বিধায়<br>আবেদন নামঞ্জুর করা<br>যেতে পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

| নং   | প্রস্তুতকারকে<br>নাম              | ঔষধের নাম  | জেনেরিক নাম  | থেরাপিউটিক<br>ক্লাস     | নিৰ্দেশনা   | Contra-indication &<br>Side-effect  | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                                    | সভার সিদ্ধান্ত  |
|------|-----------------------------------|--|--|-------------------------|---|---|--|---|---|---|
|      |                                   |  |  |                         | highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).  Limitations of Use • The safety and effectiveness have not been established in patients with hypercholesterolemia who do not have HoFH. • The effect on cardiovascular morbidity and mortality has | Most common adverse reactions (incidence ≥28%) are diarrhea, nausea, vomiting, dyspepsia, and abdominal pain.   |  |   |   |   |
| 161. | Ziska<br>Pharmaceutical<br>s Ltd. | Methyl salicylate<br>10.2%, Menthol<br>5.44% and<br>Eugenol 1.36%<br>cream | Methyl salicylate BP<br>10.2%, Menthol BP<br>5.44% and Eugenol BP<br>1.36% | Topical<br>Analgesic    | not been determined.  It is indicated for sufferers from stiff neck, aching feet, tennis elbow, or any sore, stiff, strained and painful muscles.   | Contraindications: Not to be used on infected and/or injured areas of skin. Side effects: There are no known side-effects.  | New                                      |   | প্রয়োজনীয় রেফারেস<br>নেই বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে।         | প্রয়োজনীট<br>রেফারেস নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 162. | Ziska<br>Pharmaceutical<br>s Ltd. | Propiverine Hydroch<br>loride 15 mg Tablet                                 | Propiverine Hydrochloride<br>INN 15 mg                                     | Anticholinergic<br>drug | It is Indicated for Urinary frequency, urgency & incontinence associated with overactive bladder  | Contraindications: Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation. Side effects: Possible side effects of Propiverine are dryness of the mouth, blurred sight, constipation, tiredness, nausea (feeling sick), vomiting, dizziness, tremor, urinary retention, flushing, low blood pressure (with drowsiness) etc. | New                                      | BNF-74,<br>Page-735                             | অনুমোদন করা যেতে<br>পারে।   | অনুমোদন করা<br>হল।  |
| 163. | Ziska<br>Pharmaceutical<br>s Ltd. | Propiverine Hydroch<br>loride 30 mg<br>modified release<br>capsule         | Propiverine Hydrochloride<br>INN 30 mg                                     | Anticholinergic<br>drug | It is Indicated for Urinary frequency, urgency & incontinence associated with overactive bladder  | Contraindications: Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation.  Side effects: Possible side effects of   | New                                      | BNF-74,<br>Page-735                             | উচ্চ ডোজের এবং<br>modified release<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। |   |

| নং   | প্রস্তুতকারকে<br>নাম              | ঔষধের নাম  | জেনেরিক নাম                            | থেরাপিউটিক<br>ক্লাস  | নির্দেশনা  | Contra-indication &<br>Side-effect   | Status<br>(New<br>Molecule/<br>Existing) | আবেদনকারী<br>কর্তৃক<br>USFDA/BNF<br>/ MHRA Ref. |   | সভার সিদ্ধান্ত  |
|------|-----------------------------------|--|--|----------------------|--|--|--|---|---|---|
|      |                                   |  |  |                      |  | Propiverine are dryness of the mouth, blurred sight, constipation, tiredness, nausea (feeling sick), vomiting, dizziness, tremor, urinary retention, flushing, low blood pressure (with drowsiness) etc.   |  |   |   |   |
| 164. | Ziska<br>Pharmaceutical<br>s Ltd. | Propiverine Hydroch<br>loride 45 mg<br>modified release<br>capsule | Propiverine Hydrochloride<br>INN 45 mg | Anticholinergic drug | It is Indicated for Urinary frequency, urgency & incontinence associated with overactive bladder | Contraindications: Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation.  Side effects: Possible side effects of Propiverine are dryness of the mouth, blurred sight, constipation, tiredness, nausea (feeling sick), vomiting, dizziness, tremor, urinary retention, flushing, low blood pressure (with drowsiness) etc. | New                                      | BNF-74,<br>page-735                             | উচ্চ ডোজের এবং<br>modified release<br>বিধায় আবেদন নামঞ্জুর<br>করা যেতে পারে। | উচ্চ ডোজের এবং<br>modified<br>release বিধায়<br>আবেদন নামঞ্জুর<br>করা হল। |

## Annex-B: Products for Import (Human)

| নং | প্রস্তুতকারকের নাম  | ঔষধের নাম       | জেনিরিক নাম  | থেরাপিউটিক<br>ক্লাস | নির্দেশনা                                 | Contraindication &<br>Side-effect  | Status<br>(New Molecule/<br>Existing)   | FSC/CPP                 | টেকনিক্যাল সাব-<br>কমিটির সভার সিদ্ধান্ত   | সভার সিদ্ধান্ত  |
|----|---|-----------------|--|---------------------|---|--|---|-------------------------|--|---|
| 1. | Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Brüningstraße D-65926 Frankfurt am Main, Germany.  Importer: (Sanofi Bangladesh Limited) | Toujeo Solostar | Insulin Glargine 300U/ml solution for injection (Each pen contains 1.5 ml of solution for injection, equivalent to 450 units.) | Antidiabetic        | Treatment of diabetes mellitus in adults. | Contraindications: Hypersensitivity to the active substance or to any of the excipients.  Side-effects: Immune system disorders: Rare: Allergic reactions Metabolism and nutrition disorders: Very Common: Hypoglycaemia Nervous system disorders: Very Rare: Dysgeusia Eyes disorders: Rare: Visual impairment, Retinopathy Skin and subcutaneous tissue disorders: Common: Lipohypertrophy, Uncommon: Lipoatrophy Musculoskeletal and connective tissue disorders: Very Rare: Myalgia General disorders and administration site conditions: Common: Injection site reactions, Rare: Oedema | Insulin Glargin 100IU/ml Solution For Injection Insulin Glargin 300IU/3ml Injection | Germany<br>(EMA<br>CPP) | 300U3/ml<br>দ্বানীয়ভাবে<br>উৎপাদনের জন্য<br>অনুওমাদিত বিধায়<br>300U/ml কেন<br>প্রয়োজন সে বিষয়ে<br>ব্যাখা প্রদানের জন্য<br>বলা যেতে পারে। | Insulin Glargine 300U/3ml     ছানীয়ভাবে উৎপাদনের জন্য অনুমোদিত বিধায় 300U/ml কেন প্রয়োজন সে বিষয়ে ব্যাখা প্রদানের জন্য বলা হয় কিন্তু অদ্যাবধি কোন উত্তর পাওয়া যায়নি । প্রাপ্তি সাপেক্ষে পরবর্তী টেকনিক্যাল সাব- কমিটির সভায় উপস্থাপন করা হবে। |

# Annex-C: Products for Locally Manufacture (Veterinary)

| SI.<br>No | Name of the<br>Manufacturer  | Name of the<br>Product  | Generic Name  | Therpeutic Class           | Indication   | Contra-indication & Side effect  | Status<br>(New Molecule<br>/Existing)                     | USFDA,<br>BNF or<br>MHRA<br>Reference | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----------|--|---|---|----------------------------|--|--|---|---------------------------------------|--|--------------------|
| 1.        | Al-Madina Pharmaceuticals ltd. 1/1,Tilar Gati, kakil, Sathais, Tongi, Gazipur. | Paracetamol<br>BP<br>40.0gm/100gm<br>powder<br>(For veterinary<br>use only) | Paracetamol<br>BP 40.0gm/100gm                                  | Antipyretic &<br>Analgesic | For the recovery of fever, pain and tissue swollen resulting from trauma, injury, burn or any other infectious diseases of cattle, horse, calf, sheep, goat,dog, zoo animals and poultry.  | Contraindication: It should be used with caution in those animals that are renally or hepatically impaired.  Side effects: Not applicable  | 2.0gm Bolus<br>50gm/100gm<br>water<br>soluble powder      |                                       | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |
| 2.        | Incepta Pharmaceuticals Ltd (Dhamrai Unit)                                     | Ciprofloxacin HCI<br>500mg +<br>Metronidazole<br>1000 mg<br>Tablet          | Ciprofloxacin HCI<br>USP 500mg +<br>Metronidazole BP<br>1000 mg | Antibiotic                 | Ciprofloxacin Susceptible infections, including lower respiratory tract, acute exacerbations of chronic bronchitis (AECB), skin and skin structures, bone and joint,UTIs, chronic bacterial prostatitis. Post exposure prophylaxis and treatment of anthrax. Infectious diarrhea, typhoid fever, uncomplicated cervical: oral form only.  Metronidazole Metronidazole is prescribed to treat or control infections caused by susceptible bacteria and parasites.  Metronidazole is effective against infections caused by Giardia, Trichomonas and Balantidium coli. | Contraindications: Ciprofloxacin While generally safe and effective when prescribed by a veterinarian, ciprofloxacin can cause side effects in some animals. Ciprofloxacin should not be used in animals with known hypersensitivity or allergy to the drug. Young animals treated with ciprofloxacin may develop damage to the cartilage of their joints. Swollen joints and lameness are clinical signs that may be observed. This has not been shown to happen when the ear and eye formulations are used. Ciprofloxacin should not be administered to puppies. Those between the ages of four and 28 weeks are the most susceptible. Ciprofloxacin has a good safety record and adverse reactions are uncommon. Occasionally, some animals develop diarrhea or loose stools from | Ciprofloxacin 750<br>mg Bolus  Metronidazole 2gm<br>Bolus |                                       | অনুমোদন করা যেতে<br>পারে ।                 | অনুমোদন করা<br>হল। |

| SI.<br>No | Name of the<br>Manufacturer | Name of the Product | Generic Name | Therpeutic Class | Indication | Contra-indication & Side effect                                      | Status<br>(New Molecule<br>/Existing) | USFDA,<br>BNF or<br>MHRA<br>Reference | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|-----------|-----------------------------|---------------------|--------------|------------------|------------|--|---------------------------------------|---------------------------------------|--|----------------|
|           |                             |                     |              |                  |            | ciprofloxacin.   |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Ciprofloxacin may interact with other                                |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | medications. By consulting with                                      |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | veterinarian to determine if other drugs                             |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | pet is receiving could interact with                                 |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | ciprofloxacin. Such drugs include                                    |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | theophylline, antacids, iron   |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | supplements, sucralfate, cyclosporine                                |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | and various other antibiotics.                                       |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Metronidazole  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Metronidazole should not be used in                                  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | animals with known hypersensitivity or                               |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | allergy to the drug.   |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Metronidazole should be used with caution in severely debilitated or |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | pregnant animals.  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Metronidazole should be avoided in                                   |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | animals with liver disease.  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Metronidazole may interact with other                                |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | medications. Consult with veterinarian                               |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | to determine if other drugs pet is                                   |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | receiving could interact with  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | metronidazole. Such drugs include                                    |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | phenobarbital and cimetidine.  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Adverse effects associated with                                      |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | metronidazole include neurologic                                     |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | disorders, lethargy, weakness, liver                                 |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | disease and lack of appetite.  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Prolonged use or overdose can result                                 |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | in significant neurologic signs including                            |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | nystagmus, ataxia, head tilt,  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | disorientation, tremors, seizures and                                |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | rigidity.  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Side Effects:  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Ciprofloxacin  |                                       |                                       |  |                |
|           |                             |                     |              |                  |            | Loss of appetite   |                                       |                                       |  |                |

| SI.<br>No | Name of the<br>Manufacturer | Name of the<br>Product | Generic Name    | Therpeutic Class | Indication                              | Contra-indication & Side effect   | Status<br>(New Molecule<br>/Existing) | USFDA,<br>BNF or<br>MHRA<br>Reference | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত |
|-----------|-----------------------------|------------------------|-----------------|------------------|---|---|---------------------------------------|---------------------------------------|--|----------------|
|           |                             |                        |                 |                  |   | Vomiting  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Diarrhea  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Lethargy  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Convulsions   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Seizures in pets with CNS disorders   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Cataracts if given long-term  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Metronidazole   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Most common: clinical signs related to  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | the bad taste or GI upset.  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Dogs and cats: excessive salivation,  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | gagging, regurgitation, pawing at the   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | mouth, nausea, vomiting and   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | decreased appetite are the most   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | frequent complaints.  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Less common or rare: diarrhea,  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | depression, lethargy, weakness, low   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | white blood cell count, liver failure and                                       |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | blood in the urine, or dark urine due to  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | pigment changes. Neurologic signs   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | may be seen after accidental overdose   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | or, more commonly, with long-term   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | moderate to high dose therapy as to treat difficult bacterial infections. Signs |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | often begin 7 to 12 days following the  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | start of treatment.   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | Horses: side effects are not associated   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | commonly with metronidazole. The  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | major problem with using this drug is   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | its bad taste. Many horses stop eating  |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | when this drug is mixed with feed and   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | a reliable method of administration   |                                       |                                       |  |                |
|           |                             |                        |                 |                  |   | must be found.  |                                       |                                       |  |                |
| 3.        | Incepta                     | Albendazole 1200       | Albendazole USP | Anthelmintic     | It is used as anthelmintic against most | Contraindications: Hypersensitivity to  | 150 mg, 250 mg &                      |                                       | অনুমোদন করা যেতে                           | অনুমোদন করা    |
|           | Pharmaceuticals Ltd         | mg Bolus               | 1200mg          |                  | nematodes and cestodes. Albendazole     | the benzimidazole class of  | 600 mg Bolus                          |                                       | ু পারে।                                    | হ <b>ল</b> ।   |
|           | (Dhamrai Unit).             |                        |                 |                  | is effective against these gastro-      | compounds.  | Ĭ                                     |                                       |  |                |
|           | ,                           |                        |                 |                  | intestinal parasites: Bunostomum,       |   |                                       |                                       |  |                |

| SI.<br>No | Name of the<br>Manufacturer                           | Name of the Product  | Generic Name  | Therpeutic Class | Indication   | Contra-indication & Side effect                            | Status<br>(New Molecule<br>/Existing) | USFDA,<br>BNF or<br>MHRA<br>Reference | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|-----------|---|--|---|------------------|--|--|---------------------------------------|---------------------------------------|--|--------------------|
|           |   |  |   |                  | Chabertia, Cooperia, Haemonchus,<br>Nematodirus, Ostertagia,<br>Strongyloides, Dictyocaulus viviparus,<br>Moniezia expansa, Liver flukes and<br>Paramphistomes. It is also effective<br>against different types of worms, lung<br>flukes and lung nematodes.         | Side Effects: In several cases nausea, vomiting may occur. |                                       |                                       |  |                    |
| 4.        | Eskayef<br>Pharmaceuticals<br>Limited,<br>Narayanganj | Copper 100mg + Cobalt 4mg + Manganese 50mg + Zinc 300mg + Iodine 5mg + Iron 100mg + Selenium 1mg Bolus (Vet) | Copper Sulphate Pentahydrate BP 100mg + Cobalt Sulphate Heptahydrate INN 4mg + Manganese Sulphate Monohydrate USP 50mg + Zinc Sulphate Monohydrate USP 300mg + Potassium lodide USP 5mg + Dried Ferrous Sulphate USP 100mg + Sodium Selenite BP 1mg | Minerals         | Improves health and vigor of cows, buffaloes and breeding bulls. Improves reproductive performance. Plays vital role in reproduction and hematopoiesis. Helps to overcome anestrous and repeat breeding. Helps to overcome poor libido and low sperm count in bulls. | Contraindication: Not Known Side Effect: Not Known         | New                                   |                                       | অনুমোদন করা যেতে<br>পারে।                  | অনুমোদন করা<br>হল। |

### Annex-D: Products List for Import (Veterinary)

| নং | প্রস্তুতকারকের নাম ও<br>ঠিকানা   | ঔষধের নাম  | জেনিরিক নাম   | থেরাপিউটিক ক্লাস | নি <b>ৰ্দেশ</b> না   | Contraindication & Side-effect  | Status<br>(New/Existing) | FSC/CPP            | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|----|--|--|---|------------------|--|---|--------------------------|--------------------|--|--------------------|
| 1. | Bioproperties Pty Ltd<br>11-15 Moores Road,<br>Glenorie New South<br>Wales 2157,<br>Australia<br>Local Agent:<br>Renata Limited<br>Mirpur, Dhaka                           | EIMERIAVAX-4M<br>Vaccine                                 | Eimeria acervulina strain RA 3+20 ≥ 50 oocyts Eimeria maxima strain MCK +10 ≥ 100 oocyts Eimeria necartrix strain mednec 3+8 ≥ 100 oocyts Eimeria tenellax strain Rt3+15 ≥ 150 oocyts         | Vaccine          | Live oocyst preparation to aid in the control of the four major species of Eimeria that cause coccidiosis in breeders, broilers and layer chickens.  | Contraindication: It is contraindicated for vaccinating unhealthy birds.  Side-effect: No side effect   | New                      | Australia          | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা<br>হল। |
| 2. | Manufacturer: PHARMAGAL BIO, .s.r.o. Murgašova 5;949 01 Nitra, Slovak Republic  Local Agent: Al-Madina Pharmaceuticals Ltd. 1/1, TilarGati, kakil, Sathais,Tongi, Gazipur  | BURSIPHARM<br>lyophilisate for<br>suspension for chicken | One dose (0, 1 ml) contents: Infectious Bursal Disease Virus, Live(strain 2512) min.10 <sup>3,0</sup> TCID <sub>50</sub> * *50% Tissue Culture Infective Dose                                 | Vaccine          | For active immunization of chickens against Infectious Bursal Disease of poultry.  | Contraindications: Do not use in unhealthy animals or animals suspected from any disease. Side effects: None.   | New                      | Slovak<br>Republic | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা<br>হল। |
| 3. | Manufacturer: PHARMAGAL BIO,.s.r.o. Murgašova 5;949 01 Nitra, Slovak Republic  Local Agent: Al-Madina Pharmaceuticals Ltd. 1/1, TilarGati, kakil, Sathais, Tongi, Gazipur. | PESTIPHARMB1 Lyophilisate for suspension for chicken.    | One dose (0, 1 ml) contents: Newcastle Disease Virus, Live, Strain Hitchner B1 min.10 <sup>6.0</sup> EID <sub>50</sub> -max.10 <sup>7.0</sup> EID <sub>50</sub> * *50% embryo infective dose. | Vaccine          | For the active immunisation of chickens against Newcastle disease, to prevent infection. The vaccine is suitable for use from the first day of life. | Contraindications: Do not use in animals sick or suspected from any disease.  Side effects: Soft respiratory problem may occure after vaccination, they disappear spontaneously within 7-10 days after vaccination. | New                      | Slovak<br>Republic | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা<br>হল। |

| নং | প্রস্তুতকারকের নাম ও<br>ঠিকানা  | ঔষধের নাম   | জেনিরিক নাম  | থেরাপিউটিক ক্লাস | নিৰ্দেশনা   | Contraindication & Side-effect  | Status<br>(New/Existing) | FSC/CPP            | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                 | সভার সিদ্ধান্ত                                   |
|----|---|---|--|------------------|---|---|--------------------------|--------------------|--|--|
| 4. | Manufacturer: Pharmagal Bio, .s.r.o. Murgašova 5 949 01 Nitra, Slovak Republic Local Agent: Al-Madina Pharmaceuticals Ltd. 1/1, TilarGati, kakil, Sathais,Tongi, Gazipur. | AVIPHARM ND<br>Lyophilisate for<br>suspension for chickens    | One dose (0, 1 ml) contents: Newcastle disease virus, Live, Strain La Sota min. 10 <sup>6,0</sup> EID <sub>50</sub> - max.10 <sup>7,0</sup> EID <sub>50</sub> *  * EID <sub>50</sub> = 50% Embryo infective dose | Vaccine          | Active immunisation of chickens against Newcastle disease to reduce clinical signs and mortality associated with the disease.   | Contraindications: Do not use in chickens under 7 days of age. Do not use in unhealthy animals or animals suspected from any disease. Do not use in birds in lay. Side effects: Rarely vaccination may evoke transient mild local or general reactions or respiratory reactions with a span of not more than 48 hours.  | New                      | Slovak<br>Republic | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 5. | Manufacturer Pharmagal Bio, .s.r.o. Murgašova 5 949 01 Nitra, Slovak Republic Local Agent: Al-Madina Pharmaceuticals Ltd. 1/1, TilarGati, kakil, Sathais,Tongi, Gazipur   | BRONCHIPHARM<br>Lyophilisate for<br>suspension<br>forchickens | One dose (0, 1 ml) contents: Avian Infectious Bronchitis Virus, Live, strain H 120 10 <sup>3,0</sup> EID <sub>50</sub> -10 <sup>4,5</sup> EID <sub>50</sub> *  * EID <sub>50</sub> = 50% Embryo infective dose   | Vaccine          | For active immunization of poultry against Infectious Bronchitis Virus ofpoultry.   | Contraindications: Do not vaccinate animals sick or suspected from any disease Side effects: Weak cough and slight respiratory problems may be observed after vaccination, resolving within7-10 days after vaccination.   | New                      | Slovak<br>Republic | অনুমোদন করা<br>যেতে পারে।                                  | অনুমোদন করা<br>হল।                               |
| 6. | Manufacturer: Pharmagal Bio, spol.s.r.o. Murgašova 5 Nitra, Slovak Republic  Local Agent: Al-Madina Pharmaceuticals Ltd. 1/1, TilarGati, kakil, Sathais,Tongi, Gazipur.   | ROTAGAL<br>Emulsion for injection for<br>cattle               | Each One dose (3ml) contents Bovine rotavirus, strain TM-91(inactivated) Bovine Corona virus strain C-197 (inactivated) Escherichia coli, adhesin F5(K99)  | Vaccine          | For the active immunization of pregnant cows and heifers to raise antibodies against <i>E,coli</i> adhesin F5(K 99) antigen, rotavirus and coronavirus. When calves are fed colostrums from vaccinated cows during the first week of life, these antibodies have been demonstrated to reduce the severity of diarrhea caused by bovine rotavirus, bovine coronavirus and enteropathogenic <i>E.coli</i> F5(K99) and to reduce the shedding of virus by calves infected with bovine rotavirus or bovine coronavirus. | Contraindications: None reported. Side effects: A slight swelling of 5-7cm in diameter at the site of injection is common( more than 1 but less than 10 animals in 100 animals), and may in some cases be accompanied initially by increased local temperature. Typically, such swelling resolves within 15 days. Slight, transient increases in temperature (up to 0.8°C) may be observed within 24 hours of vaccination, resolving within 4 days after vaccination. | New                      | Slovak<br>Republic | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 7. | Manufacturer:<br>Unibiotech .Co., Ltd<br>235-22,Chusa –   | Good Cleaner  | Benzalkonium Chloride<br>Concentrated Solution<br>50, KP 200gm (eq. to   | Disinfectant     | Good Cleaner is broad spectrum<br>against the organisms. It is highly<br>effective against bacteria, viruses  | Contraindications: None reported. Side effects: None reported.  | New                      | Republic of Korea  | অনুমোদন করা<br>যেতে পারে।                                  | অনুমোদন করা<br>হল।                               |

| নং | প্রস্তুতকারকের নাম ও<br>ঠিকানা  | ঔষধের নাম                       | জেনিরিক নাম  | থেরাপিউটিক ক্লাস | নিৰ্দেশনা  | Contraindication & Side-effect   | Status<br>(New/Existing) | FSC/CPP               | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত | সভার সিদ্ধান্ত     |
|----|---|---------------------------------|--|------------------|--|--|--------------------------|-----------------------|--|--------------------|
|    | ro,SinumMyeon,Yesa<br>n-Gun,<br>Chungcheongnam-<br>do, Republic of Korea<br><b>Local Agent:</b><br>Al-Madina<br>Pharmaceuticals Ltd.<br>1/1, TilarGati, kakil,<br>Sathais,Tongi,<br>Gazipur |                                 | 100gm as Benzalkonium Chloride) + Citric Acid Hydrate, KVP 200gm + Phosphoric Acid, KVP 60gm/Liter   |                  | <ul> <li>and fungi.</li> <li>For Disinfection of Bacteria or Virus.</li> <li>Bacteria: Salmonella typhimurium, Brucella ovis.</li> <li>Virus: AI, NDV, CSFV, FMD</li> <li>For disinfection of shed, animal superficies, hatchery, butchery, livestock products counter, operating room.</li> </ul>   |  |                          |                       |  |                    |
| 8. | Manufacturing: Intervet International B.V, Netherland  Local agent: M/s. Bangal Overseas Ltd  | Nobilis COR 4 + IB + ND<br>+EDS | Inactivated Avibacterium paragallinarum:  - Strain 083 at least 1CPD 70 - Strain Spross at least 1CPD 70 - Strain H-18 at least 1CPD 70 - Strain 48 at least 1CPD 70 IBV Strain M41 ≥ 2.0 log2 HI units increase in primed birds  NDV Clone 30 inducing ≥ 4.0log2 HI units per 1/50 dose or containing ≥ 50 PD50 Units per dose  EdsV' 76 Strain BC14 ≥ 3.2 log2 HI per dose | Vaccine          | For active immunization of chickens to reduce infecation and clinical signs of infectious coryza caused by avibacterium paragallinarum, and for protection against the infectious bronchitis virus covered by themassachusetts serotype, newcastle disease and Egg Drop syndrome 76. The protective effects are demonstrated for at least one laying period. | Contra-indication:  - Before using the vacine allow it to reach room temperature Shake well beforuse Use sterile syringes and needles Vaccinate only healthy animals in the lower part of the neck  Side-effect: The chickens may be less active the first day after vaccination, but all animals return to normasl the next day. A small transient swelling at the injection site may be observed in the majority of the animals within the first four week after vaccination, which disappear gradully thereafter. | New                      | The<br>Netherla<br>nd | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা<br>হল। |

| নং  | প্রস্তুতকারকের নাম ও<br>ঠিকানা  | ঔষধের নাম                         | জেনিরিক নাম  | থেরাপিউটিক ক্লাস | নির্দেশনা  | Contraindication & Side-effect   | Status<br>(New/Existing) | FSC/CPP        | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                 | সভার সিদ্ধান্ত                                   |
|-----|---|-----------------------------------|--|------------------|--|--|--------------------------|----------------|--|--|
| 9.  | Manufacturer: Meril, INC. USA.  Local Agent: Advance animal science Co. Itd. 2/10 Block- B, Lalmatia, Dhaka- 1207G                          | Prevexxion RN                     | Marek's Disease<br>Vaccine Serotype 1,<br>Live Herpesvirus<br>Chimera  | Vaccine          | The vaccine is for in Ovo Vaccination of 18/19 day old embryonated chicken eggs, The vaccine is also recommended for subcutaneous vaccination of healthy one day old chicken.  | Contraindications: None  Side effects: Vaccination with Prevexxion RN is satisfactory and has no tendency to revert the virulence after several passages in chicken. | New                      | USA            | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 10. | Manufacturer:<br>Laboratorios Calier,<br>S.A., Spain<br><b>Local Agent:</b><br>NEXUS Distributor<br>House no. 49/K jail<br>Road, Mymensingh | Flubenzim 50mg/gm<br>Powder (Vet) | Flubendazole 50 mg/gm  | Antihelminthic   | This product is indicated for the prevention and treatment of infestations of the following namatodes of the gastrointestinal tract of the pig: Ascaris suum (large roundworm) Hyostrongylus rubidus (red stomach worm) Oesophagstomum dentatum (nodular worm) | Do not use in case of hypersensitivity to the active substance or to any of the excipients   | New                      | Spain          | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 11. | Eagle Vet Tech Co.,<br>Ltd., 235-34, Chusa-<br>ro, Shinam-myun,<br>Yesan-kun,<br>Chungchongnam-do,<br>Korea<br>Local agent: ACI Ltd.        | VITAPOWER Injection 50ml & 100ml  | Retinol Palmitate USP 4,000IU + Cholecalciferol USP 800IU + Tocopherol Acetate USP 10mg + Thiamin Hydrochloride USP 10mg + Riboflavin USP 2mg + Pyridoxine hydrochloride USP 10mg + Folic acid USP 0.1mg + Menadion Sodium Bisulfite USP 1mg + Nicotinamide USP 20mg + Choline Chloride USP 50mg + | Vitamin          | Treatment of deficiency disease of vitamin A, D <sub>3</sub> , E, C, B groups and etc. in livestock, improvement to inappetence, milk yield of high producing cow and conception rate, promotion of pre- and post-parturition and disease recovery.            | Contraindication: Keep out of reach of children.  Side Effects: No undesirable side effects are known  | New                      | South<br>Korea | আপাততঃ ছুগিত<br>করা যেতে পারে।                             | আপাততঃ ছুগিত<br>করা হল ।                         |

| নং  | প্রস্তুতকারকের নাম ও<br>ঠিকানা  | ঔষধের নাম  | জেনিরিক নাম  | থেরাপিউটিক ক্লাস | নিৰ্দেশনা   | Contraindication & Side-effect  | Status<br>(New/Existing) | FSC/CPP        | টেকনিক্যাল সাব<br>কমিটির সভার<br>সিদ্ধান্ত                 | সভার সিদ্ধান্ত                                   |
|-----|---|--|--|------------------|---|---|--------------------------|----------------|--|--|
|     |   |  | Biotin USP 0.15mg +<br>Panthenol USP 10mg<br>+Taurine USP 10mg<br>/ml                            |                  |   |   |                          |                |  |  |
| 12. | WooGene B&G Co.,<br>Ltd., 230,<br>Jeongmunsongsan-<br>ro, Yanggam-myeon,<br>Hwaseong-si,<br>Gyeonggi-do, Korea<br>Local agent: ACI Ltd. | SUPERPIRIN Powder of oral suspension 1kg, 5kg, 10kg, 20kg & 25kg | Aspirin 300gm + Ascorbic Acid 33.3gm + Anhydrous Citric acid 200gm + Sodium carbonate 1.0gm/ 1kg | Analgesic        | Use in cattle and chicken as an antipyretic and analgesic.  | Contraindication: Not to be used in poultry producing eggs for human consumption. Not to be used in cattle producing milk for human consumption.  Side Effects: Narrow therapeutic index. High doses frequently causes vomiting. Other GI effects can include ulceration and bleeding. Aspirin inhibits platelets and increases risk of bleeding.                                 | New                      | South<br>Korea | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |
| 13. | WooGene B&G Co.,<br>Ltd. 230,<br>Jeongmunsongsan-<br>ro, Yanggam-myeon,<br>Hwaseong-si,<br>Gyeonggi-do, Korea<br>Local agent: ACI Ltd.  | AMSTRONG Powder of oral suspension 50g, 100g, 200g, 500g & 1kg   | Ampicillin Trihydrate<br>500 gm + Colistin<br>Sulfate 1,250,000,000<br>IU /1kg                   | Antibiotic       | Prevention and treatment of disease caused by ampicillin and colistin sensitive bacteria. Cattle: E. Coli, Pasteurellamultocida Chicken: E. Coli, Staphylococcus aureus | Contraindication: Do not use this product and penicillin in animal who have a history of hypersensitivity or shock to it.  Side Effects: Penicillin derivative antibiotics can cause diarrhea because of suppress intestinal normal flora and loss of appetite, watery diarrhea or bloody stools, nausea and vomiting, abnormal digestive systems by gastroenteritis and colitis. | New                      | South<br>Korea | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা যেতে<br>পারে। | প্রয়োজন নেই<br>বিধায় আবেদন<br>নামঞ্জুর করা হল। |

# Annex-E: Product list for Local (Medical Devices)

| SI<br>No | প্রস্তুতকারকের নাম   | বাণিজ্যিক নাম  | মেডিকেল ডিভাইসের নাম  | ক্লাস | নির্দেশনা/ব্যবহার   | টেকনিক্যাল সাব-কমিটির সভার সিদ্ধান্ত | সভার সিদ্ধান্ত   |
|----------|--|--|---|-------|---|--------------------------------------|------------------|
| 1.       | JMI hospital<br>Requisite Mfg. Ltd.,<br>7/A Shantibag,<br>Dhaka-1217 | JMI Sterile<br>Disposable Scalpel                          | Scalpel handle (Acrynonitrile Butadine<br>Styrine Medical grade 4.89gm) + Blade<br>(Stainless steel Medical grade) +<br>Protective cap (Liner low density<br>polyethylene Medical grade 2.303gm) +<br>Sterilization (Ethylene oxide gas)  | В     | Sterile Disposable Scalpel use for surgery, anatomical dissection in surgical operation. Also used to make small incision in skin and muscle.   | অনুমোদন করা যেতে পারে।               | অনুমোদন করা হল । |
| 2.       | JMI hospital<br>Requisite Mfg. Ltd.,<br>7/A Shantibag,<br>Dhaka-1217 | JMI Sononned  Atraumitic Needle for peripheral nerve block | Cannula (Stainless steel Medical grade) + Tubing (Poly vinyl Chloride Medical grate 2.73gm) + Wings hub (Poly vinyl Chloride Medical grate 0.3gm) + Needle cap (Poly vinyl Chloride Medical grate 0.5gm) + Luer hub (Acrynonitrile Butadine Styrine Medical grade 0.238gm) + Thread Stopper (High Density polyethylene Medical grade 0.35gm + Master Batch Medical grade 0.014gm) + Adhesive (Epoxy resin Medical grade 0.001ml + Epoxy Hardener Medical Grade 0.001ml) + Cylohexanone Medical Grade 0.001ml + Siliconization (Silicoat Medical grade 0.01ml) + Sterilization (Ethylene di oxide gas mixture with CO <sub>2</sub> ) | В     | Sononned used for facilitating a principal nerve block procedure. The needle has several fenestration along it's length to allow and efflux of local anesthetic into particular facial compartment to treat a corresponding peripheral nerve. | অনুমোদন করা যেতে পারে।               | অনুমোদন করা হল । |

#### Annex-F: Products for Import (Medical Devices)

| SI<br>No | প্রস্তুতকারকের নাম   | বাণিজ্যিক নাম                                | মেডিকেল ডিভাইসের নাম   | ক্লাস  | নিৰ্দেশনা  | Contraindication & Side-effect  | FSC/CPP           | টেকনিক্যাল<br>সাব কমিটির<br>সভার সিদ্ধান্ত  | সভার সিদ্ধান্ত   |
|----------|--|--|--|--|--|---|-------------------|---|--|
| 3.       | Manufacturer: Lisapharma SpA, Address: Via Licinio, 11, 22036 Erba (CO), Italy  Supplier: River Pharma Srl; Address: Via Marconi, 36/38 20078 San Colombano, Italy  Importer: Benvue International Ltd. Address: 14/1, Joy Tower, Joynagar R/A, Chatteshawri Road, Chittagong, Bangladesh. | Syaloset Intra-articular Injection           | Hyaluronic acid as sodium hyluronate viscosupplement agent 64 mg /4 ml  Cartilaginous Defect Repair Agent                            | D<br>(As per<br>https://ww<br>w.ncbi.nl<br>m.nih.gov<br>/pmc/artic<br>les/PMC4<br>948701/) | It is indicated for knee osteoarthritis  | Contraindications: Must not be injected if the joint is infected or seriously inflamed or if the patient has a skin infection or other problem in in the area where the injection is to be made. Must be administered with caution in patients with diabetes or affected by chronic pathologies.  Side Effects: Infiltration may cause localised side effects. During the use, following symptoms may appear around the injection site: pain, heat, redness or swelling. These secondary effects may be alleviated by applying ice to the treated joint. These symptoms will normally disappear after a short period. The doctor must ensure that patients inform him of any adverse effects occurring after treatment. | Italy             | রেজিস্ট্রেশনের<br>পূর্বে<br>Conformity<br>Assesment<br>Certificet or<br>equivalent<br>Certificate<br>দাখিলের শর্তে<br>অনুমোদন করা<br>যেতে পারে। | রেজিস্ট্রেশনের<br>পূর্বে<br>Conformity<br>Assesment<br>Certificet or<br>equivalent<br>Certificate<br>দাখিলের শর্তে<br>অনুমোদন করা<br>হল। |
| 4.       | Manufacturer: Matrixcell s.r.o. Na vinci 43, 290 01, Podebrady-Prodebrady II, Czech Republic.  MAH: Proximo Health Solucion.   | Aquafilling Faceline<br>(1ml gel in syringe) | Hydrophilic Gel for endoprosthetics of human soft tissues (Cation copolyamide-2%, 0.9% physiologic solution of sodium chloride-98%). | D<br>(As per<br>FSC)   | Hydrophilic gel is recommended for application under the following indications:  1. Contour correction of facial soft tissues;  2. Removal of age-related changes of face.  3. Change of lips form and volume.  4. Removal of asymmetry of facial soft tissues;  5. Removal of post traumatic, post surgical, congenital malformations and defects of facial soft tissues.  6. Removal of atrophic changes of soft tissues in face zone. | Contraindication: Do not use the product if the package is damaged or the sterility of material is broken.  Do not perform the procedure under the following conditions, if a person: -is pregnant or breast feeding; -has poor mental health; -currently takes anticoagulants or aspirin; -has a skin infection or inflammatory disease; -has permanent implants; -has acute contagious disease of a specific and nonspecific etiology; -has chronic contagious diseases in sustained remission stage or recrudescence; -has intolerability or allergy to medicines; -has vessels diseases of different etiology;  Side effects: The most common adverse events  | Czech<br>Republic | স্থৃগিত করা হল।   | স্থৃগিত করা হল।  |

| SI<br>No | প্রস্তুতকারকের নাম   | বাণিজ্যিক নাম                                 | মেডিকেল ডিভাইসের নাম  | ক্লাস                | নির্দেশনা  | Contraindication & Side-effect   | FSC/CPP           | টেকনিক্যাল<br>সাব কমিটির<br>সভার সিদ্ধান্ত | সভার সিদ্ধান্ত  |
|----------|--|---|---|----------------------|--|--|-------------------|--|-----------------|
|          |  |   |   |                      |  | observed during the application period of Aquafilling are bruising, edema, redness, itching, and pain. In case of infiltrations formation n in the soft tissues the intensive local and general antibiotic therapy is recommended during 5-7 days, thus pain is arrested.  |                   |  |                 |
| 5.       | Manufacturer: Matrixcell s.r.o. Na vinci 43, 290 01, Podebrady-Prodebrady II, Czech Republic.  MAH: Proximo Health Solucion. | Aquafilling Bodyline (100gm gel in container) | Hydrophilic Gel for endoprosthetics of human soft tissues(Cation copolyamide-2%, 0.9% physiologic solution of sodium chloride-98%). | D<br>(As per<br>FSC) | It is recommended for application under the following indications 1. Contour correction of body soft tissues; 2. Removal of mammary aplasia; 3. Removal of mammary hypomastia; 4. Removal of mammary hypomastia accompanied by glandulous; 5. Removal of asymmetry of soft breast tissues; 6. Removal of deformities of the breast tissues; 7. Improvement of breast volume and shape; 8. Buttocks augmentation. | Contraindications:  Do not use the product if the package is damaged or the sterility of material is broken. Do not perform the procedure under the following conditions, if a person: -is younger than 18 years; -has poor mental health; -has apparent ptois(type 2-3); -has mastopathy; Is within 9 months after delivery: -has very small distance from the tear to the submammary fold; -has blood coagulation troubles, menstruation abnormalities; -currently takes anticoagulants or aspirin; -has a skin infection or inflammatory disease; -has permanent implants; -has acute contagious disease of a specific and nonspecific etiology; -has chronic contagious diseases in sustained remission stage or recrudescence; -has intolerability or allergy to medicines; -has vessels diseases of different etiology; -has severe general somatic diseases, oncology.  Side effects: The most common adverse events observed during the application period of Aquafilling are bruising, edema, redness, itching, and pain. In case of infiltrations formation n in the soft tissues the intensive local and general antibiotic therapy is recommended during 5-7 | Czech<br>Republic | ছ্পিত করা হল।                              | স্থৃগিত করা হল। |

| SI<br>No | প্রস্তুতকারকের নাম   | বাণিজ্যিক নাম     | মেডিকেল ডিভাইসের নাম   | ক্লাস                                  | নির্দেশনা   | Contraindication & Side-effect   | FSC/CPP  | টেকনিক্যাল<br>সাব কমিটির<br>সভার সিদ্ধান্ত | সভার সিদ্ধান্ত  |
|----------|--|-------------------|--|--|---|--|----------|--|-----------------|
|          |  |                   |  |  |   | days, thus pain is arrested.   |          |  |                 |
| 6.       | Manufacturer: Pharmadab d.o.o., Cesta na Brdo 100, 1000 Ljubljana, Slovenia  MAH: Proximo Health Solucion. | RECONVAL B6 Cream | Reconval B6(Vitamin B6,purified water, olive oil, glyceryl stearate, vaseline, urea, cholesterol, propylene glycol, allantoin, cetyl alcohol, phenoxyethanol, Stearate(75) oe, beeswax, cetyl palmitate, triethanolamine, 1,2 hexanedyol, caprylyl glycol, cetil(20)oe, stearil(20)oe, acrylates/C 10-30 alkyl acrylate crosspolymer, pentaerithrityl tetra-dibutyl hydroxyhydrocinnamate, ethylhexylglycerin, sodium hydroxide. t | A (As per EC Declara tion              | Reconval B6 is recommended for application under the following indications: - Inflamed skin (i.e. Hand Foot syndrome) and - skin reactions during and after dermatological treatment& oncological treatment   | Contraindication: Do not use the product if the package is damaged. Do not use in cases of established or suspected hypersensitivity for one or more than one components present in the product. It is suggested to consult a doctor before use, particularly if you are treating the skin with other topical products. In case of undesired reactions suspend the treatment and consult a doctor.  Side Effects:N/A   | Slovenia | দ্বৃগিত করা হল।                            | স্থৃগিত করা হল। |
| 7.       | Manufacturer: Pharmadab d.o.o., Cesta na Brdo 100, 1000 Ljubljana, Slovenia.  MAH: Proximo Health Solucion | RECONVAL K1 Cream | Reconval K1 Cream(Vitamin k1,dimineralized water,olive oil, glyceryl stearate, petrolatum, urea, cholesterol, propylene glycol, allantoin, cetyl alcohol, phenoxyethanol, stearate (75)oe, beeswax, cetyl palmitate, cetyl(20)oe, stearyl(20)oe, acrylates/C10-30 alkyl acrylate crosspolymer,   | A<br>(As per<br>EC<br>Declara<br>tion) | Reconval K1 cream is recommended for application under the following indications:  1. Irritated skin(for example after drug treatment); 2. Skin with acne; 3. Protective Cream for restoring the physiological conditions of the skin damaged by external and chemical factors; | Contraindication: Do not use the product if the package is damaged or the sterility of material is broken.  Do not perform the procedure under the following conditions, if a person: -is younger than 18 years; -has poor mental health; -has apparent ptois(type 2-3); -has mastopathy; Is within 9 months after delivery: -has very small distance from the tear to the submammary fold; -has blood coagulation troubles, menstruation abnormalities; -currently takes anticoagulants or aspirin; | Slovenia | ছ্ণিত করা হল।                              | স্থৃগিত করা হল। |

| SI<br>No | প্রস্তুতকারকের নাম   | বাণিজ্যিক নাম                | মেডিকেল ডিভাইসের নাম  | ক্লাস                | নির্দেশনা  | Contraindication & Side-effect   | FSC/CPP               | টেকনিক্যাল<br>সাব কমিটির<br>সভার সিদ্ধান্ত | সভার সিদ্ধান্ত   |
|----------|--|------------------------------|---|----------------------|--|--|-----------------------|--|------------------|
|          |  |                              | polyperfluromethylisopro<br>pyl ether, pentaerithrityl<br>tetra-di-t-butyl<br>hydroxyhydrocinnamate,<br>ethylhexylglycerin,<br>triethanolamine.   |                      |  | -has a skin infection or inflammatory disease; -has permanent implants; -has acute contagious disease of a specific and nonspecific etiology; -has chronic contagious diseases in sustained remission stage or recrudescence; -has intolerability or allergy to medicines; -has vessels diseases of different etiology; -has severe general somatic diseases, oncology.  Side effect: N/A                        |                       |  |                  |
| 8.       | Manufacturer: FARMA-DERMA s.r.l, Via Dei Bersaglieri, 10- 40010 Sala Bolgnese(BO), Italy.  Local Agent: Proximo Health Solucion. | CICATRIDINA Ointment         | Hyaluronic acid sodium salt, water, liquid paraffin, cetyl-stearyl alcohol, sweet almond oil, polyoxyethylene (2) steryl ether, polyoxyethylene(21) steryl ether, glycerine, sorbitol, silicone oil, chlorhexidine digluconate, imidazolidinyl urea, EDTA bisodium salt, BHT. | C<br>(As per<br>FSC) | Adjuvant treatment of reparative process in the case of: -Irritations and reddenings -After peeling interventions, epilation and laser -Superficial wounds: cracks, scratches, abrasions, rashes, first and second degree burns, superficial cutsDeep wounds: surgical wounds, decubitus sores and ulcers. | Contraindication: Cicatridina cream must not be used in case of individual hypersensitivity to one of the components of the product. In case of pregnancy and breast feeding it is advisable to consult the doctor.  Side effect: Use of all products for tropical use, especially if prolonged, may cause sensitization. If this occurs, stop treatment and consult a doctor to start suitable therapy.         | Italy EC Certificate  | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা হল । |
| 9.       | Manufacturer: FARMA-DERMA s.r.l, Via Dei Bersaglieri, 10- 40010 Sala Bolgnese(BO), Italy.  Local Agent: Proximo Health Solucion  | CICATRIDINA<br>Suppositories | CICATRIDINA suppositories (Hyaluronic acid sodium salt 5mg, cantella asiatica oil extract, Calendula officinalis oil extract, aloe vera oil extract, tea tree essential oil, semi synthetic glycerides, BHT).   | C<br>(As per<br>FSC) | Adjuvant treatment of reparative process of the anorectal canal following proctological surgery; internal and external haemorrhoids; proctitis; cryptitis; anal rhagades; fissures: perianal fistulae.   | Contraindication: Cicatridina Suppositories must not be used in case of individual hypersensitivity to one of the components of the product. In case of pregnancy and breast feeding it is advisable to consult the doctor.  Side effect: Use of all products for tropical use, especially if prolonged, may cause sensitization. If this occurs, stop treatment and consult a doctor to start suitable therapy. | Italy  EC Certificate | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা হল । |

| SI<br>No | প্রস্তুতকারকের নাম  | বাণিজ্যিক নাম                 | মেডিকেল ডিভাইসের নাম  | ক্লাস                | নির্দেশনা   | Contraindication & Side-effect  | FSC/CPP               | টেকনিক্যাল<br>সাব কমিটির<br>সভার সিদ্ধান্ত | সভার সিদ্ধান্ত   |
|----------|---|-------------------------------|---|----------------------|---|---|-----------------------|--|------------------|
| 10.      | Manufacturer: FARMA-DERMA s.r.l, Via Dei Bersaglieri, 10- 40010 Sala Bolgnese(BO), Italy.  Local Agent: Proximo Health Solucion | CICATRIDINA Vaginal<br>Ovules | CICTRIDINA Vaginal ovules (Hyaluronic acid sodium salt 5mg, cantella asiatica oil extract, Calendula officinalis oil extract, aloe vera oil extract, tea tree essential oil, semi synthetic glycerides, BHT). | C<br>(As per<br>FSC) | Adjuvant treatment of reparative process in atrophic and dystrophic conditions of the vaginal mucosa. It helps healing after childbirth, in gynecological surgery, in cases of dystrophy resulting from chemotherapy, ionizing radiation vaginal dryness also due to estrogen deficiency. | Contraindication: Cicatridina vaginal ovules must not be used in case of individual hypersensitivity to one of the components of the product.  In case of pregnancy and breast feeding it is advisable to consult the doctor.  Side Effect:  Use of all products for tropical use, especially if prolonged, may cause sensitization. If this occurs, the user has to stop treatment and consult a doctor to start suitable therapy. | Italy  EC Certificate | অনুমোদন করা<br>যেতে পারে।                  | অনুমোদন করা হল । |